Variant Annotation ID	Variant/Haplotypes	Drug(s)	Phenotype Category	Significance	Sentence	Allele Of Frequency In Cases	Allele Of Frequency In Controls	P Value	Ratio Stat Type	Ratio Stat	Confidence Interval Start	Confidence Interval Stop
1449191920	rs113993960	ivacaftor / lumacaftor	Efficacy	yes	Genotype del/del is associated with response to ivacaftor / lumacaftor in people with Cystic Fibrosis.			= 0.009	OR			
1449192330	rs74551128	ivacaftor / lumacaftor	Efficacy	not stated	Allele A is associated with response to ivacaftor / lumacaftor.				OR			
1449192352	rs113993960	ivacaftor / lumacaftor	Efficacy	not stated	Allele del is associated with response to ivacaftor / lumacaftor.				OR			
1451206834	rs2032582	codeine,morphine	Metabolism/PK	no	Allele T is not associated with concentrations of codeine or morphine as compared to allele C.			= 0.58				
1451206834	rs2032582	codeine,morphine	Metabolism/PK	no	Allele T is not associated with concentrations of codeine or morphine as compared to allele C.			= 0.79				
1451206853	rs1799971	codeine,morphine	Metabolism/PK	no	Allele G is not associated with concentrations of codeine or morphine as compared to allele A.			= 0.28				
1451206853	rs1799971	codeine,morphine	Metabolism/PK	no	Allele G is not associated with concentrations of codeine or morphine as compared to allele A.			= 0.42				
1451206886	rs1045642	codeine,morphine	Metabolism/PK	no	Allele A is not associated with concentrations of codeine or morphine as compared to allele G.			= 0.33				
1451206886	rs1045642	codeine,morphine	Metabolism/PK	no	Allele A is not associated with concentrations of codeine or morphine as compared to allele G.			= 0.68				
1449310660	rs1057910	sulfonamides, urea derivatives	Efficacy	no	Allele C is not associated with response to sulfonamides, urea derivatives in people with Diabetes Mellitus as compared to allele A.	A	C	> 0.05	OR			
1444705578	rs8099917	peginterferon alfa-2b,ribavirin	Efficacy	yes	Allele G is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele T.			= 7.06E-8	OR	1.98	1.57	2.52
1444705578	rs8099917	peginterferon alfa-2b,ribavirin	Efficacy	yes	Allele G is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele T.			= 9.39e-4				
1446898218	rs1799971	acetaminophen,tramadol	Efficacy	yes	Genotype AA is associated with increased response to acetaminophen and tramadol in people with neuropathic pain as compared to genotypes AG + GG.	A		< 0.001	OR			
1183681975	rs1045642	buprenorphine,dihydrocodeine,fentanyl,hydromorphone,methadone,morphine,oxycodone,piritramide,tilidine,tramadol	Dosage	yes	Allele A is associated with decreased dose of buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, morphine, oxycodone, piritramide, tilidine or tramadol in people with Pain as compared to allele G.	A		= 0.004	OR			
1183681975	rs1045642	buprenorphine,dihydrocodeine,fentanyl,hydromorphone,methadone,morphine,oxycodone,piritramide,tilidine,tramadol	Dosage	yes	Allele A is associated with decreased dose of buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, morphine, oxycodone, piritramide, tilidine or tramadol in people with Pain as compared to allele G.			= 0.007	OR			
1451159083	rs1799971	buprenorphine,dihydrocodeine,fentanyl,hydromorphone,methadone,morphine,oxycodone,piritramide,tilidine,tramadol	Dosage	no	Genotype G is not associated with dose of buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, morphine, oxycodone, piritramide, tilidine or tramadol in people with Pain as compared to genotype A.	G		= 0.15	OR			
1183682029	rs4680	buprenorphine,dihydrocodeine,fentanyl,hydromorphone,methadone,oxycodone,piritramide,tilidine,tramadol	Dosage	no	Allele A is not associated with dose of buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, oxycodone, piritramide, tilidine or tramadol in people with Pain as compared to allele G.	A		= 0.58	OR			
1451351220	rs79910351	fentanyl,remifentanil	Efficacy	not stated	Genotype TT is associated with decreased response to fentanyl or remifentanil in children.							
1451351280	rs11322783	ribavirin,sofosbuvir	Efficacy	yes	Genotype TT/TT is associated with increased response to ribavirin and sofosbuvir in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.			= 0.028				
1451354882	rs2306283	atorvastatin,fluvastatin,lovastatin,pravastatin,simvastatin	Efficacy	no	Allele G is not associated with decreased response to atorvastatin, fluvastatin, lovastatin, pravastatin or simvastatin in people with Dyslipidaemia as compared to genotype AA.			> 0.05	OR			
1451354981	rs2306283	atorvastatin,simvastatin	Efficacy	no	Genotypes AG + GG are not associated with decreased response to atorvastatin or simvastatin as compared to genotype AA.			> 0.05				
1451354962	rs4149056	atorvastatin,simvastatin	Efficacy	no	Genotypes CC + CT are not associated with decreased response to atorvastatin or simvastatin as compared to genotype TT.			> 0.05				
1446904199	rs12979860	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b or ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	C	T	< 0.001	OR	3.12	1.72	5.67
1446904199	rs12979860	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b or ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	C	T	< 0.05	OR			
769251002	rs12979860	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype TT.	C	C	= 1.37E-28	OR	3.1	2.1	4.7
1444930897	rs12979860	daclatasvir,peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	not stated	Genotype CC is associated with increased response to daclatasvir, peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.				OR			
1444706780	rs12979860	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic and HIV Infections as compared to genotypes CT + TT.	C		= 0.002	OR	3.5	1.59	7.71
981478958	rs12979860	peginterferon alfa-2a,ribavirin	Efficacy	yes	Genotype CC is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C as compared to genotype TT.			< 0.05	Unknown			
1444665865	rs12979860	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin,telaprevir	Efficacy	yes	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to genotypes CT + TT.			= 0.0029	OR	2.94	1.44	5.99
1444665865	rs12979860	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin,telaprevir	Efficacy	yes	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to genotypes CT + TT.			< 0.01	OR			
827864542	rs9923231	phenprocoumon,warfarin	Dosage	yes	Genotype TT is associated with decreased dose of phenprocoumon or warfarin as compared to genotype CC.			= 0.011	Unknown			
1450372683	rs7905446	fluoxetine,paroxetine	Efficacy	yes	Genotype TT is associated with decreased response to fluoxetine or paroxetine in people with Bipolar Disorder as compared to genotypes GG + GT.			= 0.008	OR	2.883		
1448634666	rs1870377	carfilzomib,dexamethasone,lenalidomide	Efficacy	yes	Genotypes AT + TT is associated with increased response to carfilzomib, dexamethasone and lenalidomide in people with Multiple Myeloma as compared to genotype AA.	T	T	= 0.011	OR			
1446897938	rs1045642	cytarabine,daunorubicin,dexrazoxane	Efficacy	no	Genotype AA is not associated with response to cytarabine, daunorubicin and dexrazoxane in people with Leukemia, Myeloid, Acute as compared to genotypes AG + GG.	A		= 0.063	HR	0.651	0.414	1.023
1446897938	rs1045642	cytarabine,daunorubicin,dexrazoxane	Efficacy	no	Genotype AA is not associated with response to cytarabine, daunorubicin and dexrazoxane in people with Leukemia, Myeloid, Acute as compared to genotypes AG + GG.	A		= 0.237	HR	0.704	0.394	1.26
1448634646	rs833061	carfilzomib,dexamethasone,lenalidomide	Efficacy	yes	Genotypes CT + TT is associated with increased response to carfilzomib, dexamethasone and lenalidomide in people with Multiple Myeloma as compared to genotype CC.	C		= 0.009	OR	0.1	0.01	0.72
1448634646	rs833061	carfilzomib,dexamethasone,lenalidomide	Efficacy	yes	Genotypes CT + TT is associated with increased response to carfilzomib, dexamethasone and lenalidomide in people with Multiple Myeloma as compared to genotype CC.	C	C	= 0.023	OR			
1446897929	rs2032582	cytarabine,daunorubicin,dexrazoxane	Efficacy	no	Genotype AA is not associated with response to cytarabine, daunorubicin and dexrazoxane in people with Leukemia, Myeloid, Acute as compared to genotypes AC + CC.	A		= 0.096	HR	0.633	0.37	1.084
1446897929	rs2032582	cytarabine,daunorubicin,dexrazoxane	Efficacy	no	Genotype AA is not associated with response to cytarabine, daunorubicin and dexrazoxane in people with Leukemia, Myeloid, Acute as compared to genotypes AC + CC.	A		= 0.146	HR	0.736	0.486	1.113
1183701415	rs6883877	carbamazepine,gabapentin,lamotrigine,oxcarbazepine,phenytoin,topiramate,valproic acid	Efficacy	no	Genotype CT is not associated with increased response to carbamazepine, gabapentin, lamotrigine, oxcarbazepine, phenytoin, topiramate or valproic acid in people with Epilepsy as compared to genotype CC.			< 0.01	OR			
982044075	rs776746	atorvastatin,lovastatin,simvastatin	Efficacy	yes	Genotype CC is associated with increased response to atorvastatin, lovastatin or simvastatin in people with Arteriosclerosis as compared to genotype CT.	C		= 0.026	Unknown			
769245456	rs4244285	aspirin,clopidogrel	Efficacy	yes	Allele A is associated with decreased response to aspirin and clopidogrel in people with Coronary Artery Disease as compared to allele G.			= 0.01	Unknown			
769245459	rs12248560	aspirin,clopidogrel	Efficacy	no	Allele T is not associated with increased response to aspirin and clopidogrel in people with Coronary Artery Disease.			= 0.08	Unknown			
769245459	rs12248560	aspirin,clopidogrel	Efficacy	no	Allele T is not associated with increased response to aspirin and clopidogrel in people with Coronary Artery Disease.			= 0.25	Unknown			
769245468	rs12248560	aspirin,clopidogrel		yes	Allele T is associated with increased response to aspirin and clopidogrel in people with Coronary Artery Disease as compared to allele C.			= 0.016	Unknown			
1450928591	rs12041331	aspirin,clopidogrel,prasugrel	Efficacy	yes	Genotypes AA + AG are associated with increased response to aspirin, clopidogrel or prasugrel as compared to genotype GG.			< 0.00001				
1450928591	rs12041331	aspirin,clopidogrel,prasugrel	Efficacy	yes	Genotypes AA + AG are associated with increased response to aspirin, clopidogrel or prasugrel as compared to genotype GG.			< 0.00001				
1450928591	rs12041331	aspirin,clopidogrel,prasugrel	Efficacy	yes	Genotypes AA + AG are associated with increased response to aspirin, clopidogrel or prasugrel as compared to genotype GG.			< 0.00001				
1183701468	rs1112122	carbamazepine,gabapentin,lamotrigine,oxcarbazepine,phenytoin,topiramate,valproic acid	Efficacy	no	Genotype GG is not associated with response to carbamazepine, gabapentin, lamotrigine, oxcarbazepine, phenytoin, topiramate or valproic acid in people with Epilepsy as compared to genotype TT.			< 0.04	OR			
1183701456	rs1157122	carbamazepine,gabapentin,lamotrigine,oxcarbazepine,phenytoin,topiramate,valproic acid	Efficacy	no	Genotype CC is not associated with response to carbamazepine, gabapentin, lamotrigine, oxcarbazepine, phenytoin, topiramate or valproic acid in people with Epilepsy as compared to genotype TT.			< 0.02	OR			
1183701464	rs10068980	carbamazepine,gabapentin,lamotrigine,oxcarbazepine,phenytoin,topiramate,valproic acid	Efficacy	no	Genotype AA is not associated with response to carbamazepine, gabapentin, lamotrigine, oxcarbazepine, phenytoin, topiramate or valproic acid in people with Epilepsy as compared to genotype GG.			< 0.02	OR			
1183701460	rs6892782	carbamazepine,gabapentin,lamotrigine,oxcarbazepine,phenytoin,topiramate,valproic acid	Efficacy	no	Genotype CC is not associated with response to carbamazepine, gabapentin, lamotrigine, oxcarbazepine, phenytoin, topiramate or valproic acid in people with Epilepsy as compared to genotype TT.			< 0.01	OR			
1183701441	rs4828696	carbamazepine,gabapentin,lamotrigine,oxcarbazepine,phenytoin,topiramate,valproic acid	Efficacy	no	Genotype TT is not associated with increased response to carbamazepine, gabapentin, lamotrigine, oxcarbazepine, phenytoin, topiramate or valproic acid in people with Epilepsy as compared to genotype CC.			< 0.01	OR			
1183701437	rs511310	carbamazepine,gabapentin,lamotrigine,oxcarbazepine,phenytoin,topiramate,valproic acid	Efficacy	no	Genotype GG is not associated with decreased response to carbamazepine, gabapentin, lamotrigine, oxcarbazepine, phenytoin, topiramate or valproic acid in people with Epilepsy as compared to genotype AA.			< 0.01	OR			
982044093	rs776746	fluvastatin,pravastatin	Efficacy	no	Genotype CC is not associated with increased response to fluvastatin or pravastatin in people with Arteriosclerosis as compared to genotype CT.	C		= 0.99	Unknown			
1448519749	rs1045642	fluorouracil,irinotecan,oxaliplatin	Efficacy	no	Genotype GG is not associated with response to fluorouracil, irinotecan or oxaliplatin in people with Colorectal Neoplasms as compared to genotypes AA + AG.	A		> 0.01	OR			
1451338240	rs11322783	ribavirin,sofosbuvir	Efficacy	yes	Genotype GG is associated with decreased response to ribavirin and sofosbuvir in people with Hepatitis C, Chronic as compared to genotypes G/TT + TT/TT.			= 0.048	OR			
1184471715	rs4244285	aspirin,clopidogrel	Efficacy	yes	Genotypes AA + AG is associated with decreased response to aspirin and clopidogrel in people with percutaneous coronary interventions and drug-eluting stents as compared to genotype GG.	A		= 0.047	OR	3.43	1.01	12.78
1184471715	rs4244285	aspirin,clopidogrel	Efficacy	yes	Genotypes AA + AG is associated with decreased response to aspirin and clopidogrel in people with percutaneous coronary interventions and drug-eluting stents as compared to genotype GG.	A		= 0.049	OR	2.7	1.0	8.42
1450928783	rs2036527	bupropion,nicotine,varenicline	Efficacy	no	Allele A is not associated with response to bupropion, nicotine or varenicline in men with Tobacco Use Disorder as compared to allele G.			= 0.53				
1450928789	rs2472553	bupropion,nicotine,varenicline	Efficacy	no	Allele A is not associated with response to bupropion, nicotine or varenicline in people with Tobacco Use Disorder as compared to allele G.			= 0.19				
1450928789	rs2472553	bupropion,nicotine,varenicline	Efficacy	no	Allele A is not associated with response to bupropion, nicotine or varenicline in people with Tobacco Use Disorder as compared to allele G.			= 0.26				
1450928789	rs2472553	bupropion,nicotine,varenicline	Efficacy	no	Allele A is not associated with response to bupropion, nicotine or varenicline in people with Tobacco Use Disorder as compared to allele G.	A		= 0.42	OR	1.17	0.81	1.69
1450928798	rs1051730	bupropion,nicotine,varenicline	Efficacy	no	Allele A is not associated with response to bupropion, nicotine or varenicline in people with Tobacco Use Disorder as compared to allele G.			= 0.14				
1450928798	rs1051730	bupropion,nicotine,varenicline	Efficacy	no	Allele A is not associated with response to bupropion, nicotine or varenicline in people with Tobacco Use Disorder as compared to allele G.			= 0.52				
1450928798	rs1051730	bupropion,nicotine,varenicline	Efficacy	no	Allele A is not associated with response to bupropion, nicotine or varenicline in people with Tobacco Use Disorder as compared to allele G.	A		= 0.88	OR	1.02	0.75	1.4
1449192069	rs113993960	ivacaftor,lumacaftor	Efficacy	yes	Allele del is associated with response to ivacaftor and lumacaftor in people with Cystic Fibrosis.				OR			
1450928806	rs6474413	bupropion,nicotine,varenicline	Efficacy	no	Allele T is not associated with response to bupropion, nicotine or varenicline in people with Tobacco Use Disorder as compared to allele C.			= 0.64				
1450928806	rs6474413	bupropion,nicotine,varenicline	Efficacy	no	Allele T is not associated with response to bupropion, nicotine or varenicline in people with Tobacco Use Disorder as compared to allele C.			= 0.67				
1450928806	rs6474413	bupropion,nicotine,varenicline	Efficacy	no	Allele T is not associated with response to bupropion, nicotine or varenicline in people with Tobacco Use Disorder as compared to allele C.	C		= 1	OR	1.0	0.57	1.75
1450928764	rs2036527	bupropion,nicotine,varenicline	Efficacy	yes	Genotypes AA + AG are associated with increased response to bupropion, nicotine or varenicline in women with Tobacco Use Disorder as compared to genotype GG.			= 0.04	OR	1.59	1.02	2.48
1450928770	rs16969968	bupropion,nicotine,varenicline	Efficacy	yes	Genotypes AA + AG are associated with increased response to bupropion, nicotine or varenicline in women with Tobacco Use Disorder as compared to genotype GG.			= 0.03	OR	1.63	1.04	2.54
1450371727	CYP3A5 poor metabolizers and intermediate metabolizers	efavirenz,maraviroc	Efficacy	no	CYP3A5 poor metabolizers and intermediate metabolizers are not associated with response to efavirenz or maraviroc in people with HIV as compared to CYP3A5 normal metabolizers.				OR			
1450928777	rs16969968	bupropion,nicotine,varenicline	Efficacy	no	Allele A is not associated with response to bupropion, nicotine or varenicline in men with Tobacco Use Disorder as compared to genotype GG.			= 0.87				
1183685341	rs11807862	atorvastatin,hmg coa reductase inhibitors,simvastatin	Efficacy	no	Genotype AA is associated with decreased response to atorvastatin, hmg coa reductase inhibitors or simvastatin as compared to genotype TT.			= 1.13	OR			
1449192108	rs113993960	ivacaftor,lumacaftor	Efficacy	yes	Genotype del/del is associated with response to ivacaftor and lumacaftor in children with Cystic Fibrosis.			< 0.0001	OR			
769261461	rs3212948	fluorouracil,leucovorin,oxaliplatin	Efficacy	yes	Allele C is associated with increased response to fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotype GG.			= 0.02	Unknown			
1448995614	rs8099917	peginterferon alfa-2b,ribavirin	Efficacy	yes	Allele G is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to allele T.	G		= 2.59E-7	OR	1.77	1.42	2.2
1184471936	rs11479	capecitabine,fluorouracil	Dosage	yes	Genotypes AA + AG is associated with dose of capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype GG.	A	A	= 0.042	OR	2.02	1.03	4.0
1184471941	rs3918290	capecitabine,fluorouracil	Dosage	yes	Genotype CT is associated with dose of capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	T		= 0.026	OR	3.96	1.17	13.33
1184471949	rs75017182	capecitabine,fluorouracil	Dosage	yes	Genotype CG is associated with dose of capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype GG.	C		= 0.026	OR	3.96	1.17	13.33
1184471945	rs67376798	capecitabine,fluorouracil	Dosage	yes	Genotype AT is associated with dose of capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype TT.	A		= 0.026	OR	3.96	1.17	13.33
1449192342	rs80034486	ivacaftor,lumacaftor	Efficacy	not stated	Allele G is not associated with response to ivacaftor or lumacaftor.				OR			
1449192347	rs77932196	ivacaftor,lumacaftor	Efficacy	not stated	Allele G is not associated with response to ivacaftor or lumacaftor in people with Cystic Fibrosis.				OR			
1450814412	rs1801131	Vitamin B-complex, Incl. Combinations	Efficacy	yes	Allele G is associated with increased response to Vitamin B-complex, Incl. Combinations in people with Depressive Disorder, Major.			< 0.001				
1446897318	rs34548976	adrenergics, inhalants	Efficacy	yes	Allele T is associated with decreased response to adrenergics, inhalants in children with Asthma as compared to allele C.			< 8.8E-4	OR			
1446897254	rs9369421	carboplatin,taxanes	Efficacy	yes	Genotypes CC + CT are associated with increased response to carboplatin and taxanes in women with as compared to genotype TT.	C	T	= 0.012	HR	1.58		
1448568344	rs1695	bevacizumab,capecitabine,cisplatin,docetaxel,epirubicin,oxaliplatin,trastuzumab	Efficacy	no	Genotypes AA + AG are not associated with response to bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotype GG.			> 0.05	OR			
1449192520	rs113993960	ivacaftor,lumacaftor	Efficacy	no	Genotype CTT/del is not associated with response to ivacaftor and lumacaftor in people with Cystic Fibrosis.			< 0.26	OR			
1449192520	rs113993960	ivacaftor,lumacaftor	Efficacy	no	Genotype CTT/del is not associated with response to ivacaftor and lumacaftor in people with Cystic Fibrosis.			= 0.37	OR			
1449192520	rs113993960	ivacaftor,lumacaftor	Efficacy	no	Genotype CTT/del is not associated with response to ivacaftor and lumacaftor in people with Cystic Fibrosis.			= 0.60	OR			
1448257049	rs1801253	Beta Blocking Agents,flecainide	Efficacy	yes	Allele G is associated with decreased response to Beta Blocking Agents and flecainide in people with Tachycardia as compared to allele C.			= 0.001	OR			
1449192508	rs113993960	ivacaftor,lumacaftor	Efficacy	yes	Genotype CTT/del is associated with response to ivacaftor and lumacaftor in people with Cystic Fibrosis.			< 0.0001	OR			
1449192508	rs113993960	ivacaftor,lumacaftor	Efficacy	yes	Genotype CTT/del is associated with response to ivacaftor and lumacaftor in people with Cystic Fibrosis.			= 0.01	OR			
1448568317	rs13181	bevacizumab,capecitabine,cisplatin,docetaxel,epirubicin,oxaliplatin,trastuzumab	Efficacy	yes	Genotype GG is associated with increased response to bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotypes GT + TT.			= 0.031	OR	3.3	1.1	9.8
1448568311	rs1799793	bevacizumab,capecitabine,cisplatin,docetaxel,epirubicin,oxaliplatin,trastuzumab	Efficacy	no	Genotype CC is not associated with response to bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotypes CT + TT.			> 0.05	OR			
1448568304	rs11615	bevacizumab,capecitabine,cisplatin,docetaxel,epirubicin,oxaliplatin,trastuzumab	Efficacy	yes	Genotype GG is associated with decreased response to bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotypes AA + AG.			= 0.047	OR	1.7	1.0	3.1
1448568298	rs3212986	bevacizumab,capecitabine,cisplatin,docetaxel,epirubicin,oxaliplatin,trastuzumab	Efficacy	no	Genotype CC are not associated with response to bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotypes AA + AC.			> 0.05	OR			
1448568292	rs2072671	bevacizumab,capecitabine,cisplatin,docetaxel,epirubicin,oxaliplatin,trastuzumab	Efficacy	no	Genotypes AA + AC are not associated with response to bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotype CC.			> 0.05	OR			
1448568284	rs11479	bevacizumab,capecitabine,cisplatin,docetaxel,epirubicin,oxaliplatin,trastuzumab	Efficacy	no	Genotypes AA + AG are not associated with response to bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotype GG.			> 0.05	OR			
1448568276	rs1801133	bevacizumab,capecitabine,cisplatin,docetaxel,epirubicin,oxaliplatin,trastuzumab	Efficacy	yes	Genotype AA is associated with decreased response to bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotypes AG + GG.			= 0.04	OR	1.7	1.0	2.7
1448568276	rs1801133	bevacizumab,capecitabine,cisplatin,docetaxel,epirubicin,oxaliplatin,trastuzumab	Efficacy	yes	Genotype AA is associated with decreased response to bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotypes AG + GG.			= 0.041	OR	1.7	1.0	2.7
1449192588	rs113993960	ivacaftor,lumacaftor	Efficacy	yes	Genotype del/del is associated with response to ivacaftor and lumacaftor in people with Cystic Fibrosis.			< 0.05	OR			
1185002405	rs3772810	capecitabine,fluorouracil	Efficacy	no	Allele G is associated with decreased response to capecitabine and fluorouracil in people with Neoplasm Metastasis as compared to allele A.	A	A	= 0.036	OR			
1449192632	rs113993960	ivacaftor,lumacaftor	Efficacy	yes	Genotype del/del is associated with response to ivacaftor and lumacaftor in children with Cystic Fibrosis.			< 0.0001	OR			
1449192632	rs113993960	ivacaftor,lumacaftor	Efficacy	yes	Genotype del/del is associated with response to ivacaftor and lumacaftor in children with Cystic Fibrosis.			< 0.0001	OR			
1449192632	rs113993960	ivacaftor,lumacaftor	Efficacy	yes	Genotype del/del is associated with response to ivacaftor and lumacaftor in children with Cystic Fibrosis.			= 0.0018	OR			
1449192632	rs113993960	ivacaftor,lumacaftor	Efficacy	yes	Genotype del/del is associated with response to ivacaftor and lumacaftor in children with Cystic Fibrosis.			= 0.0085	OR			
1448568229	rs2612091	bevacizumab,capecitabine,cisplatin,docetaxel,epirubicin,oxaliplatin,trastuzumab	Efficacy	no	Genotype CC is not associated with response to bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotypes CT + TT.			> 0.05	OR			
1449192645	rs113993960	ivacaftor,lumacaftor	Efficacy	no	Genotype del/del is not associated with response to ivacaftor and lumacaftor in children with Cystic Fibrosis.			< 0.0671	OR			
1185002399	rs3772809	capecitabine,fluorouracil	Efficacy	no	Allele G is associated with decreased response to capecitabine and fluorouracil in people with Neoplasm Metastasis as compared to allele A.	A	A	= 0.036	OR			
1449192671	rs75527207	ivacaftor,tezacaftor	Efficacy	yes	Allele A is associated with response to ivacaftor and tezacaftor in people with Cystic Fibrosis.			< 0.05	OR			
1449192689	rs113993960	ivacaftor,lumacaftor	Efficacy	yes	Genotype del/del is associated with response to ivacaftor and lumacaftor in people with Cystic Fibrosis.			= 0.001	OR			
1449192689	rs113993960	ivacaftor,lumacaftor	Efficacy	yes	Genotype del/del is associated with response to ivacaftor and lumacaftor in people with Cystic Fibrosis.			< 0.001	OR			
1449192689	rs113993960	ivacaftor,lumacaftor	Efficacy	yes	Genotype del/del is associated with response to ivacaftor and lumacaftor in people with Cystic Fibrosis.			< 0.001	OR			
1449192689	rs113993960	ivacaftor,lumacaftor	Efficacy	yes	Genotype del/del is associated with response to ivacaftor and lumacaftor in people with Cystic Fibrosis.			= 0.005	OR			
1449192689	rs113993960	ivacaftor,lumacaftor	Efficacy	yes	Genotype del/del is associated with response to ivacaftor and lumacaftor in people with Cystic Fibrosis.			= 0.011	OR			
1444706410	rs12979860	peginterferon alfa-2b,ribavirin	Efficacy	no	Genotype TT is not associated with response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic.	T		= 2.47E-5	OR			
1449192749	rs113993960	ivacaftor,lumacaftor	Efficacy	yes	Genotype del/del is associated with response to ivacaftor and lumacaftor in men with Cystic Fibrosis.			= 0.0003	OR			
1449192749	rs113993960	ivacaftor,lumacaftor	Efficacy	yes	Genotype del/del is associated with response to ivacaftor and lumacaftor in men with Cystic Fibrosis.			= 0.031	OR			
1449192749	rs113993960	ivacaftor,lumacaftor	Efficacy	yes	Genotype del/del is associated with response to ivacaftor and lumacaftor in men with Cystic Fibrosis.			= 0.072	OR			
1449192749	rs113993960	ivacaftor,lumacaftor	Efficacy	yes	Genotype del/del is associated with response to ivacaftor and lumacaftor in men with Cystic Fibrosis.			= 0.149	OR			
1449192749	rs113993960	ivacaftor,lumacaftor	Efficacy	yes	Genotype del/del is associated with response to ivacaftor and lumacaftor in men with Cystic Fibrosis.			= 0.218	OR			
1449192749	rs113993960	ivacaftor,lumacaftor	Efficacy	yes	Genotype del/del is associated with response to ivacaftor and lumacaftor in men with Cystic Fibrosis.			= 0.220	OR			
1449192749	rs113993960	ivacaftor,lumacaftor	Efficacy	yes	Genotype del/del is associated with response to ivacaftor and lumacaftor in men with Cystic Fibrosis.			= 0.292	OR			
769146005	rs1045642	carbamazepine,phenobarbital,phenytoin,valproic acid	Efficacy	no	Allele A is not associated with increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele G.				Unknown			
1447679211	rs7094248	donepezil,galantamine,rivastigmine	Efficacy	no	Allele G is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele C.	C	C	= 1	OR			
769146001	rs2032582	carbamazepine,phenobarbital,phenytoin,valproic acid	Efficacy	no	Allele C is not associated with increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele T.				Unknown			
769145998	rs1128503	carbamazepine,phenobarbital,phenytoin,valproic acid	Efficacy	no	Allele A is not associated with increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele G.				Unknown			
1447679196	rs1917818	donepezil,galantamine,rivastigmine	Efficacy	no	Allele G is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele T.	G	G	= 1	OR			
1447679203	rs11101192	donepezil,galantamine,rivastigmine	Efficacy	no	Allele G is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele A.	A	A	= 1	OR			
1447679245	rs12264845	donepezil,galantamine,rivastigmine	Efficacy	no	Allele C is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele A.	A	A	= 1	OR			
1447679252	rs7076926	donepezil,galantamine,rivastigmine	Efficacy	no	Allele C is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele T.	C	C	= 1	OR			
1447679224	rs3793797	donepezil,galantamine,rivastigmine	Efficacy	no	Allele C is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele T.	C	C	= 1	OR			
1447679234	rs10776586	donepezil,galantamine,rivastigmine	Efficacy	no	Allele C is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele T.	C	C	= 1	OR			
1183554747	rs7921977	docetaxel,gemcitabine,paclitaxel,Platinum compounds,vinorelbine	Efficacy	no	Genotype CC is not associated with response to docetaxel, gemcitabine, paclitaxel, Platinum compounds or vinorelbine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.	T		= 0.480	HR	0.8	0.42	1.5
1446896983	rs4149056	simvastatin,simvastatin acid	Metabolism/PK	yes	Allele C is associated with increased concentrations of simvastatin and simvastatin acid in people with Hypercholesterolemia as compared to allele T.	C	T	< 0.001	OR			
1447679019	rs11101187	donepezil,galantamine,rivastigmine	Efficacy	no	Allele C is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele T.	C	C	= 1	OR			
1446765748	rs2279343	bupropion,varenicline	Efficacy	no	Genotype AA is not associated with response to bupropion and varenicline in people with Tobacco Use Disorder as compared to genotypes AG + GG.	A	G	= 0.13	OR			
1446765748	rs2279343	bupropion,varenicline	Efficacy	no	Genotype AA is not associated with response to bupropion and varenicline in people with Tobacco Use Disorder as compared to genotypes AG + GG.	A	G	= 0.73	OR			
1446765748	rs2279343	bupropion,varenicline	Efficacy	no	Genotype AA is not associated with response to bupropion and varenicline in people with Tobacco Use Disorder as compared to genotypes AG + GG.	A	G	= 0.98	OR			
1447679025	rs3793791	donepezil,galantamine,rivastigmine	Efficacy	no	Allele C is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele T.	C	C	= 1	OR			
1447678999	rs4838391	donepezil,galantamine,rivastigmine	Efficacy	no	Allele C is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele T.	C	C	= 1	OR			
1444930780	rs12979860	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin,simeprevir	Efficacy	not stated	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin and simeprevir in people with Hepatitis C as compared to genotypes CT + TT.				OR			
1447679013	rs12246528	donepezil,galantamine,rivastigmine	Efficacy	no	Allele G is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele A.	A	A	= 1	OR			
1444668546	rs12979860	interferon alfa-2a, recombinant,interferon alfa-2b, recombinant,ribavirin	Efficacy	yes	Genotype CC is associated with increased response to interferon alfa-2a, recombinant, interferon alfa-2b, recombinant and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.			= 0.0001	OR	2.39	1.19	3.81
981502435	rs9923231	acenocoumarol,warfarin	Efficacy	yes	Genotypes CC + CT are associated with increased dose of acenocoumarol or warfarin as compared to genotype TT.	T		< 0.001	Unknown			
982043114	rs5370	atenolol,irbesartan	Efficacy	no	Genotype GT is not associated with response to atenolol and irbesartan in men with Essential hypertension as compared to genotype GG.	G		= 0.12	Unknown			
981502399	rs2228145	adalimumab,etanercept,infliximab,Tumor necrosis factor alpha (TNF-alpha) inhibitors	Efficacy	no	Allele A is not associated with response to adalimumab, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele C.	C			Unknown			
1444930731	rs12979860	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin,simeprevir	Efficacy	not stated	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin and simeprevir in people with Hepatitis C, Chronic as compared to genotypes CT + TT.				OR			
1444668581	rs9939609	interferon alfa-2a, recombinant,interferon alfa-2b, recombinant,ribavirin	Efficacy	yes	Genotypes AA + AT is associated with decreased response to interferon alfa-2a, recombinant, interferon alfa-2b, recombinant and ribavirin in people with Hepatitis C, Chronic and HIV Infections as compared to genotype TT.			= 0.044	OR	0.58	0.34	0.99
1444707037	rs11322783	peginterferon alfa-2b,ribavirin	Efficacy	no	Genotype TT/TT is not associated with response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.	TT		= 0.093	OR	1.514	0.933	2.458
1449160191	rs168924	3,4-methylenedioxymethamphetamine	Other	no	Allele G is not associated with response to 3,4-methylenedioxymethamphetamine as compared to allele A.	A	G	> 0.05	OR			
1449160191	rs168924	3,4-methylenedioxymethamphetamine	Other	no	Allele G is not associated with response to 3,4-methylenedioxymethamphetamine as compared to allele A.	A	G	> 0.05	OR			
1449160191	rs168924	3,4-methylenedioxymethamphetamine	Other	no	Allele G is not associated with response to 3,4-methylenedioxymethamphetamine as compared to allele A.	A	A	> 0.05	OR			
1450372589	rs6166	follitropin beta,urofollitropin	Toxicity	not stated	Allele T is associated with increased response to follitropin beta or urofollitropin as compared to allele C.			= 0.04	OR	1.7	1.0	2.8
1447679044	rs12266458	donepezil,galantamine,rivastigmine	Efficacy	no	Allele C is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele T.	C	C	= 1	OR			
1444668491	rs12979860	interferon alfa-2a, recombinant,interferon alfa-2b, recombinant,ribavirin	Efficacy	yes	Genotype CC is associated with increased response to interferon alfa-2a, recombinant, interferon alfa-2b, recombinant and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.			= 0.001	OR	13.48	2.95	61.69
1444668499	rs8099917	interferon alfa-2a, recombinant,interferon alfa-2b, recombinant,ribavirin	Efficacy	yes	Genotype TT is associated with increased response to interferon alfa-2a, recombinant, interferon alfa-2b, recombinant and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.			= 0.027	OR	7.5	1.25	44.88
982043126	rs5370	atenolol,irbesartan	Efficacy	yes	Genotypes GT + TT are not associated with response to atenolol and irbesartan in women with Essential hypertension as compared to genotype GG.	G		= 0.12	Unknown			
982043126	rs5370	atenolol,irbesartan	Efficacy	yes	Genotypes GT + TT are not associated with response to atenolol and irbesartan in women with Essential hypertension as compared to genotype GG.	G		= 0.28	Unknown			
1449160206	rs47958	3,4-methylenedioxymethamphetamine	Other	no	Allele C is not associated with response to 3,4-methylenedioxymethamphetamine as compared to allele A.	A	A	> 0.05	OR			
1449160206	rs47958	3,4-methylenedioxymethamphetamine	Other	no	Allele C is not associated with response to 3,4-methylenedioxymethamphetamine as compared to allele A.	A	A	> 0.05	OR			
1449160206	rs47958	3,4-methylenedioxymethamphetamine	Other	no	Allele C is not associated with response to 3,4-methylenedioxymethamphetamine as compared to allele A.	A	A	> 0.05	OR			
1449160218	rs1861647	3,4-methylenedioxymethamphetamine	Other	yes	Genotype GG is associated with increased response to 3,4-methylenedioxymethamphetamine as compared to genotypes AA + AG.	A	G	= 0.045	OR			
1449160218	rs1861647	3,4-methylenedioxymethamphetamine	Other	yes	Genotype GG is associated with increased response to 3,4-methylenedioxymethamphetamine as compared to genotypes AA + AG.	A	G	> 0.05	OR			
1449160218	rs1861647	3,4-methylenedioxymethamphetamine	Other	yes	Genotype GG is associated with increased response to 3,4-methylenedioxymethamphetamine as compared to genotypes AA + AG.	A	G	> 0.05	OR			
1449160225	rs2242446	3,4-methylenedioxymethamphetamine	Other	yes	Genotype TT are associated with decreased response to 3,4-methylenedioxymethamphetamine as compared to genotypes CC + CT.	C	C	= 0.038	OR			
1449160225	rs2242446	3,4-methylenedioxymethamphetamine	Other	yes	Genotype TT are associated with decreased response to 3,4-methylenedioxymethamphetamine as compared to genotypes CC + CT.	C	C	> 0.05	OR			
1449160225	rs2242446	3,4-methylenedioxymethamphetamine	Other	yes	Genotype TT are associated with decreased response to 3,4-methylenedioxymethamphetamine as compared to genotypes CC + CT.	C	C	> 0.05	OR			
1444668429	rs1800629	adalimumab,etanercept,infliximab	Efficacy	yes	Genotype GG is associated with increased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to genotypes AA + AG.	A		< 0.0001	OR			
1450372702	rs7905446	atomoxetine,desvenlafaxine,duloxetine,Selective serotonin reuptake inhibitors,venlafaxine	Efficacy	yes	Genotype TT is associated with decreased response to atomoxetine, desvenlafaxine, duloxetine, Selective serotonin reuptake inhibitors or venlafaxine in people with Depression as compared to genotypes GG + GT.			= 0.044	OR	1.46		
1444668437	rs1800629	adalimumab,infliximab	Efficacy	yes	Genotype GG is associated with increased response to adalimumab or infliximab in people with Spondylitis, Ankylosing as compared to genotype AG.	A		< 0.005	OR			
1450372728	rs7905446	escitalopram,nortriptyline	Efficacy	no	Genotype TT is not associated with response to escitalopram or nortriptyline in people with Depression as compared to genotypes GG + GT.			= 0.390	OR	1.141		
1183620738	CYP2C19*1	famotidine,rabeprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to famotidine and rabeprazole in healthy individuals.	*1		= 0.05	Unknown			
1183620738	CYP2C19*1	famotidine,rabeprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to famotidine and rabeprazole in healthy individuals.	*1		= 0.150	Unknown			
1183702665	rs8191992	fluticasone/salmeterol	Efficacy	yes	Allele A is associated with response to fluticasone/salmeterol in people with Asthma as compared to allele T.			< 0.05	OR			
981502673	rs2227310	paclitaxel,Platinum compounds	Efficacy	yes	Genotypes CG + GG are associated with increased response to paclitaxel and Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.			= 0.008	HR	0.6	0.41	0.87
1444706639	rs10877012	peginterferon alfa-2b,ribavirin	Efficacy	no	Allele T is not associated with response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic.	T		= 0.218	OR	0.65	0.327	1.29
982043371	rs1799752	enalapril,losartan	Efficacy	yes	Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with increased response to enalapril and losartan in men with Coronary Disease as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del.	del		= 0.02	Unknown			
982043371	rs1799752	enalapril,losartan	Efficacy	yes	Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with increased response to enalapril and losartan in men with Coronary Disease as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del.	del		= 0.024	Unknown			
981502687	rs1127687	paclitaxel,Platinum compounds	Efficacy	yes	Genotypes AA + AG are associated with decreased response to paclitaxel and Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.			= 0.041	HR	1.48	1.02	2.16
981502697	rs1127687	gemcitabine,Platinum compounds	Efficacy	yes	Genotypes AA + AG are associated with decreased response to gemcitabine and Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.			= 0.034	HR	1.55	1.03	2.32
981502641	rs12415607	paclitaxel,Platinum compounds	Efficacy	yes	Genotypes AA + AC are associated with increased response to paclitaxel and Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.			= 0.01	HR	0.61	0.42	0.89
981502647	rs12415607	gemcitabine,Platinum compounds	Efficacy	no	Genotypes AA + AC are not associated with response to gemcitabine and Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.			= 0.092	HR	0.69	0.45	1.06
1447678993	rs3810950	donepezil,galantamine,rivastigmine	Efficacy	no	Allele G is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele A.	A	A	= 1	OR			
981502653	rs4353229	paclitaxel,Platinum compounds	Efficacy	yes	Genotypes CC + CT are associated with increased response to paclitaxel and Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.			= 0.004	HR	0.58	0.39	0.84
981502663	rs4353229	gemcitabine,Platinum compounds	Efficacy	no	Genotypes CC + CT are not associated with response to gemcitabine and Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.			= 0.048	HR	0.65	0.42	1.0
1447679275	rs3793800	donepezil,galantamine,rivastigmine	Efficacy	no	Allele A is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele G.	A	A	= 1	OR			
1447682840	rs116855232	azathioprine,mercaptopurine	Metabolism/PK	no	Genotypes CT + TT is not associated with metabolism of azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to genotype CC.	C			OR			
1447679282	rs3793801	donepezil,galantamine,rivastigmine	Efficacy	no	Allele C is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele T.	C	C	= 1	OR			
981501273	rs12979860	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Dosage,Efficacy	no	Allele C is not associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b or ribavirin in people with Hepatitis C, Chronic as compared to allele T.	C			OR			
1447944960	rs396991	adalimumab,etanercept,infliximab,Tumor necrosis factor alpha (TNF-alpha) inhibitors	Efficacy	no	Genotype CC is not associated with response to adalimumab, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to genotypes AA + AC.			= 0.5	OR			
981500787	rs1360780	citalopram,fluoxetine,mirtazapine,paroxetine,Selective serotonin reuptake inhibitors,venlafaxine	Efficacy	no	Allele T is not associated with increased response to citalopram, fluoxetine, mirtazapine, paroxetine, Selective serotonin reuptake inhibitors or venlafaxine in people with Mood Disorders as compared to allele C.			= 0.36	OR	1.15	0.85	1.56
981500787	rs1360780	citalopram,fluoxetine,mirtazapine,paroxetine,Selective serotonin reuptake inhibitors,venlafaxine	Efficacy	no	Allele T is not associated with increased response to citalopram, fluoxetine, mirtazapine, paroxetine, Selective serotonin reuptake inhibitors or venlafaxine in people with Mood Disorders as compared to allele C.			= 0.68	OR	1.05	0.82	1.35
1447944951	rs1050501	adalimumab,etanercept,infliximab,Tumor necrosis factor alpha (TNF-alpha) inhibitors	Efficacy	no	Genotypes CC + CT is associated with increased response to adalimumab, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to genotype TT.			= 0.03	OR			
1444930241	rs16969968	nicotine,varenicline	Efficacy	no	Genotype GG is not associated with response to nicotine or varenicline in people with Tobacco Use Disorder as compared to genotypes AA + AG.	A	G	= 0.36	OR	1.3		
1444930241	rs16969968	nicotine,varenicline	Efficacy	no	Genotype GG is not associated with response to nicotine or varenicline in people with Tobacco Use Disorder as compared to genotypes AA + AG.	A	G	= 0.99	OR	1.01		
1447679267	rs3793798	donepezil,galantamine,rivastigmine	Efficacy	no	Allele A is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele T.	A	A	= 1	OR			
1444930247	rs588765	nicotine,varenicline	Efficacy	no	Genotype TT is not associated with response to nicotine or varenicline in people with Tobacco Use Disorder as compared to genotypes CC + CT.	C	T	= 0.29	OR	0.74		
1444930247	rs588765	nicotine,varenicline	Efficacy	no	Genotype TT is not associated with response to nicotine or varenicline in people with Tobacco Use Disorder as compared to genotypes CC + CT.	C	T	= 0.58	OR	0.84		
1447813823	rs3025033	anthracyclines and related substances,bevacizumab,cyclophosphamide,docetaxel,epirubicin,taxanes	Efficacy	no	Allele G is not associated with response to anthracyclines and related substances, bevacizumab, cyclophosphamide, docetaxel, epirubicin and taxanes in women with Breast Neoplasms as compared to allele A.	G	A	= 0.074	OR	1.68	1.17	2.41
1444930252	rs578776	nicotine,varenicline	Efficacy	no	Genotype GG is not associated with response to nicotine or varenicline in people with Tobacco Use Disorder as compared to genotypes AA + AG.	A	G	= 0.35	OR	0.75		
1444930252	rs578776	nicotine,varenicline	Efficacy	no	Genotype GG is not associated with response to nicotine or varenicline in people with Tobacco Use Disorder as compared to genotypes AA + AG.	A	G	= 0.51	OR	1.2		
1447679311	rs11685873	donepezil,galantamine,rivastigmine	Efficacy	no	Allele G is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele A.	A	A	= 1	OR			
1447679290	rs6542746	donepezil,galantamine,rivastigmine	Efficacy	no	Allele C is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele T.	C	C	= 1	OR			
1447682735	rs116855232	azathioprine,mercaptopurine	Dosage	yes	Genotype CT is associated with decreased dose of azathioprine and mercaptopurine in people with Inflammatory Bowel Diseases as compared to genotype CC.	C		= 6.21E-4	OR			
1447813811	rs3768728	anthracyclines and related substances,bevacizumab,cyclophosphamide,docetaxel,epirubicin,taxanes	Efficacy	no	Allele C is not associated with response to anthracyclines and related substances, bevacizumab, cyclophosphamide, docetaxel, epirubicin and taxanes in women with Breast Neoplasms as compared to allele T.	C	T	= 0.067	OR	1.61	1.14	2.27
1447679299	rs6720783	donepezil,galantamine,rivastigmine	Efficacy	no	Allele G is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele T.	G	G	= 1	OR			
1183620980	rs1045642	omeprazole,pantoprazole	Efficacy	yes	Genotype AA is associated with increased response to omeprazole or pantoprazole in people with Helicobacter Infections as compared to genotypes AG + GG.	G		= 0.05	OR	5.78	1.48	22.62
1447813817	rs1374749	anthracyclines and related substances,bevacizumab,cyclophosphamide,docetaxel,epirubicin,taxanes	Efficacy	no	Allele A is not associated with response to anthracyclines and related substances, bevacizumab, cyclophosphamide, docetaxel, epirubicin and taxanes in women with Breast Neoplasms as compared to allele G.	A	G	= 0.073	OR	1.88	1.16	3.03
1447682726	rs116855232	azathioprine,mercaptopurine	Toxicity	yes	Genotype CT is associated with increased discontinuation of azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to genotype CC.	C		= 1.45E-4	OR			
1447813803	rs4953344	anthracyclines and related substances,bevacizumab,cyclophosphamide,docetaxel,epirubicin,taxanes	Efficacy	no	Allele C is not associated with response to anthracyclines and related substances, bevacizumab, cyclophosphamide, docetaxel, epirubicin and taxanes in women with Breast Neoplasms as compared to allele T.	C	T	= 0.058	OR	1.65	1.15	2.35
1447813757	rs3025030	anthracyclines and related substances,bevacizumab,cyclophosphamide,docetaxel,epirubicin,taxanes	Efficacy	no	Allele C is not associated with response to anthracyclines and related substances, bevacizumab, cyclophosphamide, docetaxel, epirubicin and taxanes in women with Breast Neoplasms as compared to allele G.	G	C	= 0.041	OR	1.72	1.2	2.45
1447813768	rs7995976	anthracyclines and related substances,bevacizumab,cyclophosphamide,docetaxel,epirubicin,taxanes	Efficacy	no	Allele A is not associated with response to anthracyclines and related substances, bevacizumab, cyclophosphamide, docetaxel, epirubicin and taxanes in women with Breast Neoplasms as compared to allele C.	A	C	= 0.049	OR	1.06	0.72	1.56
1447813745	rs699947	anthracyclines and related substances,bevacizumab,cyclophosphamide,docetaxel,epirubicin,taxanes	Efficacy	no	Allele C is not associated with response to anthracyclines and related substances, bevacizumab, cyclophosphamide, docetaxel, epirubicin and taxanes in women with Breast Neoplasms as compared to allele A.	A	A	= 0.032	OR	2.24	1.31	3.84
1447813751	rs3025039	anthracyclines and related substances,bevacizumab,cyclophosphamide,docetaxel,epirubicin,taxanes	Efficacy	no	Allele T is not associated with response to anthracyclines and related substances, bevacizumab, cyclophosphamide, docetaxel, epirubicin and taxanes in women with Breast Neoplasms as compared to allele C.	T	C	= 0.040	OR	1.71	1.2	2.44
1449717828	CYP2C19 poor metabolizer phenotype	citalopram,escitalopram	Efficacy	yes	CYP2C19 poor metabolizer phenotype is associated with increased response to citalopram or escitalopram in people with Depressive Disorder, Major as compared to CYP2C19 normal metabolizer phenotype.			= 0.00025	OR	1.55	1.23	1.96
1449717828	CYP2C19 poor metabolizer phenotype	citalopram,escitalopram	Efficacy	yes	CYP2C19 poor metabolizer phenotype is associated with increased response to citalopram or escitalopram in people with Depressive Disorder, Major as compared to CYP2C19 normal metabolizer phenotype.			= 0.00037	Unknown	0.43	0.19	0.66
1447682497	rs12944940	boceprevir,peginterferon alfa-2a,peginterferon alfa-2b,ribavirin,telaprevir	Efficacy	no	Allele T is not associated with increased response to boceprevir, peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to allele C.			= 0.98	OR	1.01	0.64	1.57
1449717924	rs1799971	Opioid anesthetics,Other general anesthetics,volatile anesthetics	Efficacy	yes	Genotype GG is associated with increased response to Opioid anesthetics, Other general anesthetics or volatile anesthetics as compared to genotypes AA + AG.	G		< 0.001	OR			
1447682504	rs10048158	boceprevir,peginterferon alfa-2a,peginterferon alfa-2b,ribavirin,telaprevir	Efficacy	no	Allele C is not associated with increased response to boceprevir, peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to allele T.			= 0.84	OR	0.96	0.68	1.36
1449717930	rs2231142	Opioid anesthetics,Other general anesthetics,volatile anesthetics	Efficacy	yes	Genotype TT is associated with increased response to Opioid anesthetics, Other general anesthetics or volatile anesthetics as compared to genotypes GG + GT.	T		< 0.001	OR			
1447682476	rs1801689	boceprevir,peginterferon alfa-2a,peginterferon alfa-2b,ribavirin,telaprevir	Efficacy	no	Allele A is not associated with increased response to boceprevir, peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to allele C.			= 0.35	OR	0.65	0.26	1.61
1447682483	rs52797880	boceprevir,peginterferon alfa-2a,peginterferon alfa-2b,ribavirin,telaprevir	Efficacy	no	Allele A is not associated with increased response to boceprevir, peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to allele G.			= 0.33	OR	1.4	0.71	2.94
1447682490	rs8178822	boceprevir,peginterferon alfa-2a,peginterferon alfa-2b,ribavirin,telaprevir	Efficacy	no	Allele G is not associated with increased response to boceprevir, peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to allele T.			= 0.43	OR	1.31	0.67	2.57
1447682467	rs1801690	boceprevir,peginterferon alfa-2a,peginterferon alfa-2b,ribavirin,telaprevir	Efficacy	no	Allele C is not associated with increased response to boceprevir, peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to allele G.			= 0.28	OR	1.47	0.73	2.96
1183703247	rs6962027	fluticasone/salmeterol	Efficacy	yes	Allele A is associated with response to fluticasone/salmeterol in people with Asthma as compared to allele T.			< 0.05	OR			
1447682452	rs12979860	boceprevir,peginterferon alfa-2a,peginterferon alfa-2b,ribavirin,telaprevir	Efficacy	yes	Allele C is associated with increased response to boceprevir, peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to allele T.			= 2e-4	OR	2.35	1.5	3.7
1183703276	rs6962027	fluticasone/salmeterol	Efficacy	yes	Allele A is associated with response to fluticasone/salmeterol in people with Asthma as compared to allele T.			< 0.05	OR			
1183699283	rs1800795	adalimumab,etanercept,infliximab	Efficacy	yes	Allele G is associated with increased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to allele C.			< 0.05	OR			
1451106720	rs1042714	atenolol,metoprolol	Efficacy	yes	Genotype CC is associated with increased response to atenolol or metoprolol in people with Tachycardia as compared to genotypes CG + GG.			= 0.0003				
1451106720	rs1042714	atenolol,metoprolol	Efficacy	yes	Genotype CC is associated with increased response to atenolol or metoprolol in people with Tachycardia as compared to genotypes CG + GG.	C		= 0.0007				
1451106720	rs1042714	atenolol,metoprolol	Efficacy	yes	Genotype CC is associated with increased response to atenolol or metoprolol in people with Tachycardia as compared to genotypes CG + GG.	C		= 0.01				
1451106720	rs1042714	atenolol,metoprolol	Efficacy	yes	Genotype CC is associated with increased response to atenolol or metoprolol in people with Tachycardia as compared to genotypes CG + GG.	C		= 0.23				
1451405702	CYP2D6 poor metabolizer and intermediate metabolizer genotypes	noroxycodone,oxycodone	Metabolism/PK	yes	CYP2D6 poor metabolizer and intermediate metabolizer genotypes are associated with increased concentrations of noroxycodone or oxycodone as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer genotypes.			= 0.020				
1451405702	CYP2D6 poor metabolizer and intermediate metabolizer genotypes	noroxycodone,oxycodone	Metabolism/PK	yes	CYP2D6 poor metabolizer and intermediate metabolizer genotypes are associated with increased concentrations of noroxycodone or oxycodone as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer genotypes.			= 0.024				
1451405760	CYP2D6 poor metabolizer and intermediate metabolizer genotypes	noroxymorphone,oxymorphone	Metabolism/PK	no	CYP2D6 poor metabolizer and intermediate metabolizer genotypes are not associated with concentrations of noroxymorphone or oxymorphone as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer genotypes.							
981501391	rs12979860	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	C		< 0.001	OR	8.0	3.1	21.0
981501391	rs12979860	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	C		= 0.002	OR	3.7	1.6	8.5
982042071	rs1799752	benazepril,perindopril	Efficacy	yes	Genotype del/del is associated with increased response to benazepril or perindopril in people with Diabetes Mellitus as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	del		< 0.05	Unknown			
982009266	rs1137617	atenolol,bisoprolol,celiprolol,doxazosin	Efficacy	not stated	Genotype GG is associated with response to atenolol, bisoprolol, Celiprolol or doxazosin in people with Essential hypertension as compared to genotypes AA + AG.	A			Unknown			
1184747986	rs6494223	donepezil,galantamine,rivastigmine	Efficacy	yes	Allele T is associated with increased response to donepezil, galantamine and rivastigmine in people with Alzheimer Disease as compared to allele C.	C		= 0.049	OR	1.894	1.003	3.578
1183699550	rs396991	adalimumab,etanercept,infliximab	Efficacy	yes	Genotype AA is associated with decreased response to adalimumab, etanercept or infliximab in people with Psoriasis as compared to genotypes AC + CC.	A		= 0.02	OR			
1183699550	rs396991	adalimumab,etanercept,infliximab	Efficacy	yes	Genotype AA is associated with decreased response to adalimumab, etanercept or infliximab in people with Psoriasis as compared to genotypes AC + CC.	A		= 0.30	OR			
1183699550	rs396991	adalimumab,etanercept,infliximab	Efficacy	yes	Genotype AA is associated with decreased response to adalimumab, etanercept or infliximab in people with Psoriasis as compared to genotypes AC + CC.	A		= 0.90	OR			
1183699556	rs396991	adalimumab,etanercept,infliximab	Efficacy	no	Genotype AA is not associated with response to adalimumab, etanercept or infliximab in people with Psoriasis as compared to genotypes AC + CC.	A		= 0.13	OR			
1183699556	rs396991	adalimumab,etanercept,infliximab	Efficacy	no	Genotype AA is not associated with response to adalimumab, etanercept or infliximab in people with Psoriasis as compared to genotypes AC + CC.	A		= 0.25	OR			
1183699556	rs396991	adalimumab,etanercept,infliximab	Efficacy	no	Genotype AA is not associated with response to adalimumab, etanercept or infliximab in people with Psoriasis as compared to genotypes AC + CC.	A		= 0.33	OR			
1183699556	rs396991	adalimumab,etanercept,infliximab	Efficacy	no	Genotype AA is not associated with response to adalimumab, etanercept or infliximab in people with Psoriasis as compared to genotypes AC + CC.	A		= 0.69	OR			
1183699535	rs1801274	adalimumab,etanercept,infliximab	Efficacy	no	Genotype GG is not associated with response to adalimumab, etanercept or infliximab in people with Psoriasis as compared to genotypes AA + AG.	G		= 0.18	OR			
1183699535	rs1801274	adalimumab,etanercept,infliximab	Efficacy	no	Genotype GG is not associated with response to adalimumab, etanercept or infliximab in people with Psoriasis as compared to genotypes AA + AG.	G		= 0.19	OR			
1183699535	rs1801274	adalimumab,etanercept,infliximab	Efficacy	no	Genotype GG is not associated with response to adalimumab, etanercept or infliximab in people with Psoriasis as compared to genotypes AA + AG.	G		= 0.52	OR			
1183699535	rs1801274	adalimumab,etanercept,infliximab	Efficacy	no	Genotype GG is not associated with response to adalimumab, etanercept or infliximab in people with Psoriasis as compared to genotypes AA + AG.	G		= 0.77	OR			
1183699530	rs1801274	adalimumab,etanercept,infliximab	Efficacy	yes	Genotype GG is associated with decreased response to adalimumab, etanercept or infliximab in people with Psoriasis as compared to genotypes AA + AG.	G		= 0.03	OR			
1183699530	rs1801274	adalimumab,etanercept,infliximab	Efficacy	yes	Genotype GG is associated with decreased response to adalimumab, etanercept or infliximab in people with Psoriasis as compared to genotypes AA + AG.	G		= 0.78	OR			
1183699530	rs1801274	adalimumab,etanercept,infliximab	Efficacy	yes	Genotype GG is associated with decreased response to adalimumab, etanercept or infliximab in people with Psoriasis as compared to genotypes AA + AG.	G		= 0.80	OR			
1183634151	rs7247267	diuretics,hydrochlorothiazide,Thiazides, plain	Efficacy	no	Allele T is not associated with response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele G.	T		= 2.9	OR			
1183634151	rs7247267	diuretics,hydrochlorothiazide,Thiazides, plain	Efficacy	no	Allele T is not associated with response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele G.	T		= 7.8	Unknown			
1183634151	rs7247267	diuretics,hydrochlorothiazide,Thiazides, plain	Efficacy	no	Allele T is not associated with response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele G.			= 1573	OR			
1448993523	rs3745274	efavirenz,non-nucleoside reverse transcriptase inhibitors	Efficacy	yes	Allele T is associated with increased response to efavirenz or non-nucleoside reverse transcriptase inhibitors in women with HIV Infections as compared to genotype GG.			= 0.03	OR	3.61	1.16	11.22
1446899545	rs776746	cyclosporine,tacrolimus	Dosage,Metabolism/PK	yes	Genotype CC is associated with increased concentrations of cyclosporine or tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	C	T	< 0.001	OR			
1446899545	rs776746	cyclosporine,tacrolimus	Dosage,Metabolism/PK	yes	Genotype CC is associated with increased concentrations of cyclosporine or tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	C	T	< 0.001	OR			
1448993530	rs28399499	efavirenz,non-nucleoside reverse transcriptase inhibitors	Efficacy	no	Allele C is not associated with response to efavirenz or non-nucleoside reverse transcriptase inhibitors in women with HIV Infections as compared to genotype TT.			= 0.13	OR	3.61	0.69	19.18
1446899553	rs776746	cyclosporine,tacrolimus	Dosage,Metabolism/PK	yes	Genotype CC is associated with decreased dose of cyclosporine or tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	C	T	< 0.001	OR			
1446899553	rs776746	cyclosporine,tacrolimus	Dosage,Metabolism/PK	yes	Genotype CC is associated with decreased dose of cyclosporine or tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	C	T	< 0.001	OR			
1448993538	rs34097093	efavirenz,non-nucleoside reverse transcriptase inhibitors	Efficacy	no	Allele C is not associated with response to efavirenz or non-nucleoside reverse transcriptase inhibitors in women with HIV Infections as compared to genotype TT.			= 0.72	OR	1.25	0.37	4.22
1448993544	rs1042389	efavirenz,non-nucleoside reverse transcriptase inhibitors	Efficacy	no	Allele C is not associated with response to efavirenz or non-nucleoside reverse transcriptase inhibitors in women with HIV Infections as compared to genotype TT.			= 0.80	OR	1.13	0.43	2.94
1449566972	rs13002976	bevacizumab,ranibizumab	Efficacy	no	Allele G is not associated with response to bevacizumab and ranibizumab in people with as compared to allele A.			= 1.21E-6	OR			
1449566972	rs13002976	bevacizumab,ranibizumab	Efficacy	no	Allele G is not associated with response to bevacizumab and ranibizumab in people with as compared to allele A.			= 0.219	OR			
1449566972	rs13002976	bevacizumab,ranibizumab	Efficacy	no	Allele G is not associated with response to bevacizumab and ranibizumab in people with as compared to allele A.			= 0.265	OR			
1448993550	rs8192709	efavirenz,non-nucleoside reverse transcriptase inhibitors	Efficacy	no	Genotype CT is not associated with response to efavirenz or non-nucleoside reverse transcriptase inhibitors in women with HIV Infections as compared to genotype CC.			= 1	OR	2.96	0.3	28.87
1449566994	rs241692	bevacizumab,ranibizumab	Efficacy	no	Allele G is not associated with response to bevacizumab and ranibizumab in people with as compared to allele A.			= 4.46E-7	OR			
1449566994	rs241692	bevacizumab,ranibizumab	Efficacy	no	Allele G is not associated with response to bevacizumab and ranibizumab in people with as compared to allele A.			= 0.187	OR			
1449566994	rs241692	bevacizumab,ranibizumab	Efficacy	no	Allele G is not associated with response to bevacizumab and ranibizumab in people with as compared to allele A.			= 0.493	OR			
1449567006	rs2237435	bevacizumab,ranibizumab	Efficacy	no	Allele A is not associated with response to bevacizumab and ranibizumab in people with as compared to allele C.			= 1.21E-6	OR			
1449567006	rs2237435	bevacizumab,ranibizumab	Efficacy	no	Allele A is not associated with response to bevacizumab and ranibizumab in people with as compared to allele C.			= 0.219	OR			
1449567006	rs2237435	bevacizumab,ranibizumab	Efficacy	no	Allele A is not associated with response to bevacizumab and ranibizumab in people with as compared to allele C.			= 0.265	OR			
1451107160	rs1801252	atenolol,metoprolol	Efficacy	no	Allele G is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele A.			= 0.06				
1451107160	rs1801252	atenolol,metoprolol	Efficacy	no	Allele G is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele A.			= 0.18				
1451107160	rs1801252	atenolol,metoprolol	Efficacy	no	Allele G is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele A.			= 0.32				
1451107160	rs1801252	atenolol,metoprolol	Efficacy	no	Allele G is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele A.			= 0.73				
1451107160	rs1801252	atenolol,metoprolol	Efficacy	no	Allele G is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele A.			= 0.89				
1451107160	rs1801252	atenolol,metoprolol	Efficacy	no	Allele G is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele A.			= 0.89				
1451107160	rs1801252	atenolol,metoprolol	Efficacy	no	Allele G is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele A.			= 0.89				
1451107160	rs1801252	atenolol,metoprolol	Efficacy	no	Allele G is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele A.			= 0.98				
1451408820	rs5030655	atorvastatin,rosuvastatin,simvastatin	Efficacy	no	Allele del is not associated with response to atorvastatin, rosuvastatin or simvastatin as compared to allele A.	del						
1451408825	rs1799853	atorvastatin,rosuvastatin,simvastatin	Efficacy	no	Allele T is not associated with response to atorvastatin, rosuvastatin or simvastatin as compared to allele C.	T						
1451107121	rs1042713	atenolol,metoprolol	Efficacy	no	Allele A is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele G.			= 0.17				
1451107121	rs1042713	atenolol,metoprolol	Efficacy	no	Allele A is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele G.			= 0.20				
1451107121	rs1042713	atenolol,metoprolol	Efficacy	no	Allele A is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele G.			= 0.53				
1451107121	rs1042713	atenolol,metoprolol	Efficacy	no	Allele A is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele G.			= 0.81				
1451107121	rs1042713	atenolol,metoprolol	Efficacy	no	Allele A is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele G.			= 0.93				
1451408830	rs1057910	atorvastatin,rosuvastatin,simvastatin	Efficacy	no	Allele C is not associated with response to atorvastatin, rosuvastatin or simvastatin as compared to allele A.	C						
1451408080	rs2230806	atorvastatin,rosuvastatin,simvastatin	Efficacy	yes	Allele T is associated with decreased response to atorvastatin, rosuvastatin or simvastatin as compared to allele C.	T		= 0.004				
1451408080	rs2230806	atorvastatin,rosuvastatin,simvastatin	Efficacy	yes	Allele T is associated with decreased response to atorvastatin, rosuvastatin or simvastatin as compared to allele C.	T		= 0.012	OR	7.56	0.13	14.99
1451408080	rs2230806	atorvastatin,rosuvastatin,simvastatin	Efficacy	yes	Allele T is associated with decreased response to atorvastatin, rosuvastatin or simvastatin as compared to allele C.	T		= 0.020	OR	0.59	0.37	0.93
1451408080	rs2230806	atorvastatin,rosuvastatin,simvastatin	Efficacy	yes	Allele T is associated with decreased response to atorvastatin, rosuvastatin or simvastatin as compared to allele C.	T		= 0.030	OR	0.57	0.35	0.94
1451408080	rs2230806	atorvastatin,rosuvastatin,simvastatin	Efficacy	yes	Allele T is associated with decreased response to atorvastatin, rosuvastatin or simvastatin as compared to allele C.	T		= 0.046	OR	12.1	2.73	21.46
1451408101	rs3892097	atorvastatin,rosuvastatin,simvastatin	Efficacy	yes	Allele T is associated with decreased response to atorvastatin, rosuvastatin or simvastatin as compared to allele C.	T		= 0.02				
1451408106	rs35742686	atorvastatin,rosuvastatin,simvastatin	Efficacy	no	Allele del is associated with decreased response to atorvastatin, rosuvastatin or simvastatin as compared to allele T.	del		= 0.020	OR	0.16	0.03	0.74
1451408106	rs35742686	atorvastatin,rosuvastatin,simvastatin	Efficacy	no	Allele del is associated with decreased response to atorvastatin, rosuvastatin or simvastatin as compared to allele T.	del		= 0.040	OR	0.23	0.05	0.93
1451408106	rs35742686	atorvastatin,rosuvastatin,simvastatin	Efficacy	no	Allele del is associated with decreased response to atorvastatin, rosuvastatin or simvastatin as compared to allele T.	del		= 0.098				
1183634307	rs13223171	diuretics,hydrochlorothiazide,Thiazides, plain	Efficacy	no	Allele T is not associated with response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele C.	T		= 9.44E-06	Unknown			
1183634307	rs13223171	diuretics,hydrochlorothiazide,Thiazides, plain	Efficacy	no	Allele T is not associated with response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele C.	T		= 9.67E-01	OR			
1183634313	rs689979	diuretics,hydrochlorothiazide,Thiazides, plain	Efficacy	no	Allele T is not associated with response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele C.	T		= 2.02E-06	Unknown			
1183634313	rs689979	diuretics,hydrochlorothiazide,Thiazides, plain	Efficacy	no	Allele T is not associated with response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele C.	T		= 6.79E-01	OR			
1448259259	rs9923231	acenocoumarol,phenprocoumon	Dosage	not stated	Allele T is associated with dose of acenocoumarol or phenprocoumon.				OR			
1448259259	rs9923231	acenocoumarol,phenprocoumon	Dosage	not stated	Allele T is associated with dose of acenocoumarol or phenprocoumon.				OR			
1451107302	rs1800888	atenolol,metoprolol	Efficacy	no	Allele T is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele C.			= 0.24				
1451107302	rs1800888	atenolol,metoprolol	Efficacy	no	Allele T is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele C.			= 0.55				
1451107302	rs1800888	atenolol,metoprolol	Efficacy	no	Allele T is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele C.			= 0.65				
1451107302	rs1800888	atenolol,metoprolol	Efficacy	no	Allele T is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele C.			= 0.82				
1451107302	rs1800888	atenolol,metoprolol	Efficacy	no	Allele T is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele C.			= 0.83				
1451107302	rs1800888	atenolol,metoprolol	Efficacy	no	Allele T is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele C.			= 0.91				
1451107302	rs1800888	atenolol,metoprolol	Efficacy	no	Allele T is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele C.			= 0.99				
1451107261	rs1801253	atenolol,metoprolol	Efficacy	no	Allele C is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele G.			= 0.14				
1451107261	rs1801253	atenolol,metoprolol	Efficacy	no	Allele C is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele G.			= 0.28				
1451107261	rs1801253	atenolol,metoprolol	Efficacy	no	Allele C is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele G.			= 0.44				
1451107261	rs1801253	atenolol,metoprolol	Efficacy	no	Allele C is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele G.			= 0.46				
1451107261	rs1801253	atenolol,metoprolol	Efficacy	no	Allele C is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele G.			= 0.73				
1451107261	rs1801253	atenolol,metoprolol	Efficacy	no	Allele C is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele G.			= 0.84				
1451107261	rs1801253	atenolol,metoprolol	Efficacy	no	Allele C is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele G.			= 0.88				
1451107261	rs1801253	atenolol,metoprolol	Efficacy	no	Allele C is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele G.			= 0.94				
1451107275	rs5443	atenolol,metoprolol	Efficacy	no	Allele T is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele C.			= 0.12				
1451107275	rs5443	atenolol,metoprolol	Efficacy	no	Allele T is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele C.			= 0.18				
1451107275	rs5443	atenolol,metoprolol	Efficacy	no	Allele T is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele C.			= 0.25				
1451107275	rs5443	atenolol,metoprolol	Efficacy	no	Allele T is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele C.			= 0.25				
1451107275	rs5443	atenolol,metoprolol	Efficacy	no	Allele T is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele C.			= 0.30				
1451107275	rs5443	atenolol,metoprolol	Efficacy	no	Allele T is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele C.			= 0.38				
1451107275	rs5443	atenolol,metoprolol	Efficacy	no	Allele T is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele C.			= 0.50				
1451107275	rs5443	atenolol,metoprolol	Efficacy	no	Allele T is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele C.			= 0.95				
1183634361	rs56294817	citalopram,fluoxetine,paroxetine	Efficacy	no	Allele A is not associated with response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to allele C.			> 0.05	OR			
1184175124	rs2306744	cytarabine,idarubicin	Efficacy	yes	Allele T is associated with increased response to cytarabine and idarubicin in people with Leukemia, Myeloid, Acute as compared to allele C.	C	T	= 0.025	OR			
1184175124	rs2306744	cytarabine,idarubicin	Efficacy	yes	Allele T is associated with increased response to cytarabine and idarubicin in people with Leukemia, Myeloid, Acute as compared to allele C.	C	T	= 0.0423	OR			
1451159800	rs67624739	bupropion,nicotine,varenicline	Efficacy	no	Allele del is not associated with response to bupropion, nicotine and varenicline in people with Tobacco Use Disorder as compared to allele CAGAGGGAAATAGGGGCGGGGC.	del		= 0.082	OR	1.4	0.96	2.0
1450320924	UGT1A1*28	morphine,morphine-3-glucuronide,morphine-6-glucuronide	Metabolism/PK	no	UGT1A1 *28 is not associated with concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide in people with Neoplasms.			> 0.653	OR			
1450320917	rs7439366	morphine,morphine-3-glucuronide,morphine-6-glucuronide	Metabolism/PK	no	Allele T is not associated with concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide in people with Neoplasms as compared to allele C.	C		> 0.05	OR			
1449192662	rs113993960	ivacaftor,tezacaftor	Efficacy	yes	Genotype del/del is associated with response to ivacaftor and tezacaftor in people with Cystic Fibrosis.			< 0.05	OR			
1184470125	rs5215	glibenclamide,gliclazide,glimepiride,glipizide,gliquidone	Dosage	no	Allele C is not associated with dose of glibenclamide, gliclazide, glimepiride, glipizide and gliquidone in people with Diabetes Mellitus as compared to allele T.	C	T	= 0.348	OR			
1184470130	rs5219	glibenclamide,gliclazide,glimepiride,glipizide,gliquidone	Dosage	no	Allele C is not associated with dose of glibenclamide, gliclazide, glimepiride, glipizide and gliquidone in people with Diabetes Mellitus as compared to allele T.	T	C	= 0.452	OR			
1447682070	CYP2D6 poor metabolizer	haloperidol,paliperidone,zuclopenthixol	Metabolism/PK	no	CYP2D6 poor metabolizer is not associated with concentrations of haloperidol, paliperidone or zuclopenthixol in people with Bipolar Disorder, schizoaffective disorder or Schizophrenia as compared to CYP2D6 intermediate metabolizer and normal metabolizer.			> 0.05	OR			
1447682070	CYP2D6 poor metabolizer	haloperidol,paliperidone,zuclopenthixol	Metabolism/PK	no	CYP2D6 poor metabolizer is not associated with concentrations of haloperidol, paliperidone or zuclopenthixol in people with Bipolar Disorder, schizoaffective disorder or Schizophrenia as compared to CYP2D6 intermediate metabolizer and normal metabolizer.			> 0.05	OR			
1447682070	CYP2D6 poor metabolizer	haloperidol,paliperidone,zuclopenthixol	Metabolism/PK	no	CYP2D6 poor metabolizer is not associated with concentrations of haloperidol, paliperidone or zuclopenthixol in people with Bipolar Disorder, schizoaffective disorder or Schizophrenia as compared to CYP2D6 intermediate metabolizer and normal metabolizer.			> 0.05	OR			
1184516551	TPMT low activity	azathioprine,mercaptopurine	Metabolism/PK	yes	TPMT low activity phenotype is associated with decreased metabolism of azathioprine and mercaptopurine as compared to TPMT high activity phenotype.			< 0.001	OR			
1184516551	TPMT low activity	azathioprine,mercaptopurine	Metabolism/PK	yes	TPMT low activity phenotype is associated with decreased metabolism of azathioprine and mercaptopurine as compared to TPMT high activity phenotype.			< 0.001	OR			
1184511241	CYP2C19 poor metabolizers	escitalopram,venlafaxine	Efficacy	no	CYP2C19 poor metabolizers is not associated with response to escitalopram or venlafaxine in people with Depressive Disorder, Major as compared to CYP2C19 normal metabolizers.				OR			
1184511241	CYP2C19 poor metabolizers	escitalopram,venlafaxine	Efficacy	no	CYP2C19 poor metabolizers is not associated with response to escitalopram or venlafaxine in people with Depressive Disorder, Major as compared to CYP2C19 normal metabolizers.				OR			
1451432060	rs1801133	antipsychotics,chlorpromazine,clozapine,haloperidol,olanzapine,quetiapine,risperidone	Efficacy	yes	Genotype AG is associated with decreased clinical benefit to antipsychotics, chlorpromazine, clozapine, haloperidol, olanzapine, quetiapine or risperidone in women with Schizophrenia as compared to genotype GG.			= 0.008				
1451437000	rs2740574	cyclosporine,tacrolimus	Metabolism/PK	yes	Allele C is associated with decreased concentrations of cyclosporine or tacrolimus in people with Kidney Transplantation as compared to allele T.			= 2.7E-7	OR			
1451437000	rs2740574	cyclosporine,tacrolimus	Metabolism/PK	yes	Allele C is associated with decreased concentrations of cyclosporine or tacrolimus in people with Kidney Transplantation as compared to allele T.			= 6E-4	OR			
1451437000	rs2740574	cyclosporine,tacrolimus	Metabolism/PK	yes	Allele C is associated with decreased concentrations of cyclosporine or tacrolimus in people with Kidney Transplantation as compared to allele T.			= 0.004	OR			
1451437000	rs2740574	cyclosporine,tacrolimus	Metabolism/PK	yes	Allele C is associated with decreased concentrations of cyclosporine or tacrolimus in people with Kidney Transplantation as compared to allele T.			= 0.039	OR			
1451439740	rs2740574	acenocoumarol,phenprocoumon	Dosage	no	Allele C is not associated with increased dose of acenocoumarol or phenprocoumon as compared to allele T.	*1B			Unknown			
1451439740	rs2740574	acenocoumarol,phenprocoumon	Dosage	no	Allele C is not associated with increased dose of acenocoumarol or phenprocoumon as compared to allele T.	*1B			Unknown			
1451256960	rs4149056	atorvastatin,hmg coa reductase inhibitors,pravastatin,simvastatin	Efficacy	yes	Genotypes CC + CT are associated with decreased response to atorvastatin, hmg coa reductase inhibitors, pravastatin or simvastatin in people with Hyperlipidemias as compared to genotype TT.			< 0.05				
1451474460	rs2236225	cisplatin,doxorubicin,methotrexate	Efficacy	yes	Genotypes AA + AG is associated with increased response to cisplatin, doxorubicin and methotrexate in people with Osteosarcoma as compared to genotype GG.	A		= 0.03	OR	0.2	0.05	0.9
1451474540	rs717620	cisplatin,doxorubicin,methotrexate	Efficacy	yes	Genotypes CT + TT is associated with decreased response to cisplatin, doxorubicin and methotrexate in people with Osteosarcoma as compared to genotype CC.	T		= 0.017	OR	6.3	1.4	28.5
1451474580	rs1695	cisplatin,doxorubicin,methotrexate	Efficacy	yes	Genotypes AG + GG is associated with decreased response to cisplatin, doxorubicin and methotrexate in people with Osteosarcoma as compared to genotype AA.	G		= 0.016	OR	7.9	1.5	42.5
1451493500	rs4762	atenolol,irbesartan	Efficacy	yes	Genotype AG is associated with increased response to atenolol or irbesartan in people with Hypertrophy, Left Ventricular as compared to genotype GG.	A		= 0.005				
1451493552	rs1799752	atenolol,irbesartan	Efficacy	no	Allele ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is not associated with response to atenolol or irbesartan in people with Hypertrophy, Left Ventricular as compared to allele del.	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC						
1451493560	rs1799998	atenolol,irbesartan	Efficacy	no	Allele G is not associated with response to atenolol or irbesartan in people with Hypertrophy, Left Ventricular as compared to allele A.	G						
1451531660	rs1523127	efavirenz,nevirapine	Efficacy	yes	Genotypes AA + AC is associated with decreased response to efavirenz or nevirapine in people with HIV Infections as compared to genotype CC.	C		= 0.043	HR	0.68	0.46	0.99
1451531684	rs3003596	efavirenz,nevirapine	Efficacy	yes	Genotypes AG + GG is associated with decreased response to efavirenz or nevirapine in people with HIV Infections as compared to genotype AA.	A		= 0.026	HR	0.52	0.29	0.92
1451531684	rs3003596	efavirenz,nevirapine	Efficacy	yes	Genotypes AG + GG is associated with decreased response to efavirenz or nevirapine in people with HIV Infections as compared to genotype AA.	A		= 0.036	HR	0.62	0.4	0.97
1451531684	rs3003596	efavirenz,nevirapine	Efficacy	yes	Genotypes AG + GG is associated with decreased response to efavirenz or nevirapine in people with HIV Infections as compared to genotype AA.	A		= 0.156	HR	0.77	0.53	1.1
1451531760	rs2307424	efavirenz,nevirapine	Efficacy	yes	Genotypes AA + AG is associated with increased response to efavirenz or nevirapine in people with HIV Infections as compared to genotype GG.	G		= 0.01	HR	1.59	1.11	2.27
1451581560	CYP2C19 normal metabolizer genotype	amoxicillin,clarithromycin,omeprazole	Efficacy	yes	CYP2C19 normal metabolizer genotype is associated with decreased clinical benefit to amoxicillin, clarithromycin and omeprazole in people with Helicobacter Infections as compared to CYP2C19 poor metabolizer genotype.			= 0.01	RR	1.66	1.12	2.46
1451581580	CYP2C19 normal metabolizer genotype	amoxicillin,clarithromycin,lansoprazole	Efficacy	yes	CYP2C19 normal metabolizer genotype is associated with decreased clinical benefit to amoxicillin, clarithromycin and lansoprazole in people with Helicobacter Infections as compared to CYP2C19 poor metabolizer genotype.			= 0.001	RR	2.47	1.44	4.23
1451581620	CYP2C19 normal metabolizer genotype	amoxicillin,clarithromycin,rabeprazole	Efficacy	no	CYP2C19 normal metabolizer genotype is not associated with decreased clinical benefit to amoxicillin, clarithromycin and rabeprazole in people with Helicobacter Infections as compared to CYP2C19 poor metabolizer genotype.			= 0.27	RR			
1451581644	CYP2C19 normal metabolizer genotype	amoxicillin,clarithromycin,esomeprazole	Efficacy	no	CYP2C19 normal metabolizer genotype is not associated with decreased clinical benefit to amoxicillin, clarithromycin and esomeprazole in people with Helicobacter Infections as compared to CYP2C19 poor metabolizer genotype.			= 0.31	RR			
1451505980	CYP2D6 intermediate metabolizer genotype	alpha-dihydrodeutetrabenazine,beta-dihydrodeutetrabenazine	Metabolism/PK	not stated	CYP2D6 intermediate metabolizer genotype is associated with increased exposure to alpha-dihydrodeutetrabenazine and beta-dihydrodeutetrabenazine in healthy individuals as compared to CYP2D6 normal metabolizer genotype.							
1451550232	rs39339	aripiprazole,olanzapine,perphenazine,quetiapine,risperidone	Efficacy	no	Allele G is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	G		= 0.841				
1451550247	rs3808035	aripiprazole,olanzapine,perphenazine,quetiapine,risperidone	Efficacy	no	Allele C is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele A.	A		= 0.695				
1451550226	rs7341475	aripiprazole,olanzapine,perphenazine,quetiapine,risperidone	Efficacy	no	Allele A is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele G.	A		= 0.978				
1451550301	rs362726	aripiprazole,olanzapine,perphenazine,quetiapine,risperidone	Efficacy	no	Allele C is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	C		= 0.862				
1451550220	rs362719	aripiprazole,olanzapine,perphenazine,quetiapine,risperidone	Efficacy	no	Allele A is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele C.	A		= 0.732				
1451550253	rs2535764	aripiprazole,olanzapine,perphenazine,quetiapine,risperidone	Efficacy	no	Allele T is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele C.	T		= 0.179				
1451550265	rs2237628	aripiprazole,olanzapine,perphenazine,quetiapine,risperidone	Efficacy	no	Allele C is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	C		= 0.160				
1451550241	rs3819479	aripiprazole,olanzapine,perphenazine,quetiapine,risperidone	Efficacy	no	Allele A is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	A		= 0.529				
1451550259	rs12705169	aripiprazole,olanzapine,perphenazine,quetiapine,risperidone	Efficacy	no	Allele G is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	G		= 0.596				
1451550271	rs362626	aripiprazole,olanzapine,perphenazine,quetiapine,risperidone	Efficacy	no	Allele C is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele A.	A		= 0.394				
1451550280	rs362814	aripiprazole,olanzapine,perphenazine,quetiapine,risperidone	Efficacy	no	Allele A is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	T		= 0.973				
1451550286	rs362813	aripiprazole,olanzapine,perphenazine,quetiapine,risperidone	Efficacy	no	Allele C is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	T		= 0.903				
1451550292	rs362731	aripiprazole,olanzapine,perphenazine,quetiapine,risperidone	Efficacy	no	Allele C is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	C		= 0.134				
1183700726	rs11615	cisplatin,gemcitabine	Efficacy	yes	Genotype AA is associated with increased response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.	G		= 0.03	OR			
1451608120	rs1937840	docetaxel,doxorubicin	Efficacy	yes	Genotype GG is associated with increased response to docetaxel and doxorubicin in women with Breast Neoplasms as compared to genotypes CC + CG.			= 0.006	Unknown			
1451608120	rs1937840	docetaxel,doxorubicin	Efficacy	yes	Genotype GG is associated with increased response to docetaxel and doxorubicin in women with Breast Neoplasms as compared to genotypes CC + CG.			= 0.017	Unknown			
1451552300	rs352139	adalimumab,etanercept,infliximab,Tumor necrosis factor alpha (TNF-alpha) inhibitors	Efficacy	yes	Genotypes CT + TT is associated with increased response to adalimumab, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to genotype CC.			= 0.018	OR	5.05	1.325	19.231
1451614884	rs4696	daclatasvir,sofosbuvir	Efficacy	no	Genotype AA is not associated with increased clinical benefit to daclatasvir null sofosbuvir in people with Hepatitis C, Chronic as compared to genotypes AG + GG.			= 0.528	Unknown			
1451614766	rs7728773	daclatasvir,sofosbuvir	Efficacy	yes	Genotypes CT + TT is associated with increased clinical benefit to daclatasvir null sofosbuvir in people with Hepatitis C, Chronic as compared to genotype CC.			= 0.005	OR	2.119	1.263	3.559
1451614773	rs12979860	daclatasvir,sofosbuvir	Efficacy	yes	Genotype CC is associated with increased clinical benefit to daclatasvir null sofosbuvir in people with Hepatitis C, Chronic as compared to genotypes CT + TT.			= 0.0001	OR	3.995	2.126	7.74
1451614846	rs3760468	daclatasvir,sofosbuvir	Efficacy	no	Genotype AA is not associated with increased clinical benefit to daclatasvir null sofosbuvir in people with Hepatitis C, Chronic as compared to genotypes AT + TT.			= 0.29	Unknown			
1451566720	rs1800497	bupropion,naltrexone	Efficacy	yes	Genotypes AA + AG are associated with increased response to bupropion and naltrexone in people with Obesity as compared to genotype GG.			= 0.035				
1451569620	rs11887534	atorvastatin,simvastatin	Efficacy	yes	Genotypes CC + CG is associated with decreased clinical benefit to atorvastatin or simvastatin in people with Dyslipidaemia as compared to genotype GG.	G		= 0.002				
982009313	rs1137617	candesartan,imidapril,irbesartan	Efficacy	not stated	Genotype GG is not associated with response to candesartan, imidapril or irbesartan in people with Essential hypertension as compared to genotypes AA + AG.	A			Unknown			
1451645100	CYP2D6 poor metabolizers and intermediate metabolizers	codeine,fentanyl,hydrocodone,hydromorphone,methadone,morphine,oxycodone,tramadol	Efficacy	yes	CYP2D6 poor metabolizers and intermediate metabolizers are associated with decreased response to codeine, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone or tramadol in people with Neoplasms and Pain as compared to CYP2D6 normal metabolizers.			= 0.03	OR	5.4	1.2	23.6
1451645100	CYP2D6 poor metabolizers and intermediate metabolizers	codeine,fentanyl,hydrocodone,hydromorphone,methadone,morphine,oxycodone,tramadol	Efficacy	yes	CYP2D6 poor metabolizers and intermediate metabolizers are associated with decreased response to codeine, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone or tramadol in people with Neoplasms and Pain as compared to CYP2D6 normal metabolizers.			= 0.03	OR	3.3	1.1	9.8
1451646480	rs35599367	atorvastatin,simvastatin	Efficacy	no	Genotypes AA + AG is not associated with response to atorvastatin or simvastatin in people with Hypercholesterolemia as compared to genotype GG.	A						
1451692560	rs1056836	codeine,tramadol	Efficacy	yes	Allele C is associated with decreased clinical benefit to codeine or tramadol in men with Pain as compared to allele G.	C		= 8.0e-6				
1451692660	rs1056837	codeine,tramadol	Efficacy	yes	Allele A is associated with decreased clinical benefit to codeine or tramadol in men with Pain as compared to allele G.	A		= 7.8e-6				
1451692692	rs76026520	hydrocodone,oxycodone	Efficacy	yes	Allele G is associated with increased clinical benefit to hydrocodone or oxycodone in people with Pain as compared to allele A.	G		= 2.1e-5				
1451692704	rs35742686	hydrocodone,oxycodone	Efficacy	yes	Allele DELT is associated with increased clinical benefit to hydrocodone or oxycodone in people with Pain as compared to allele T.	DELT		= 7.6e-5				
1184470133	rs757110	glibenclamide,gliclazide,glimepiride,glipizide,gliquidone	Dosage	no	Allele C is not associated with dose of glibenclamide, gliclazide, glimepiride, glipizide and gliquidone in people with Diabetes Mellitus as compared to allele A.	C	A	= 0.551	OR			
1451719580	rs28379954	paliperidone,risperidone	Metabolism/PK	yes	Genotype CT is associated with increased concentrations of paliperidone and risperidone as compared to genotype TT.	C		= 0.007				
1451720380	rs1801133	capecitabine,fluorouracil	Dosage	yes	Genotypes AA + AG is associated with decreased dose of capecitabine or fluorouracil in women with Neoplasms as compared to genotype GG.			= 0.016	OR	5.05	1.346	18.948
1451720380	rs1801133	capecitabine,fluorouracil	Dosage	yes	Genotypes AA + AG is associated with decreased dose of capecitabine or fluorouracil in women with Neoplasms as compared to genotype GG.			= 0.029				
1451726355	rs1045642	docetaxel,paclitaxel	Efficacy	no	Genotypes AG + GG are associated with increased response to docetaxel or paclitaxel in people with Neoplasms as compared to genotype AA.			= 0.0876	RR	0.22	0.03	1.51
1451729080	rs1057911	AR-C124910XX,ticagrelor	Metabolism/PK	no	Genotype AT is not associated with decreased concentrations of AR-C124910XX or ticagrelor in healthy individuals as compared to genotype AA.	T						
1451729097	rs9332245	AR-C124910XX,ticagrelor	Metabolism/PK	no	Genotype AT is not associated with decreased concentrations of AR-C124910XX or ticagrelor in healthy individuals as compared to genotype TT.	A						
1451729123	rs2279342	AR-C124910XX,ticagrelor	Metabolism/PK	no	Genotypes AT + TT is not associated with decreased concentrations of AR-C124910XX or ticagrelor in healthy individuals as compared to genotype AA.	A						
1451727971	rs17847029	AR-C124910XX,ticagrelor	Metabolism/PK	no	Genotype CT is not associated with decreased concentrations of AR-C124910XX or ticagrelor in healthy individuals as compared to genotype CC.	T						
1451729129	rs35930845	AR-C124910XX,ticagrelor	Metabolism/PK	no	Genotypes CG + GG is not associated with decreased concentrations of AR-C124910XX or ticagrelor in healthy individuals as compared to genotype CC.	C						
1451729160	rs3745276	AR-C124910XX,ticagrelor	Metabolism/PK	no	Genotypes AA + AG is not associated with decreased concentrations of AR-C124910XX or ticagrelor in healthy individuals as compared to genotype GG.	A						
1451729164	rs434606	AR-C124910XX,ticagrelor	Metabolism/PK	no	Genotypes AA + AG is not associated with decreased concentrations of AR-C124910XX or ticagrelor in healthy individuals as compared to genotype GG.	A						
1451729214	rs56156262	AR-C124910XX,ticagrelor	Metabolism/PK	no	Genotypes AA + AG is not associated with decreased concentrations of AR-C124910XX or ticagrelor in healthy individuals as compared to genotype GG.	A						
1451729281	rs4244285	AR-C124910XX,ticagrelor	Metabolism/PK	no	Genotypes AA + AG is not associated with decreased concentrations of AR-C124910XX or ticagrelor in healthy individuals as compared to genotype GG.	A						
1451729346	rs28371759	AR-C124910XX,ticagrelor	Metabolism/PK	no	Genotype AG is not associated with decreased concentrations of AR-C124910XX or ticagrelor in healthy individuals as compared to genotype AA.	G						
1451729240	rs12769205	AR-C124910XX,ticagrelor	Metabolism/PK	no	Genotypes AG + GG is not associated with decreased concentrations of AR-C124910XX or ticagrelor in healthy individuals as compared to genotype AA.	G						
1451729340	rs3758580	AR-C124910XX,ticagrelor	Metabolism/PK	no	Genotypes CT + TT is not associated with decreased concentrations of AR-C124910XX or ticagrelor in healthy individuals as compared to genotype CC.	T						
1451729352	rs15524	AR-C124910XX,ticagrelor	Metabolism/PK	no	Genotypes AG + GG is not associated with decreased concentrations of AR-C124910XX or ticagrelor in healthy individuals as compared to genotype AA.	G						
1451729358	rs4646453	AR-C124910XX,ticagrelor	Metabolism/PK	no	Genotypes AA + AC is not associated with decreased concentrations of AR-C124910XX or ticagrelor in healthy individuals as compared to genotype CC.	A						
1451729373	rs4149032	AR-C124910XX,ticagrelor	Metabolism/PK	no	Genotypes CT + TT is not associated with decreased concentrations of AR-C124910XX or ticagrelor in healthy individuals as compared to genotype CC.	C						
1451729393	rs2306283	AR-C124910XX,ticagrelor	Metabolism/PK	no	Genotypes AA + AG is not associated with decreased concentrations of AR-C124910XX or ticagrelor in healthy individuals as compared to genotype GG.	A						
1451729440	rs141257984	AR-C124910XX,ticagrelor	Metabolism/PK	no	Genotype GT is not associated with decreased concentrations of AR-C124910XX or ticagrelor in healthy individuals as compared to genotype TT.	G						
1183631253	rs16960228	diuretics,hydrochlorothiazide,Thiazides, plain	Efficacy	yes	Allele A is associated with increased response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele G.	A		= 1.37e-6	Unknown			
1183631253	rs16960228	diuretics,hydrochlorothiazide,Thiazides, plain	Efficacy	yes	Allele A is associated with increased response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele G.	A		= 5.96E-03	Unknown			
1183631253	rs16960228	diuretics,hydrochlorothiazide,Thiazides, plain	Efficacy	yes	Allele A is associated with increased response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele G.			= 0.04	Unknown			
1183631253	rs16960228	diuretics,hydrochlorothiazide,Thiazides, plain	Efficacy	yes	Allele A is associated with increased response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele G.			= 0.58	Unknown			
1183632007	rs2776546	diuretics,hydrochlorothiazide,Thiazides, plain	Efficacy	yes	Allele A is associated with increased response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele C.	A		= 4.9e-8	Unknown			
1183632007	rs2776546	diuretics,hydrochlorothiazide,Thiazides, plain	Efficacy	yes	Allele A is associated with increased response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele C.	A		= 0.098	OR			
1183631267	rs2273359	diuretics,hydrochlorothiazide,Thiazides, plain	Efficacy	no	Genotype CG is associated with increased response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to genotype CC.			= 5.54E-08	Unknown			
1183631267	rs2273359	diuretics,hydrochlorothiazide,Thiazides, plain	Efficacy	no	Genotype CG is associated with increased response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to genotype CC.	C		= 4.15E-07	Unknown			
1183631267	rs2273359	diuretics,hydrochlorothiazide,Thiazides, plain	Efficacy	no	Genotype CG is associated with increased response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to genotype CC.			= 0.15	Unknown			
1183632046	rs4815273	diuretics,hydrochlorothiazide,Thiazides, plain	Efficacy	yes	Allele T is associated with increased response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele C.	C		= 4.5e-08	Unknown			
1183632046	rs4815273	diuretics,hydrochlorothiazide,Thiazides, plain	Efficacy	yes	Allele T is associated with increased response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele C.	C		= 7.36E-01	OR			
1183632057	rs4791040	diuretics,hydrochlorothiazide,Thiazides, plain	Efficacy	yes	Allele T is associated with decreased response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele C.	T		= 1.36E-06	Unknown			
1183632057	rs4791040	diuretics,hydrochlorothiazide,Thiazides, plain	Efficacy	yes	Allele T is associated with decreased response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele C.	T		= 6.25E-03	Unknown			
1183634111	rs221903	diuretics,hydrochlorothiazide,Thiazides, plain	Efficacy	no	Allele T is associated with decreased response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele C.	T		= 6.98E-06	Unknown			
1183634111	rs221903	diuretics,hydrochlorothiazide,Thiazides, plain	Efficacy	no	Allele T is associated with decreased response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele C.	T		= 4.33E-01	Unknown			
1183634117	rs9933692	diuretics,hydrochlorothiazide,Thiazides, plain	Efficacy	no	Allele A is not associated with response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele G.	A		= 6.93E-06	Unknown			
1183634117	rs9933692	diuretics,hydrochlorothiazide,Thiazides, plain	Efficacy	no	Allele A is not associated with response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele G.	A		= 6.79E-01	Unknown			
1183634138	rs4074471	diuretics,hydrochlorothiazide,Thiazides, plain	Efficacy	no	Allele T is not associated with response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele G.	T		= 6.92E-06	Unknown			
1183634138	rs4074471	diuretics,hydrochlorothiazide,Thiazides, plain	Efficacy	no	Allele T is not associated with response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele G.	T		= 6.80E-01	Unknown			
1183634268	rs6083538	diuretics,hydrochlorothiazide,Thiazides, plain	Efficacy	no	Allele T is associated with increased response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele C.	T		= 6.84E-08	Unknown			
1183634268	rs6083538	diuretics,hydrochlorothiazide,Thiazides, plain	Efficacy	no	Allele T is associated with increased response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele C.	T		= 3.38E-01	Unknown			
1183634284	rs17010902	diuretics,hydrochlorothiazide,Thiazides, plain	Efficacy	no	Allele A is not associated with response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele G.	A		= 8.11E-01	Unknown			
1183634284	rs17010902	diuretics,hydrochlorothiazide,Thiazides, plain	Efficacy	no	Allele A is not associated with response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele G.	A		= 8.11E-01	OR			
1183634290	rs4376293	diuretics,hydrochlorothiazide,Thiazides, plain	Efficacy	no	Allele T is not associated with response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele C.	T		= 5.01E-06	Unknown			
1183634290	rs4376293	diuretics,hydrochlorothiazide,Thiazides, plain	Efficacy	no	Allele T is not associated with response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele C.	T		= 7.14E-01	OR			
1183634301	rs11763492	diuretics,hydrochlorothiazide,Thiazides, plain	Efficacy	no	Allele A is not associated with response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele G.	A		= 9.35E-06	Unknown			
1183634301	rs11763492	diuretics,hydrochlorothiazide,Thiazides, plain	Efficacy	no	Allele A is not associated with response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele G.	A		= 9.69E-01	OR			
1451788360	rs9923231	acenocoumarol,warfarin	Dosage	yes	Genotypes CT + TT is associated with decreased dose of acenocoumarol or warfarin in people with heart valve replacement as compared to genotype CC.	T		< 0.0001				
1451788400	rs2108622	acenocoumarol,warfarin	Dosage	yes	Genotypes CT + TT is associated with increased dose of acenocoumarol or warfarin in people with heart valve replacement as compared to genotype CC.	C		= 0.0028				
1451788440	rs1057910	acenocoumarol,warfarin	Dosage	yes	Genotypes AC + CC is associated with decreased dose of acenocoumarol or warfarin in people with heart valve replacement as compared to genotype AA.	C		< 0.0001				
1451788412	rs1799853	acenocoumarol,warfarin	Dosage	no	Genotype CT is not associated with decreased dose of acenocoumarol or warfarin in people with heart valve replacement as compared to genotype CC.	T		= 0.998				
1183703678	rs17798800	donepezil,galantamine,rivastigmine	Efficacy	yes	Allele T is associated with decreased response to donepezil, galantamine and rivastigmine in people with Alzheimer Disease as compared to allele C.			= 6.74E-6	OR	0.38	0.25	0.58
1183703678	rs17798800	donepezil,galantamine,rivastigmine	Efficacy	yes	Allele T is associated with decreased response to donepezil, galantamine and rivastigmine in people with Alzheimer Disease as compared to allele C.	T		= 1.24E-4	OR	0.34	0.19	0.6
1183703678	rs17798800	donepezil,galantamine,rivastigmine	Efficacy	yes	Allele T is associated with decreased response to donepezil, galantamine and rivastigmine in people with Alzheimer Disease as compared to allele C.	T		= 8.78E-3	OR	0.44	0.24	0.82
1183703663	rs6720975	donepezil,galantamine,rivastigmine	Efficacy	yes	Allele T is associated with increased response to donepezil, galantamine and rivastigmine in people with Alzheimer Disease as compared to allele C.			= 3.87E-4	OR	1.76	1.29	2.4
1183703663	rs6720975	donepezil,galantamine,rivastigmine	Efficacy	yes	Allele T is associated with increased response to donepezil, galantamine and rivastigmine in people with Alzheimer Disease as compared to allele C.	T		= 5.14E-4	OR	2.19	1.4	3.42
1183703663	rs6720975	donepezil,galantamine,rivastigmine	Efficacy	yes	Allele T is associated with increased response to donepezil, galantamine and rivastigmine in people with Alzheimer Disease as compared to allele C.	T		= 0.112	OR	1.43	0.92	2.21
1451770120	rs553668	doxazosin,phenoxybenzamine	Dosage	no	Allele G is associated with decreased dose of doxazosin or phenoxybenzamine in people with Pheochromocytoma or Paraganglioma as compared to allele A.	G		= 0.024				
1451770080	rs10515807	doxazosin,phenoxybenzamine	Dosage	no	Allele G is associated with decreased dose of doxazosin or phenoxybenzamine in people with Pheochromocytoma or Paraganglioma as compared to allele A.	G		= 0.047				
1451770141	rs521674	doxazosin,phenoxybenzamine	Dosage	no	Allele T is associated with increased dose of doxazosin or phenoxybenzamine in people with Pheochromocytoma or Paraganglioma as compared to allele A.	T		= 0.014				
1444707052	rs8099917	peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype GT.	T		= 0.014	OR			
1450943585	rs17117817	atenolol,metoprolol	PD	yes	Allele G is associated with decreased response to atenolol or metoprolol in people with Hypertension as compared to allele T.			= 2E-09				
981502054	rs2227310	docetaxel,gemcitabine,paclitaxel,Platinum compounds,vinorelbine	Efficacy	yes	Genotypes CG + GG are associated with increased response to docetaxel, gemcitabine, paclitaxel, Platinum compounds or vinorelbine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	C		= 0.002	HR	0.74	0.61	0.89
1447947784	rs12979860	peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype CC is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.			< 0.0001	OR	20.83	11.63	37.04
1447947763	rs1059150	adalimumab,certolizumab pegol,etanercept,glucocorticoids,infliximab,methotrexate	Efficacy	yes	Genotype GG is associated with decreased response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate in women with Arthritis, Rheumatoid as compared to genotype TT.	A		= 0.014	OR	8.26	1.23	352.79
1184175254	rs1042858	carboplatin,gemcitabine	Efficacy	no	Genotype AA is not associated with response to carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.			> 0.05	OR			
1184175245	rs12806698	carboplatin,gemcitabine	Efficacy	yes	Genotype AC is associated with increased response to carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + CC.	A	C	= 0.043	OR		24.5	36.9
981502071	rs12415607	docetaxel,gemcitabine,paclitaxel,Platinum compounds,vinorelbine	Efficacy	yes	Genotypes AA + AC are associated with increased response to docetaxel, gemcitabine, paclitaxel, Platinum compounds or vinorelbine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	C		= 0.005	HR	0.76	0.63	0.92
981502079	rs4353229	docetaxel,gemcitabine,paclitaxel,Platinum compounds,vinorelbine	Efficacy	yes	Genotypes CC + CT are associated with increased response to docetaxel, gemcitabine, paclitaxel, Platinum compounds or vinorelbine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.	T		= 0.001	HR	0.73	0.6	0.89
1450943622	rs2364349	atenolol,metoprolol	PD	yes	Allele A is associated with decreased response to atenolol or metoprolol in people with Hypertension as compared to allele G.			= 1E-08				
981502089	rs7921977	docetaxel,gemcitabine,paclitaxel,Platinum compounds,vinorelbine	Efficacy	yes	Genotype CT is associated with decreased response to docetaxel, gemcitabine, paclitaxel, Platinum compounds or vinorelbine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.	T		= 0.02	HR	1.27	1.04	1.56
1447947702	rs1264457	adalimumab,certolizumab pegol,etanercept,glucocorticoids,infliximab,methotrexate	Efficacy	yes	Genotype AA is associated with increased response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate in women with Arthritis, Rheumatoid as compared to genotypes AG + GG.	G		= 0.047	OR	7.06	0.75	90.37
1183700190	rs1561876	cladribine,cytarabine	Efficacy	yes	Genotype GG is associated with decreased response to cladribine and cytarabine in children with Leukemia, Myeloid, Acute as compared to genotypes AA + AG.			= 0.001	OR			
1183700190	rs1561876	cladribine,cytarabine	Efficacy	yes	Genotype GG is associated with decreased response to cladribine and cytarabine in children with Leukemia, Myeloid, Acute as compared to genotypes AA + AG.	G		= 0.0012	OR			
1183700190	rs1561876	cladribine,cytarabine	Efficacy	yes	Genotype GG is associated with decreased response to cladribine and cytarabine in children with Leukemia, Myeloid, Acute as compared to genotypes AA + AG.	G		= 0.009	OR			
1183700199	rs1042919	cladribine,cytarabine	Efficacy	yes	Genotype AT is associated with decreased response to cladribine and cytarabine in children with Leukemia, Myeloid, Acute as compared to genotype AA.	A		= 0.0004	OR			
1183700199	rs1042919	cladribine,cytarabine	Efficacy	yes	Genotype AT is associated with decreased response to cladribine and cytarabine in children with Leukemia, Myeloid, Acute as compared to genotype AA.			= 0.071	OR			
1183680059	rs1799724	lansoprazole,omeprazole,rabeprazole	Efficacy	no	Genotypes CT + TT are not associated with response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to genotype CC.	C		= 0.3864	OR	1.354	0.682	2.69
1448639468	rs2032582	remifentanil,sevoflurane	Efficacy	no	Genotype AA is not associated with response to remifentanil and sevoflurane in children with tonsillectomy as compared to genotypes AC + CC.	A	G	> 0.05	OR			
982045336	rs5443	bumetanide,furosemide,torasemide	Efficacy	yes	Genotype TT is associated with decreased response to bumetanide, furosemide and torasemide in healthy individuals as compared to genotype CC.			= 0.007	Unknown			
982045336	rs5443	bumetanide,furosemide,torasemide	Efficacy	yes	Genotype TT is associated with decreased response to bumetanide, furosemide and torasemide in healthy individuals as compared to genotype CC.			= 0.008	Unknown			
982045336	rs5443	bumetanide,furosemide,torasemide	Efficacy	yes	Genotype TT is associated with decreased response to bumetanide, furosemide and torasemide in healthy individuals as compared to genotype CC.			= 0.047	Unknown			
1448639460	rs1045642	remifentanil,sevoflurane	Efficacy	no	Genotype GG is not associated with response to remifentanil and sevoflurane in children with tonsillectomy as compared to genotypes AA + AG.			> 0.05	OR			
982045346	rs5063	bumetanide,furosemide,torasemide	Efficacy	yes	Genotype TT is associated with decreased response to bumetanide, furosemide and torasemide in healthy individuals as compared to genotype CC.			= 0.05	Unknown			
1183680131	rs16944	omeprazole,rabeprazole	Efficacy	no	Genotype AA is not associated with response to omeprazole and rabeprazole in people with Helicobacter Infections as compared to genotypes AG + GG.	G		= 0.815	OR			
1183680131	rs16944	omeprazole,rabeprazole	Efficacy	no	Genotype AA is not associated with response to omeprazole and rabeprazole in people with Helicobacter Infections as compared to genotypes AG + GG.	G		= 0.906	OR			
1183680137	rs1143634	omeprazole,rabeprazole	Efficacy	no	Genotype GG is not associated with response to omeprazole and rabeprazole in people with Helicobacter Infections as compared to genotypes AA + AG.	G		= 0.447	OR			
1183680137	rs1143634	omeprazole,rabeprazole	Efficacy	no	Genotype GG is not associated with response to omeprazole and rabeprazole in people with Helicobacter Infections as compared to genotypes AA + AG.	G		= 1.00	OR			
1448639423	rs1128503	remifentanil,sevoflurane	Efficacy	yes	Genotype GG is associated with increased response to remifentanil and sevoflurane in children with tonsillectomy as compared to genotypes AA + AG.	A	G	< 0.05	OR			
1448639423	rs1128503	remifentanil,sevoflurane	Efficacy	yes	Genotype GG is associated with increased response to remifentanil and sevoflurane in children with tonsillectomy as compared to genotypes AA + AG.	A	G	< 0.05	OR			
1448639423	rs1128503	remifentanil,sevoflurane	Efficacy	yes	Genotype GG is associated with increased response to remifentanil and sevoflurane in children with tonsillectomy as compared to genotypes AA + AG.	A	G	< 0.05	OR			
982045391	rs1799752	bumetanide,furosemide,torasemide	Efficacy	yes	Genotype del/del is associated with increased response to bumetanide, furosemide and torasemide in healthy individuals as compared to genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC.			= 0.006	Unknown			
1450342061	rs4793665	morphine-3-glucuronide,morphine-6-glucuronide	Metabolism/PK	yes	Genotype CC is associated with increased concentrations of morphine-3-glucuronide and morphine-6-glucuronide in children with Scoliosis or tonsillectomy as compared to genotypes CT + TT.			< 0.05	OR			
1450342061	rs4793665	morphine-3-glucuronide,morphine-6-glucuronide	Metabolism/PK	yes	Genotype CC is associated with increased concentrations of morphine-3-glucuronide and morphine-6-glucuronide in children with Scoliosis or tonsillectomy as compared to genotypes CT + TT.			< 0.05	OR			
1450342061	rs4793665	morphine-3-glucuronide,morphine-6-glucuronide	Metabolism/PK	yes	Genotype CC is associated with increased concentrations of morphine-3-glucuronide and morphine-6-glucuronide in children with Scoliosis or tonsillectomy as compared to genotypes CT + TT.			< 0.05	OR			
1450342061	rs4793665	morphine-3-glucuronide,morphine-6-glucuronide	Metabolism/PK	yes	Genotype CC is associated with increased concentrations of morphine-3-glucuronide and morphine-6-glucuronide in children with Scoliosis or tonsillectomy as compared to genotypes CT + TT.			< 0.05	OR			
982045404	rs4961	bumetanide,furosemide,torasemide	Efficacy	yes	Genotype TT is associated with increased response to bumetanide, furosemide and torasemide in healthy individuals as compared to genotype GG.			= 0.023	Unknown			
982045366	rs5065	bumetanide,furosemide,torasemide	Efficacy	yes	Genotype GG is associated with decreased response to bumetanide, furosemide and torasemide in healthy individuals as compared to genotype AA.			= 0.023	Unknown			
982045356	rs5065	bumetanide,furosemide,torasemide	Efficacy	yes	Genotype GG is associated with increased response to bumetanide, furosemide and torasemide in healthy individuals as compared to genotype AA.			= 0.007	Unknown			
1444870968	rs12979860	ledipasvir,sofosbuvir	Efficacy	yes	Genotype CC is associated with increased response to ledipasvir and sofosbuvir in people with Hepatitis C as compared to genotypes CT + TT.			= 0.03	OR			
982045433	rs1529927	bumetanide,furosemide,torasemide	Efficacy	yes	Genotype CC is associated with increased response to bumetanide, furosemide and torasemide in healthy individuals as compared to genotype GG.			< 0.05	Unknown			
982045422	rs1045642	lamivudine,nevirapine	Efficacy	not stated	Allele A is associated with response to lamivudine or nevirapine in people with HIV Infections as compared to allele G.	A			Unknown			
1444707059	rs1127354	peginterferon alfa-2b,ribavirin	Efficacy	no	Genotype CC is not associated with response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype AC.	C		= 0.64	OR			
1446902514	rs1061170	bevacizumab,ranibizumab	Efficacy	yes	Genotype CC is associated with decreased response to bevacizumab and ranibizumab in people with Macular Degeneration as compared to genotypes CT + TT.			= 0.004	OR	0.4	0.21	0.74
1446902514	rs1061170	bevacizumab,ranibizumab	Efficacy	yes	Genotype CC is associated with decreased response to bevacizumab and ranibizumab in people with Macular Degeneration as compared to genotypes CT + TT.	C		= 0.02	OR	0.59	0.38	0.9
1446902514	rs1061170	bevacizumab,ranibizumab	Efficacy	yes	Genotype CC is associated with decreased response to bevacizumab and ranibizumab in people with Macular Degeneration as compared to genotypes CT + TT.	C		= 0.03	OR	0.63	0.42	0.95
1446902514	rs1061170	bevacizumab,ranibizumab	Efficacy	yes	Genotype CC is associated with decreased response to bevacizumab and ranibizumab in people with Macular Degeneration as compared to genotypes CT + TT.	C		= 1.0	OR	1.0	0.2	4.92
1445296829	rs12979860	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	no	Genotype CC is not associated with response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	T			OR			
1444707026	rs11322783	peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype TT/TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.	TT		< 0.001	OR	2.539	1.745	3.693
1444707026	rs11322783	peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype TT/TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.	TT		< 0.001	OR	12.573	3.427	46.133
699639389	rs12255372	sulfonamides, urea derivatives	Efficacy	yes	Genotype TT is associated with decreased response to sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to genotype GG.			= 0.005	OR	1.95	1.23	3.06
1444707045	rs8099917	peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT.	T		< 0.001	OR			
1451128780	rs6923761	sitagliptin,vildagliptin	Efficacy	yes	Genotype AA is associated with decreased clinical benefit to sitagliptin or vildagliptin in people with Diabetes Mellitus, Type 2 as compared to genotypes AG + GG.			= 0.006				
608431246	rs2842030	olanzapine,perphenazine	Efficacy	not stated	Genotype TT is associated with increased response to olanzapine and perphenazine in people with Schizophrenia as compared to genotypes GG + GT.			= 0.05	Unknown			
1444936314	rs12044852	interferon beta-1a,interferon beta-1b	Efficacy	yes	Genotype CC is associated with decreased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to genotypes AA + AC.			< 0.05	OR			
1451128748	rs163184	sitagliptin,vildagliptin	Efficacy	no	Allele G is associated with decreased clinical benefit to sitagliptin or vildagliptin in people with Diabetes Mellitus, Type 2 as compared to allele T.			= 0.083				
1445296808	rs8099917	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotypes GG + GT is associated with decreased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype TT.	G		= 0.003	OR	7.9	1.99	31.18
981750809	rs1805054	citalopram,fluoxetine,paroxetine	Efficacy	no	Allele C is not associated with response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to allele T.				Unknown			
981750801	rs7997012	citalopram,fluoxetine,paroxetine	Efficacy	no	Allele A is not associated with response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to allele G.				Unknown			
981750815	rs1800532	citalopram,fluoxetine,paroxetine	Efficacy	no	Allele T is not associated with response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to allele G.				Unknown			
1449162774	CYP2D6 poor metabolizer genotype	o-desmethyltramadol,tramadol	Metabolism/PK	no	CYP2D6 poor metabolizer genotype is not associated with exposure to o-desmethyl-tramadol or tramadol as compared to CYP2D6 normal metabolizer genotype.			= 0.41	OR			
981750780	rs6295	citalopram,fluoxetine,paroxetine	Efficacy	no	Allele C is not associated with response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to allele G.				Unknown			
981750786	rs6313	citalopram,fluoxetine,paroxetine	Efficacy	no	Allele A is not associated with response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to allele G.				Unknown			
655386834	rs2227631	citalopram,fluoxetine	Efficacy	yes	Allele G is associated with decreased response to citalopram and fluoxetine in people with Depressive Disorder, Major as compared to allele A.			= 0.014	Unknown			
1184467070	rs6313	fluvoxamine,paroxetine	Efficacy	no	Allele G is not associated with response to fluvoxamine or paroxetine in people with Depressive Disorder, Major as compared to allele A.				OR			
1184467075	rs6313	fluvoxamine,paroxetine	Efficacy	no	Allele G is associated with response to fluvoxamine or paroxetine in people with Depressive Disorder, Major as compared to allele A.				OR			
1448573444	rs3745274	3,4-methylenedioxymethamphetamine	Metabolism/PK	yes	Genotype TT is associated with increased concentrations of 3,4-methylenedioxymethamphetamine in healthy individuals as compared to genotype GG.			< 0.05	OR			
1184467092	rs6313	fluvoxamine,paroxetine	Efficacy	no	Allele G is associated with response to fluvoxamine or paroxetine in people with Depressive Disorder, Major as compared to allele A.				OR			
1444706841	rs12979860	peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype CC is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype CT.	C		< 0.02	OR	7.06	1.29	38.56
1444706848	rs8099917	peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT.	T		< 0.0035	OR	4.59	1.03	20.5
1183631503	rs4149601	Aldosterone antagonists,amiloride	Efficacy	yes	Allele G is associated with increased response to Aldosterone antagonists or amiloride in people with Hypertension as compared to allele A.			= 0.050	Unknown			
1444706755	rs1127354	peginterferon alfa-2b,ribavirin	Efficacy	yes	Allele A is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to allele C.			= 0.032	OR	1.4	0.93	2.09
1444706762	rs14158	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype GG is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic and HIV Infections as compared to genotypes AA + AG.	G		= 0.015	OR	2.7	1.59	7.71
1183631485	rs4149601	Beta blocking agents, selective,diuretics	Efficacy	yes	Genotypes AG + GG are associated with increased response to Beta blocking agents, selective or diuretics in people with Hypertension as compared to genotype AA.			= 0.02	Unknown			
1444706772	rs14158	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	no	Genotype GG is not associated with response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic and HIV Infections as compared to genotypes AA + AG.	G		= 0.513	OR			
1183615168	rs5186	atenolol,irbesartan	Efficacy	no	Genotype AA is not associated with response to atenolol or irbesartan in people with Hypertension as compared to genotypes AC + CC.	C			Unknown			
1444706715	rs12979860	peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype CC is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.			= 0.000031	OR	0.31	0.17	0.56
1448573308	CYP2C19 ultrarapid metabolizer genotype	3,4-methylenedioxymethamphetamine	Metabolism/PK	yes	CYP2C19 ultra-metabolizer genotype is associated with increased metabolism of 3,4-methylenedioxymethamphetamine in healthy individuals as compared to CYP2C19 intermediate metabolizer genotype.			< 0.05	OR			
1183615155	rs699	atenolol,irbesartan	Efficacy	no	Genotype GG is not associated with response to atenolol or irbesartan in people with Hypertension as compared to genotypes AA + AG.	G			Unknown			
1444706722	rs12979860	peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype CC is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	C		< 0.0001	OR	5.2	4.1	6.7
1183615160	rs4762	atenolol,irbesartan	Efficacy	no	Genotype GG is not associated with response to atenolol or irbesartan in people with Hypertension as compared to genotype AG.	G			Unknown			
1444706626	rs12979860	peginterferon alfa-2b,ribavirin	Efficacy	yes	Allele T is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele C.	T		< 0.001	OR	8.724	4.031	18.88
827825723	rs1801274	cyclophosphamide,doxorubicin,paclitaxel,trastuzumab	Efficacy	yes	Genotype AA is associated with increased response to cyclophosphamide, doxorubicin, paclitaxel and trastuzumab in women with Breast Neoplasms as compared to genotypes AG + GG.			= 0.015	Unknown			
1449576762	rs10276036	cyclophosphamide,doxorubicin	Efficacy	no	Allele A is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele T.				OR			
1449576756	rs1695	cyclophosphamide,doxorubicin	Efficacy	no	Allele G is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.				OR			
1449576777	rs2229109	cyclophosphamide,doxorubicin	Efficacy	no	Allele C is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele T.				OR			
827810841	rs1042522	cisplatin,paclitaxel	Efficacy	yes	Genotypes CG + GG are associated with decreased response to cisplatin and paclitaxel in people with Stomach Neoplasms as compared to genotype CC.	G		= 0.019	Unknown			
982035812	rs2239050	amlodipine,felodipine	Efficacy	yes	Genotype GG is associated with increased response to amlodipine and felodipine in people with Hypertension as compared to genotype CG.			= 0.05	Unknown			
1449576767	rs112783657	cyclophosphamide,doxorubicin	Efficacy	no	Allele C is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele T.				OR			
1449576792	rs4148737	cyclophosphamide,doxorubicin	Efficacy	no	Allele C is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele T.				OR			
1449576787	rs1128503	cyclophosphamide,doxorubicin	Efficacy	no	Allele G is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.				OR			
827892732	rs1045642	cisplatin,fluorouracil	Efficacy	no	Allele G is not associated with response to cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to allele A.	G		= 0.506	Unknown			
769171579	rs334558	citalopram,fluoxetine	Efficacy	yes	Genotype GG is associated with increased response to citalopram and fluoxetine in people with Depressive Disorder, Major as compared to allele A.			= 0.002	Unknown			
1449576807	rs12721655	cyclophosphamide,doxorubicin	Efficacy	no	Allele G is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.				OR			
1449576802	rs149212925	cyclophosphamide,doxorubicin	Efficacy	no	Allele G is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.				OR			
1449576797	rs1799983	cyclophosphamide,doxorubicin	Efficacy	no	Allele G is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele T.				OR			
1447954657	rs1045642	docetaxel,paclitaxel	Efficacy	no	Allele A is not associated with response to docetaxel or paclitaxel in people with Breast Neoplasms as compared to allele G.	G	G	= 0.075	OR			
1449576822	rs8192709	cyclophosphamide,doxorubicin	Efficacy	no	Allele C is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele T.				OR			
1449576817	rs3211371	cyclophosphamide,doxorubicin	Efficacy	no	Allele C is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele T.				OR			
1449576812	rs4802101	cyclophosphamide,doxorubicin	Efficacy	no	Allele C is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele T.				OR			
1447954643	rs1128503	docetaxel,paclitaxel	Efficacy	no	Allele A is not associated with response to docetaxel or paclitaxel in people with Breast Neoplasms as compared to allele G.	A	A	= 0.138	OR			
827810774	rs7121	cisplatin,fluorouracil	Efficacy	yes	Genotype CC is associated with increased response to cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to genotypes CT + TT.	C		= 0.05	Unknown			
1449576839	rs6907567	cyclophosphamide,doxorubicin	Efficacy	no	Allele G is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.				OR			
1447954649	rs2032582	docetaxel,paclitaxel	Efficacy	no	Allele A is not associated with response to docetaxel or paclitaxel in people with Breast Neoplasms as compared to allele C.	A	A	= 0.194	OR			
1449576834	rs723685	cyclophosphamide,doxorubicin	Efficacy	no	Allele G is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.				OR			
1449576829	rs3745274	cyclophosphamide,doxorubicin	Efficacy	no	Allele T is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.				OR			
1447954627	rs10509681	docetaxel,paclitaxel	Efficacy	no	Allele T is not associated with response to docetaxel or paclitaxel in people with Breast Neoplasms as compared to allele C.	C	C	= 0.888	OR			
1449576859	rs2740574	cyclophosphamide,doxorubicin	Efficacy	no	Allele C is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele T.				OR			
1449576854	rs1143684	cyclophosphamide,doxorubicin	Efficacy	no	Allele C is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele T.				OR			
1447987401	rs56160474	capecitabine,fluorouracil,tegafur / gimeracil / oteracil	Efficacy	no	Genotype AG is not associated with response to capecitabine, fluorouracil or s 1 (combination) in people with Stomach Neoplasms as compared to genotype AA.	G		= 0.0891	OR	0.156	0.018	1.328
1449576844	rs12210538	cyclophosphamide,doxorubicin	Efficacy	no	Allele G is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.				OR			
1447987376	rs1801160	capecitabine,fluorouracil,tegafur / gimeracil / oteracil	Efficacy	no	Genotype CT is not associated with response to capecitabine, fluorouracil or s 1 (combination) in people with Stomach Neoplasms as compared to genotype CC.	T		= 0.0555	OR	0.319	0.099	1.027
1449576874	rs117458836	cyclophosphamide,doxorubicin	Efficacy	no	Allele G is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.				OR			
1449576869	rs181501757	cyclophosphamide,doxorubicin	Efficacy	no	Allele G is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.				OR			
1447954607	rs2740574	docetaxel,paclitaxel	Efficacy	no	Genotype CC is not associated with response to docetaxel or paclitaxel in people with Breast Neoplasms as compared to genotypes CT + TT.			= 0.319	OR			
1447987385	rs2297595	capecitabine,fluorouracil,tegafur / gimeracil / oteracil	Efficacy	no	Genotype CT is not associated with response to capecitabine, fluorouracil or s 1 (combination) in people with Stomach Neoplasms as compared to genotype TT.	C		= 0.4294	OR	1.564	0.516	4.74
1449576864	rs3957357	cyclophosphamide,doxorubicin	Efficacy	no	Allele G is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.				OR			
1447954614	rs1056836	docetaxel,paclitaxel	Efficacy	no	Genotype GG is not associated with response to docetaxel or paclitaxel in people with Breast Neoplasms as compared to genotypes CC + CG.	G	G	= 0.454	OR			
1447987361	rs1801159	capecitabine,fluorouracil,tegafur / gimeracil / oteracil	Efficacy	yes	Genotypes CC + CT are associated with decreased response to capecitabine, fluorouracil or s 1 (combination) in people with Stomach Neoplasms as compared to genotype TT.	C		= 0.0186	OR	0.595	0.387	0.917
1451133400	rs9909004	Ace Inhibitors, Plain,Angiotensin II Antagonists,Beta Blocking Agents	Efficacy	no	Allele C is not associated with response to Ace Inhibitors, Plain, Angiotensin II Antagonists or Beta Blocking Agents in people with Heart Failure as compared to allele T.	C		= 0.157				
1451133400	rs9909004	Ace Inhibitors, Plain,Angiotensin II Antagonists,Beta Blocking Agents	Efficacy	no	Allele C is not associated with response to Ace Inhibitors, Plain, Angiotensin II Antagonists or Beta Blocking Agents in people with Heart Failure as compared to allele T.	C		= 0.500				
1447954597	rs776746	docetaxel,paclitaxel	Efficacy	yes	Genotype CC is associated with decreased response to docetaxel or paclitaxel in people with Breast Neoplasms as compared to genotypes CT + TT.	C	C	= 0.0465	OR	0.26	0.08	0.86
1449576962	rs3828743	abiraterone,prednisolone	Efficacy	yes	Allele A is associated with decreased response to abiraterone and prednisolone in people with Prostatic Neoplasms as compared to allele G.			= 0.013	OR	2.47	1.23	4.96
1451133423	rs9303504	Ace Inhibitors, Plain,Angiotensin II Antagonists,Beta Blocking Agents	Efficacy	no	Allele G is not associated with response to Ace Inhibitors, Plain, Angiotensin II Antagonists or Beta Blocking Agents in people with Heart Failure as compared to allele C.	G		= 0.301				
1451133423	rs9303504	Ace Inhibitors, Plain,Angiotensin II Antagonists,Beta Blocking Agents	Efficacy	no	Allele G is not associated with response to Ace Inhibitors, Plain, Angiotensin II Antagonists or Beta Blocking Agents in people with Heart Failure as compared to allele C.	G		= 0.445				
981478966	rs12979860	peginterferon alfa-2a,ribavirin	Efficacy	yes	Genotypes CC + CT are associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C as compared to genotype TT.			= 0.02	Unknown			
981478976	rs12979860	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.			< 0.05	Unknown			
981954215	rs2769605	lithium,valproic acid	Efficacy	yes	Genotype CC is associated with decreased response to lithium or valproic acid in people with Bipolar Disorder as compared to genotypes CT + TT.			= 0.013	Unknown			
1184168589	rs2010963	bevacizumab,pegaptanib,ranibizumab	Efficacy	yes	Genotype CC is associated with decreased response to bevacizumab, pegaptanib or ranibizumab in people with Choroidal Neovascularization as compared to genotypes CG + GG.			= 0.008	OR	11.4	2.46	103.0
1184168589	rs2010963	bevacizumab,pegaptanib,ranibizumab	Efficacy	yes	Genotype CC is associated with decreased response to bevacizumab, pegaptanib or ranibizumab in people with Choroidal Neovascularization as compared to genotypes CG + GG.	G		= 0.016	OR			
1184168589	rs2010963	bevacizumab,pegaptanib,ranibizumab	Efficacy	yes	Genotype CC is associated with decreased response to bevacizumab, pegaptanib or ranibizumab in people with Choroidal Neovascularization as compared to genotypes CG + GG.	G		= 0.04	OR	2.3	1.06	5.34
769171257	rs70991108	folic acid,hydroxychloroquine,methotrexate,sulfasalazine	Efficacy	no	Allele del is not associated with response to folic acid, hydroxychloroquine, methotrexate and sulfasalazine in people with Arthritis, Rheumatoid.	del	del	= 1.0	Unknown			
769171254	rs1979277	folic acid,hydroxychloroquine,methotrexate,sulfasalazine	Efficacy	no	Allele A is not associated with response to folic acid, hydroxychloroquine, methotrexate and sulfasalazine in people with Arthritis, Rheumatoid.	G	G	= 1.0	Unknown			
769171251	rs2372536	folic acid,hydroxychloroquine,methotrexate,sulfasalazine	Efficacy	no	Allele C is not associated with response to folic acid, hydroxychloroquine, methotrexate and sulfasalazine in people with Arthritis, Rheumatoid as compared to allele G.	C	C	= 0.56	Unknown			
769171245	rs1801131	folic acid,hydroxychloroquine,methotrexate,sulfasalazine	Efficacy	no	Allele G is not associated with response to folic acid, hydroxychloroquine, methotrexate and sulfasalazine in people with Arthritis, Rheumatoid.	T	T	= 1.0	Unknown			
982036189	rs2239128	lacidipine,nifedipine,nitrendipine	Efficacy	no	Allele C is not associated with response to lacidipine, nifedipine or nitrendipine in people with Hypertension as compared to allele T.				Unknown			
981954223	rs1565445	lithium,valproic acid	Efficacy	no	Genotype AA is not associated with response to lithium or valproic acid in people with Bipolar Disorder as compared to genotypes AG + GG.			= 0.458	Unknown			
982036156	rs2239128	amlodipine,felodipine	Efficacy	yes	Allele C is associated with increased response to amlodipine and felodipine in people with Hypertension as compared to allele T.			= 0.04	Unknown			
982036265	rs1799998	benazepril,imidapril	Efficacy	no	Genotypes AA + AG are not associated with response to benazepril or imidapril in people with Essential hypertension as compared to genotype GG.	G		= 0.09	Unknown			
982036265	rs1799998	benazepril,imidapril	Efficacy	no	Genotypes AA + AG are not associated with response to benazepril or imidapril in people with Essential hypertension as compared to genotype GG.	G		= 0.162	Unknown			
1451133680	rs1799971	morphine,nortriptyline	Efficacy	no	Allele G is not associated with response to morphine and nortriptyline in people with Pain as compared to allele A.	G		= 0.854				
1184168705	rs11322783	peginterferon alfa-2a,ribavirin	Efficacy	yes	Genotype TT/TT is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C as compared to genotypes G/TT + GG.	G	TT	= 6.153e-8	OR	4.783	2.714	8.428
1184168705	rs11322783	peginterferon alfa-2a,ribavirin	Efficacy	yes	Genotype TT/TT is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C as compared to genotypes G/TT + GG.	G	TT	= 8.940e-8	OR			
982036232	rs1799998	benazepril,imidapril	Efficacy	yes	Genotypes AA + AG are associated with increased response to benazepril or imidapril in people with Essential hypertension as compared to genotype GG.	G		= 0.001	Unknown			
982036232	rs1799998	benazepril,imidapril	Efficacy	yes	Genotypes AA + AG are associated with increased response to benazepril or imidapril in people with Essential hypertension as compared to genotype GG.	G		= 0.002	Unknown			
1183611749	rs3812718	carbamazepine,valproic acid	Efficacy	no	Allele T is not associated with response to carbamazepine or valproic acid in people with Epilepsy as compared to allele C.			= 0.39	Unknown			
1451133746	rs7997012	morphine,nortriptyline	Efficacy	no	Allele G is not associated with response to morphine and nortriptyline in people with Pain as compared to allele A.	A		= 0.786				
1446905582	rs7270101	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	no	Genotype AA is not associated with response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AC + CC.	C		= 0.27	OR	0.67	0.34	1.36
1451133752	CYP2C19 intermediate metabolizer	morphine,nortriptyline	Efficacy	no	CYP2C19 intermediate metabolizer is not associated with response to morphine and nortriptyline in people with Pain as compared to CYP2C19 normal metabolizer.			= 0.939				
1451133757	CYP2C19 poor metabolizer	morphine,nortriptyline	Efficacy	no	CYP2C19 poor metabolizer is not associated with response to morphine and nortriptyline in people with Pain as compared to CYP2C19 normal metabolizer.			= 0.729				
1446905573	rs1127354	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	no	Genotype CC is not associated with response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AA + AC.	A		= 0.27	OR	0.67	0.34	1.36
769171242	rs1801133	folic acid,hydroxychloroquine,methotrexate,sulfasalazine	Efficacy	no	Allele A is not associated with response to folic acid, hydroxychloroquine, methotrexate and sulfasalazine in people with Arthritis, Rheumatoid.	G	G	= 0.39	Unknown			
769171237	rs45445694	folic acid,hydroxychloroquine,methotrexate,sulfasalazine	Efficacy	yes	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 is associated with increased response to folic acid, hydroxychloroquine, methotrexate and sulfasalazine in people with Arthritis, Rheumatoid as compared to genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.			= 0.009	Unknown			
769171237	rs45445694	folic acid,hydroxychloroquine,methotrexate,sulfasalazine	Efficacy	yes	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 is associated with increased response to folic acid, hydroxychloroquine, methotrexate and sulfasalazine in people with Arthritis, Rheumatoid as compared to genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.	3	3	= 0.09	Unknown			
769171236	rs1805087	folic acid,hydroxychloroquine,methotrexate,sulfasalazine	Efficacy	yes	Allele A is associated with increased response to folic acid, hydroxychloroquine, methotrexate and sulfasalazine in people with Arthritis, Rheumatoid as compared to allele G.	A		= 0.06	OR	2.6	1.1	6.1
769171231	rs1051266	folic acid,hydroxychloroquine,methotrexate,sulfasalazine	Efficacy	yes	Allele T is associated with increased response to folic acid, hydroxychloroquine, methotrexate and sulfasalazine in people with Arthritis, Rheumatoid as compared to allele C.	T	T	= 0.009	OR	3.1	1.3	7.7
982036522	rs1042714	atenolol,enalapril	Efficacy	yes	Genotypes CG + GG are associated with increased response to atenolol and enalapril in people with Hypertrophy, Left Ventricular as compared to genotype CC.	G		< 0.01	Unknown			
1184349257	HLA-B*44:02:01:01	interferon alfa-2a, recombinant,ribavirin	Efficacy	yes	HLA-B *44:02:01:01 is associated with increased response to interferon alfa-2a, recombinant and ribavirin in people with Hepatitis C.			= 0.017	OR	4.84	1.31	17.8
1451101326	rs2741049	azathioprine,mycophenolic acid	Efficacy	no	Allele T is not associated with response to azathioprine or mycophenolic acid in people with lung transplantation as compared to allele C.	T	T					
1451101338	rs2306283	azathioprine,mycophenolic acid	Efficacy	no	Allele G is not associated with response to azathioprine or mycophenolic acid in people with lung transplantation as compared to allele A.	G	G					
1451101332	rs3740066	azathioprine,mycophenolic acid	Efficacy	no	Allele T is not associated with response to azathioprine or mycophenolic acid in people with lung transplantation as compared to allele C.	T	T					
1451101320	rs1042597	azathioprine,mycophenolic acid	Efficacy	no	Allele G is not associated with response to azathioprine or mycophenolic acid in people with lung transplantation as compared to allele C.	G	G					
981479639	rs8099917	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotypes GG + GT are associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT.			= 0.002	OR	17.2	1.9	100.0
1184349397	rs2032582	efavirenz,nevirapine	Metabolism/PK	no	Genotype AA is not associated with metabolism of efavirenz or nevirapine in people with HIV Infections as compared to genotype CC.			= 0.06	OR			
1184349397	rs2032582	efavirenz,nevirapine	Metabolism/PK	no	Genotype AA is not associated with metabolism of efavirenz or nevirapine in people with HIV Infections as compared to genotype CC.			= 0.50	OR			
1184349357	rs2279343	efavirenz,nevirapine	Metabolism/PK	no	Genotype GG is not associated with metabolism of efavirenz or nevirapine in people with HIV Infections as compared to genotype AA.			= 0.087	OR			
1184349357	rs2279343	efavirenz,nevirapine	Metabolism/PK	no	Genotype GG is not associated with metabolism of efavirenz or nevirapine in people with HIV Infections as compared to genotype AA.			= 0.73	OR			
981954839	rs2032582	carbamazepine,phenobarbital,phenytoin,valproic acid	Efficacy	no	Genotype AT is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy.				Unknown			
981954805	rs2032582	carbamazepine,phenobarbital,phenytoin,valproic acid	Efficacy	no	Genotype AC is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy.				Unknown			
1184513240	rs57098334	fluoxetine,sertraline	Efficacy	yes	Genotype (CCCACCCGA)12/(CCCACCCGA)12 is associated with increased response to fluoxetine or sertraline in people with Depressive Disorder, Major.			= 0.01	OR			
981479677	rs8099917	peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.			< 1.0E-4	Unknown			
981479690	rs8099917	peginterferon alfa-2b,ribavirin	Other	no	Genotype TT is not associated with resistance to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.				Unknown			
1184349427	rs1045642	efavirenz,nevirapine	Metabolism/PK	no	Genotype GG is not associated with metabolism of efavirenz or nevirapine in people with HIV Infections as compared to genotype AA.			= 0.31	OR			
1184349427	rs1045642	efavirenz,nevirapine	Metabolism/PK	no	Genotype GG is not associated with metabolism of efavirenz or nevirapine in people with HIV Infections as compared to genotype AA.			= 0.86	OR			
981954817	rs2032582	carbamazepine,phenobarbital,phenytoin,valproic acid	Efficacy	no	Genotype AA is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy.				Unknown			
1448428834	rs1884725	allopurinol,febuxostat	Dosage	yes	Allele G is associated with decreased dose of allopurinol or febuxostat in people with Gout as compared to allele A.	G		= 0.035	OR			
1448428823	rs75995567	allopurinol,febuxostat	Dosage	yes	Allele T is associated with increased dose of allopurinol or febuxostat in people with Gout as compared to allele C.	C		= 0.031	OR			
1448428814	rs3731722	allopurinol,febuxostat	Dosage	yes	Allele G is associated with dose of allopurinol or febuxostat in people with Gout as compared to allele A.	G		= 0.001	OR			
1448428803	rs11678615	allopurinol,febuxostat	Dosage	yes	Allele T is associated with dose of allopurinol or febuxostat in people with Gout as compared to allele C.	T		= 0.025	OR			
827812110	rs9679162	cisplatin,fluorouracil,mitoxantrone	Efficacy	yes	Genotype TT is associated with increased response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to genotypes GG + GT.			= 2.0E-5	Unknown			
827812110	rs9679162	cisplatin,fluorouracil,mitoxantrone	Efficacy	yes	Genotype TT is associated with increased response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to genotypes GG + GT.			= 4.43E-4	Unknown			
827812110	rs9679162	cisplatin,fluorouracil,mitoxantrone	Efficacy	yes	Genotype TT is associated with increased response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to genotypes GG + GT.			= 0.003695	Unknown			
1183612568	rs2298771	carbamazepine,valproic acid	Efficacy	no	Allele T is not associated with response to carbamazepine or valproic acid in people with Epilepsy as compared to allele C.			= 0.81	OR	0.98	0.83	1.16
1451216520	rs72552763	sulfonamides, urea derivatives	Efficacy	no	Allele del is not associated with response to sulfonamides, urea derivatives in people with Diabetes Mellitus as compared to allele GAT.	GAT		> 0.05	OR			
1184513727	rs529520	buprenorphine,methadone	Efficacy	no	Allele A is not associated with response to buprenorphine or methadone in men with Opioid-Related Disorders as compared to allele C.			= 0.64	OR			
1184513732	rs581111	buprenorphine,methadone	Efficacy	no	Allele A is not associated with response to buprenorphine or methadone in men with Opioid-Related Disorders as compared to allele G.			= 0.94	OR			
1184169737	rs1786929	fluticasone propionate,montelukast	Efficacy	yes	Genotypes AA + AG is associated with increased response to fluticasone propionate or montelukast in children with Asthma as compared to genotype GG.	G		= 0.022	OR			
608178498	rs6295	fluvoxamine,milnacipran,paroxetine	Efficacy	yes	Genotype GG is associated with increased response to fluvoxamine, milnacipran and paroxetine in people with Depressive Disorder, Major as compared to genotypes CC + CG.	G		= 5.0E-4	Unknown			
608178504	rs10042486	fluvoxamine,milnacipran,paroxetine	Efficacy	yes	Genotype CC is associated with increased response to fluvoxamine, milnacipran and paroxetine in people with Depressive Disorder, Major as compared to genotypes CT + TT.			= 1.0E-4	Unknown			
1184169710	rs967676	fluticasone propionate,montelukast	Efficacy	yes	Genotypes CC + CT is associated with increased response to fluticasone propionate or montelukast in children with Asthma as compared to genotype TT.	C		= 0.034	OR			
1183612769	rs2298771	carbamazepine,valproic acid	Efficacy	no	Allele T is not associated with response to carbamazepine or valproic acid in people with Epilepsy as compared to allele C.	C		= 0.81	Unknown			
1185234957	rs1803274	memantine,rivastigmine	Efficacy	yes	Genotypes CT + TT is associated with decreased response to memantine and rivastigmine in people with Alzheimer Disease as compared to genotype CC.	C	T	= 0.048	OR			
1450807240	CYP2C19 poor metabolizers	lansoprazole,omeprazole,pantoprazole	Metabolism/PK	not stated	CYP2C19 poor metabolizers are associated with decreased metabolism of lansoprazole, omeprazole or pantoprazole in healthy individuals as compared to CYP2C19 normal metabolizers.				OR			
827778829	rs1128503	dexamethasone,diphenhydramine,paclitaxel,ranitidine	Efficacy	not stated	Genotypes AA + AG are associated with increased response to dexamethasone, diphenhydramine, paclitaxel and ranitidine in people with Head and Neck Neoplasms as compared to genotype GG.				Unknown			
1446904209	rs13015258	peginterferon alfa-2a,peginterferon alfa-2b	Efficacy	no	Genotype GG is not associated with response to peginterferon alfa-2a or peginterferon alfa-2b in people with Hepatitis C, Chronic as compared to genotypes GT + TT.	G	T	> 0.05	OR			
1446904218	rs17848916	peginterferon alfa-2a,peginterferon alfa-2b	Efficacy	no	Genotype AC is not associated with response to peginterferon alfa-2a or peginterferon alfa-2b in people with Hepatitis C, Chronic as compared to genotype AA.	A	C	> 0.05	OR			
1446904224	rs17574	peginterferon alfa-2a,peginterferon alfa-2b	Efficacy	no	Genotype AA is not associated with response to peginterferon alfa-2a or peginterferon alfa-2b in people with Hepatitis C, Chronic as compared to genotype AG.	G	A	> 0.05	OR			
982035751	rs2238032	amlodipine,felodipine	Efficacy	yes	Genotype TT is associated with increased response to amlodipine or felodipine in people with Hypertension as compared to genotypes GG + GT.			= 2.5E-9	Unknown			
1451147601	rs10264272	ambrisentan,aripiprazole,atorvastatin,donepezil,olanzapine	Metabolism/PK	no	Allele T is not associated with metabolism of ambrisentan, aripiprazole, atorvastatin, donepezil or olanzapine in healthy individuals as compared to allele C.							
1451114801	rs776746	lopinavir,ritonavir	Metabolism/PK	no	Allele C is not associated with response to lopinavir or ritonavir in children with HIV Infections as compared to allele T.	C						
1451147565	rs776746	ambrisentan,aripiprazole,atorvastatin,donepezil,olanzapine	Metabolism/PK	no	Allele C is not associated with metabolism of ambrisentan, aripiprazole, atorvastatin, donepezil or olanzapine in healthy individuals as compared to allele T.							
1451147572	rs67666821	ambrisentan,aripiprazole,atorvastatin,donepezil,olanzapine	Metabolism/PK	no	Allele T is not associated with metabolism of ambrisentan, aripiprazole, atorvastatin, donepezil or olanzapine in healthy individuals as compared to allele del.							
1451147580	rs35599367	ambrisentan,aripiprazole,atorvastatin,donepezil,olanzapine	Metabolism/PK	no	Allele A is not associated with metabolism of ambrisentan, aripiprazole, atorvastatin, donepezil or olanzapine in healthy individuals as compared to allele G.							
1451114826	rs1045642	lopinavir,ritonavir	Metabolism/PK	no	Allele A is not associated with exposure to lopinavir or ritonavir in children with HIV Infections as compared to allele G.	A						
1451114820	rs776746	lopinavir,ritonavir	Metabolism/PK	no	Allele C is not associated with clearance of lopinavir or ritonavir in children with HIV Infections as compared to allele T.	C						
1451114900	rs2306283	lopinavir,ritonavir	Metabolism/PK	no	Allele G is not associated with response to lopinavir or ritonavir in children with HIV Infections as compared to allele A.	A						
1451114920	rs2306283	lopinavir,ritonavir	Metabolism/PK	no	Allele G is not associated with clearance of lopinavir or ritonavir in children with HIV Infections as compared to allele A.	A						
1451114866	rs2032582	lopinavir,ritonavir	Metabolism/PK	no	Allele A is not associated with exposure to lopinavir or ritonavir in children with HIV Infections as compared to allele C.	A						
1451114860	rs2032582	lopinavir,ritonavir	Metabolism/PK	no	Allele A is not associated with clearance of lopinavir or ritonavir in children with HIV Infections as compared to allele C.	A						
1451114872	rs2032582	lopinavir,ritonavir	Metabolism/PK	no	Allele A is not associated with response to lopinavir or ritonavir in children with HIV Infections as compared to allele C.	A						
1451114883	rs2306283	lopinavir,ritonavir	Metabolism/PK	no	Allele G is not associated with exposure to lopinavir or ritonavir in children with HIV Infections as compared to allele A.	A						
1444843635	rs12979860	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	no	Genotype CC is not associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.			= 0.64	OR			
1444843642	rs12979860	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.			< 0.001	OR			
1444843653	rs11322783	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype TT/TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes G/TT + GG.			< 0.001	OR			
1444843667	rs11322783	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype TT/TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes G/TT + GG.			< 0.0001	OR			
1451114925	rs4149056	lopinavir,ritonavir	Metabolism/PK	no	Allele C is not associated with response to lopinavir or ritonavir in children with HIV Infections as compared to allele T.	C						
1444843675	rs11322783	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin,telaprevir	Efficacy	yes	Genotype TT/TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C as compared to genotypes G/TT + GG.			= 0.0727	OR			
1444843578	rs8099917	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype GT.			= 0.007	OR	6.491	1.669	25.241
1444843596	rs11881222	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype AA is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype AG.			= 0.007	OR	6.491	1.669	25.241
1449165334	rs9344	cetuximab,panitumumab	Efficacy	no	Allele A is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to allele G.			= 0.652	RR	1.14	0.64	2.04
1449165345	rs20417	cetuximab,panitumumab	Efficacy	no	Allele C is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to allele G.			= 0.155	RR	2.67	0.69	10.36
1444843627	rs12979860	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.			= 0.008	OR			
1449165351	rs4444903	cetuximab,panitumumab	Efficacy	no	Allele G is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to allele A.			= 0.023	RR	1.81	1.08	3.02
1449165359	rs712829	cetuximab,panitumumab	Efficacy	no	Allele T is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to allele G.			= 0.331	RR	1.27	0.78	2.06
1449165367	rs2227983	cetuximab,panitumumab	Efficacy	no	Allele A is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to allele G.			= 0.047	RR	1.52	1.01	2.31
1449165374	rs1801274	cetuximab,panitumumab	Efficacy	no	Allele G is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to allele A.			= 0.251	RR	1.09	0.94	1.27
1448821318	rs2298771	carbamazepine,clobazam,ethosuximide,lamotrigine,levetiracetam,oxcarbazepine,valproic acid	Efficacy	yes	Allele C is associated with increased response to carbamazepine, clobazam, ethosuximide, lamotrigine, levetiracetam, oxcarbazepine or valproic acid in children with Epilepsy as compared to allele T.			= 0.013	OR	2.0	1.16	3.46
1449165380	rs396991	cetuximab,panitumumab	Efficacy	no	Allele C is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to allele A.			= 0.781	RR	1.03	0.85	1.24
1449165394	rs61764370	cetuximab,panitumumab	Efficacy	no	Allele C is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to allele A.			= 0.370	RR	1.36	0.7	2.65
1449165388	rs4073	cetuximab,panitumumab	Efficacy	no	Allele T is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to allele A.			= 0.324	RR	1.29	0.78	2.13
1449165400	rs3025039	cetuximab,panitumumab	Efficacy	no	Allele T is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to allele C.			= 0.71	RR	1.34	0.81	2.21
1184510631	rs13104811	cetuximab,panitumumab	Efficacy	yes	Genotype GG is associated with increased response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes AA + AG.			= 0.006	OR			
1447989193	rs116855232	azathioprine,mercaptopurine	Dosage	not stated	Genotypes CT + TT is associated with decreased dose of azathioprine or mercaptopurine.				OR			
1444843476	rs3828913	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AA + AC.	C		= 0.009	OR	4.47	1.46	13.7
1444843486	rs8099917	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic and Hepatitis C, Chronic as compared to genotypes GG + GT.	T		= 0.001	OR	7.14	2.19	23.22
1448267671	rs1127354	azathioprine,mercaptopurine	Metabolism/PK	yes	Genotypes AA + AC is associated with decreased metabolism of azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to genotype CC.	A		= 0.015	OR			
1184510725	rs712829	cetuximab,panitumumab	Efficacy	no	Genotype GG is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes GT + TT.			= 0.089	OR	3.27	0.83	15.14
1184510737	rs2227983	cetuximab,panitumumab	Efficacy	no	Genotype GG is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes AA + AG.			= 0.807	OR	0.88	0.33	2.5
1184510741	rs6533485	cetuximab,panitumumab	Efficacy	no	Genotype GG is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes CC + CG.			= 0.671	OR	1.23	0.47	3.38
1184510749	rs4698803	cetuximab,panitumumab	Efficacy	no	Genotype TT is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes AA + AT.			= 0.973	OR	0.98	0.25	4.13
1184510753	rs4444903	cetuximab,panitumumab	Efficacy	no	Genotype AA is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes AG + GG.			= 0.845	OR	1.1	0.41	3.1
1184510757	rs11568972	cetuximab,panitumumab	Efficacy	no	Genotype AA is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes AC + CC.			= 0.508	OR	1.5	0.46	5.47
1184510761	rs929446	cetuximab,panitumumab	Efficacy	no	Genotype CC is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes CT + TT.			= 0.845	OR	1.1	0.41	3.1
1184510640	rs11942466	cetuximab,panitumumab	Efficacy	yes	Genotype AA is associated with decreased response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes AC + CC.	A		= 0.038	OR	0.29	0.07	0.94
1184510644	rs9996584	cetuximab,panitumumab	Efficacy	yes	Genotype AA is associated with increased response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes AG + GG.	A		= 0.041	OR	3.77	1.05	16.88
1184510648	rs1353295	cetuximab,panitumumab	Efficacy	yes	Genotype GG is associated with increased response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes AA + AG.			= 0.045	OR			
769250992	rs8103142	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Allele T is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to allele C.			= 1.37E-28	OR	3.1	2.1	4.7
769250998	rs28416813	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Allele G is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to allele C.			= 1.37E-28	OR	3.1	2.1	4.7
1185002388	rs2291078	capecitabine,fluorouracil	Efficacy	no	Allele A is associated with decreased response to capecitabine and fluorouracil in people with Neoplasm Metastasis as compared to allele T.	A	T	= 0.036	OR			
1450951476	rs3918290	cisplatin,fluorouracil	Efficacy	yes	Genotype CT is associated with decreased response to cisplatin and fluorouracil in men with Head and Neck Neoplasms as compared to genotype CC.			= 0.00	OR			
1184510873	UGT1A1*60	irinotecan,oxaliplatin,tegafur / gimeracil / oteracil	Efficacy	yes	UGT1A1 *60 is associated with decreased response to irinotecan, oxaliplatin and s 1 (combination) in people with Colorectal Neoplasms.	*60		= 0.008	OR	0.16	0.03	0.94
1449001814	rs760370	tipiracil hydrochloride,trifluridine	Efficacy	yes	Genotypes AG + GG is associated with increased response to tipiracil hydrochloride and trifluridine in people with Colorectal Neoplasms as compared to genotype AA.	A	G	= 0.008	HR	0.17	0.05	0.63
1449001814	rs760370	tipiracil hydrochloride,trifluridine	Efficacy	yes	Genotypes AG + GG is associated with increased response to tipiracil hydrochloride and trifluridine in people with Colorectal Neoplasms as compared to genotype AA.	A	G	= 0.023	HR	0.44	0.22	0.89
1449001814	rs760370	tipiracil hydrochloride,trifluridine	Efficacy	yes	Genotypes AG + GG is associated with increased response to tipiracil hydrochloride and trifluridine in people with Colorectal Neoplasms as compared to genotype AA.	A	G	= 0.027	HR	0.54	0.31	0.93
1449001814	rs760370	tipiracil hydrochloride,trifluridine	Efficacy	yes	Genotypes AG + GG is associated with increased response to tipiracil hydrochloride and trifluridine in people with Colorectal Neoplasms as compared to genotype AA.	A	G	= 0.038	HR	0.65	0.43	0.98
1184510765	rs2074390	cetuximab,panitumumab	Efficacy	no	Genotype GG is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes AA + AG.			= 0.788	OR	1.14	0.43	3.18
1184510769	rs6850557	cetuximab,panitumumab	Efficacy	no	Genotype GG is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes AA + AG.			= 0.449	OR	1.59	0.49	5.84
1184985914	rs12979860	peginterferon alfa-2a,ribavirin	Efficacy	yes	Genotype CC is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	C	T	= 4.647e-7	OR	4.156	2.388	7.232
1184985914	rs12979860	peginterferon alfa-2a,ribavirin	Efficacy	yes	Genotype CC is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	C	T	= 6.459e-7	OR			
1184510773	rs3913032	cetuximab,panitumumab	Efficacy	no	Genotype CC is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes AA + AC.			= 0.069	OR	2.41	0.93	7.13
1184510777	rs6447003	cetuximab,panitumumab	Efficacy	no	Genotype CC is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes CG + GG.			= 0.081	OR	3.1	0.88	13.95
1184510781	rs10034692	cetuximab,panitumumab	Efficacy	no	Genotype GG is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes AA + AG.			= 0.371	OR	1.63	0.57	5.49
1184510785	rs11725706	cetuximab,panitumumab	Efficacy	no	Genotype GG is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes AA + AG.			= 0.586	OR	0.68	0.16	2.7
1184510789	rs2132065	cetuximab,panitumumab	Efficacy	no	Genotype AA is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes AT + TT.			= 0.803	OR	0.86	0.27	2.83
1184510793	rs1017733	cetuximab,panitumumab	Efficacy	no	Genotype TT is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes CC + CT.			= 0.303	OR	0.54	0.16	1.75
1184510797	rs7687621	cetuximab,panitumumab	Efficacy	no	Genotype CC is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes CT + TT.			= 0.484	OR	0.66	0.2	2.18
1450951563	rs1801158	cisplatin,fluorouracil	Efficacy	no	Allele T is not associated with response to cisplatin and fluorouracil in men with Head and Neck Neoplasms as compared to allele C.			= 0.06	OR			
1184985954	rs861539	cisplatin,docetaxel,irinotecan	Efficacy	yes	Genotype AA is associated with decreased response to cisplatin, docetaxel and irinotecan in people with Stomach Neoplasms as compared to genotypes AG + GG.	A		= 0.04	OR			
1185002489	rs17160359	capecitabine,fluorouracil	Efficacy	not stated	Allele T is associated with increased response to capecitabine and fluorouracil in people with Neoplasm Metastasis as compared to allele G.	T	T		OR			
769250871	rs2010963	capecitabine,oxaliplatin	Efficacy	yes	Genotype CG is associated with decreased response to capecitabine and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes CC + GG.			= 0.04	HR	1.65	0.98	2.77
1185002481	rs2236722	capecitabine,fluorouracil	Efficacy	not stated	Allele G is associated with decreased response to capecitabine and fluorouracil in people with Neoplasm Metastasis as compared to allele A.	G	G		OR			
1043818101	rs9934438	acenocoumarol,phenprocoumon	Dosage	yes	Genotypes AA + AG are associated with decreased dose of acenocoumarol or phenprocoumon as compared to genotype GG.	A		< 1.0E-4	Unknown			
1043818101	rs9934438	acenocoumarol,phenprocoumon	Dosage	yes	Genotypes AA + AG are associated with decreased dose of acenocoumarol or phenprocoumon as compared to genotype GG.	A		< 1.0E-4	Unknown			
827812238	rs1734791	cisplatin,fluorouracil,mitoxantrone	Efficacy	yes	Allele A is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele T.	A		= 6.0E-5	Unknown			
827812230	rs1734787	cisplatin,fluorouracil,mitoxantrone	Efficacy	yes	Allele A is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele C.	C		= 6.0E-5	Unknown			
827812222	rs17435	cisplatin,fluorouracil,mitoxantrone	Efficacy	yes	Allele A is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele T.	A		= 6.0E-5	Unknown			
827812217	rs5906072	cisplatin,fluorouracil,mitoxantrone	Efficacy	yes	Allele T is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele C.	T		= 1.5E-5	Unknown			
827812210	rs5934731	cisplatin,fluorouracil,mitoxantrone	Efficacy	yes	Allele C is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele T.	C		= 3.7E-5	Unknown			
827812205	rs715171	cisplatin,fluorouracil,mitoxantrone	Efficacy	yes	Allele C is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele T.	C		= 3.0E-6	Unknown			
827812200	rs4932551	cisplatin,fluorouracil,mitoxantrone	Efficacy	yes	Allele C is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele G.	C		= 2.4E-5	Unknown			
827812195	rs7170769	cisplatin,fluorouracil,mitoxantrone	Efficacy	yes	Allele T is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele C.	T		= 2.4E-5	Unknown			
1185002413	rs3218592	capecitabine,fluorouracil	Efficacy	no	Allele T is associated with decreased response to capecitabine and fluorouracil in people with Neoplasm Metastasis as compared to allele C.	C	T	= 0.003	OR			
1185002413	rs3218592	capecitabine,fluorouracil	Efficacy	no	Allele T is associated with decreased response to capecitabine and fluorouracil in people with Neoplasm Metastasis as compared to allele C.	C	T	= 0.367	OR			
827812190	rs6458232	cisplatin,fluorouracil,mitoxantrone	Efficacy	yes	Allele C is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele A.	C		= 2.4E-5	Unknown			
827812178	rs12613732	cisplatin,fluorouracil,mitoxantrone	Efficacy	yes	Allele G is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele T.	G		= 1.5E-5	Unknown			
827812166	rs6752303	cisplatin,fluorouracil,mitoxantrone	Efficacy	yes	Allele C is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele T.	C		= 2.4E-5	Unknown			
1185002444	rs2289310	capecitabine,fluorouracil	Efficacy	not stated	Allele T is associated with increased response to capecitabine and fluorouracil in people with Neoplasm Metastasis as compared to allele G.	T	T		OR			
1184510932	UGT1A1*6	irinotecan,oxaliplatin,tegafur / gimeracil / oteracil	Efficacy	no	UGT1A1 *6 is not associated with response to irinotecan, oxaliplatin and s 1 (combination) in people with Colorectal Neoplasms.	*6		= 0.169	OR			
827812160	rs10209881	cisplatin,fluorouracil,mitoxantrone	Efficacy	yes	Allele C is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele T.	C		= 2.4E-5	Unknown			
827812154	rs12999804	cisplatin,fluorouracil,mitoxantrone	Efficacy	yes	Allele A is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele T.	T		= 1.5E-5	Unknown			
1184510940	UGT1A1*28	irinotecan,oxaliplatin,tegafur / gimeracil / oteracil	Efficacy	no	UGT1A1 *28 is not associated with response to irinotecan, oxaliplatin and s 1 (combination) in people with Colorectal Neoplasms.	*28		= 0.107	OR			
1185002474	rs17431184	capecitabine,fluorouracil	Efficacy	not stated	Allele C is associated with increased response to capecitabine and fluorouracil in people with Neoplasm Metastasis as compared to allele T.	C	C		OR			
1184510946	UGT1A6*2a	irinotecan,oxaliplatin,tegafur / gimeracil / oteracil	Efficacy	no	UGT1A6 *2a is not associated with response to irinotecan, oxaliplatin and s 1 (combination) in people with Colorectal Neoplasms.			= 0.169	OR			
1184510952	UGT1A7*3	irinotecan,oxaliplatin,tegafur / gimeracil / oteracil	Efficacy	no	UGT1A7 *3 is not associated with response to irinotecan, oxaliplatin and s 1 (combination) in people with Colorectal Neoplasms.			= 0.169	OR			
1185002465	rs1047840	capecitabine,fluorouracil	Efficacy	not stated	Allele A is associated with increased response to capecitabine or fluorouracil in people with Neoplasm Metastasis as compared to allele G.	A	A		OR			
769250751	rs699947	capecitabine,oxaliplatin	Efficacy	yes	Genotype AC is associated with decreased response to capecitabine and oxaliplatin in people with Colorectal Neoplasms.			= 0.02	HR	1.74	1.04	2.92
1184511142	rs57098334	escitalopram,venlafaxine	Efficacy	no	Genotype (CCCACCCGA)12/(CCCACCCGA)12 is not associated with response to escitalopram or venlafaxine in people with Depressive Disorder, Major.			= 0.61	OR			
1184511142	rs57098334	escitalopram,venlafaxine	Efficacy	no	Genotype (CCCACCCGA)12/(CCCACCCGA)12 is not associated with response to escitalopram or venlafaxine in people with Depressive Disorder, Major.			= 0.63	OR			
769250837	rs833061	capecitabine,oxaliplatin	Efficacy	no	Genotype CT is not associated with response to capecitabine and oxaliplatin in people with Colorectal Neoplasms.			= 0.12	Unknown	1.65	0.85	2.3
981477583	rs8105790	peginterferon alfa-2a,ribavirin	Efficacy	yes	Allele C is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to allele T.			< 0.05	Unknown			
1449002171	rs12248560	clopidogrel,clopidogrel thiol metabolite H4	Metabolism/PK	no	Allele A is not associated with exposure to clopidogrel or clopidogrel thiol metabolite H4 as compared to allele C.	A	C	> 0.05	OR			
981477593	rs11881222	peginterferon alfa-2a,ribavirin	Efficacy	yes	Allele G is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to allele A.			< 0.05	Unknown			
981477599	rs8103142	peginterferon alfa-2a,ribavirin	Efficacy	yes	Allele C is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to allele T.			< 0.05	Unknown			
981477611	rs4803219	peginterferon alfa-2a,ribavirin	Efficacy	yes	Allele C is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to allele T.			< 0.05	Unknown			
1449002186	rs1045642	clopidogrel,clopidogrel thiol metabolite H4	Metabolism/PK	no	Allele A is not associated with exposure to clopidogrel or clopidogrel thiol metabolite H4 as compared to allele G.	A	G	> 0.05	OR			
1449002181	rs2242480	clopidogrel,clopidogrel thiol metabolite H4	Metabolism/PK	no	Allele T is not associated with exposure to clopidogrel or clopidogrel thiol metabolite H4 as compared to allele C.	T	C	> 0.05	OR			
981477606	rs28416813	peginterferon alfa-2a,ribavirin	Efficacy	yes	Allele C is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to allele G.			< 0.05	Unknown			
1184511250	CYP2D6 poor metabolizers	escitalopram,venlafaxine	Efficacy	no	CYP2D6 poor metabolizers is not associated with response to escitalopram or venlafaxine in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizers.				OR			
1184511250	CYP2D6 poor metabolizers	escitalopram,venlafaxine	Efficacy	no	CYP2D6 poor metabolizers is not associated with response to escitalopram or venlafaxine in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizers.				OR			
981477615	rs7248668	peginterferon alfa-2a,ribavirin	Efficacy	yes	Allele A is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to allele G.			< 0.05	Unknown			
981934499	rs12979860	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.			< 0.05	OR	4.47	3.81	5.25
1449575844	rs116855232	azathioprine,mercaptopurine	Dosage	yes	Genotype TT is associated with decreased dose of azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to genotypes CC + CT.			= 8.50E-06	OR			
1449575844	rs116855232	azathioprine,mercaptopurine	Dosage	yes	Genotype TT is associated with decreased dose of azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to genotypes CC + CT.			= 2.46E-2	OR			
982032850	rs1799752	atenolol,enalapril	Efficacy	yes	Genotype del/del is associated with increased resistance to atenolol and enalapril in people with Kidney Diseases as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	del		= 0.02	Unknown			
827699103	rs11615	carboplatin,pemetrexed	Efficacy	no	Allele A is not associated with response to carboplatin and pemetrexed in people with Mesothelioma as compared to allele G.				Unknown			
981934519	rs8099917	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT.			< 0.05	OR	5.17	4.37	6.12
1449002477	rs4476990	anastrozole,exemestane	Efficacy	no	Allele G is not associated with increased response to anastrozole and exemestane in women with Breast Neoplasms as compared to allele C.	G		= 2.51E-7	OR	0.61	0.5	0.74
1449002490	rs746460	anastrozole,exemestane	Efficacy	no	Allele T is not associated with increased response to anastrozole and exemestane in women with Breast Neoplasms as compared to allele C.	T	C	= 3.05E-7	OR	0.62	0.51	0.75
1449002484	rs2891356	anastrozole,exemestane	Efficacy	no	Allele G is not associated with increased response to anastrozole and exemestane in women with Breast Neoplasms as compared to allele A.	G	A	= 2.76E-7	OR	0.61	0.51	0.74
1449002508	rs3802201	anastrozole,exemestane	Efficacy	no	Allele C is not associated with increased response to anastrozole and exemestane in women with Breast Neoplasms as compared to allele G.	G	C	= 6.24E-07	OR	0.6	0.48	0.74
1451116020	rs776746	amprenavir,saquinavir	Metabolism/PK	no	Allele C is not associated with trough concentration of amprenavir or saquinavir in people with HIV Infections as compared to allele T.	C		= 0.23				
1451116020	rs776746	amprenavir,saquinavir	Metabolism/PK	no	Allele C is not associated with trough concentration of amprenavir or saquinavir in people with HIV Infections as compared to allele T.	C		= 0.38				
1451116020	rs776746	amprenavir,saquinavir	Metabolism/PK	no	Allele C is not associated with trough concentration of amprenavir or saquinavir in people with HIV Infections as compared to allele T.	C		= 0.46				
1451116020	rs776746	amprenavir,saquinavir	Metabolism/PK	no	Allele C is not associated with trough concentration of amprenavir or saquinavir in people with HIV Infections as compared to allele T.	C		= 0.61				
1451116020	rs776746	amprenavir,saquinavir	Metabolism/PK	no	Allele C is not associated with trough concentration of amprenavir or saquinavir in people with HIV Infections as compared to allele T.	C		= 0.87				
1451116020	rs776746	amprenavir,saquinavir	Metabolism/PK	no	Allele C is not associated with trough concentration of amprenavir or saquinavir in people with HIV Infections as compared to allele T.	C		= 0.91				
1447676959	rs8099917	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT.			= 0.0058	OR			
1447676959	rs8099917	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT.			= 0.6517	OR			
1450378806	rs587783672	sulfonamides, urea derivatives	Efficacy	not stated	Allele T is associated with response to sulfonamides, urea derivatives in children as compared to allele C.				OR			
1451116180	rs55663133	anakinra,canakinumab	Efficacy	no	Allele AATAATAATAATAATAAT is not associated with response to anakinra or canakinumab in children with Arthritis, Juvenile Rheumatoid as compared to allele AATAATAATAAT.			= 0.80				
1451116180	rs55663133	anakinra,canakinumab	Efficacy	no	Allele AATAATAATAATAATAAT is not associated with response to anakinra or canakinumab in children with Arthritis, Juvenile Rheumatoid as compared to allele AATAATAATAAT.			= 0.91				
1447676885	rs12979860	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.			< 0.001	OR	6.624		
1447676885	rs12979860	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.			= 0.001	OR	0.055		
1451116200	rs62158853	anakinra,canakinumab	Efficacy	no	Allele C is not associated with response to anakinra or canakinumab in children with Arthritis, Juvenile Rheumatoid as compared to allele T.			= 0.75				
1451116200	rs62158853	anakinra,canakinumab	Efficacy	no	Allele C is not associated with response to anakinra or canakinumab in children with Arthritis, Juvenile Rheumatoid as compared to allele T.			= 0.95				
1450935925	rs1042713	fluticasone propionate,salmeterol	Efficacy	no	Allele A is not associated with response to fluticasone propionate and salmeterol in people with Asthma as compared to allele G.			= 0.774				
1450935931	rs1042714	fluticasone propionate,salmeterol	Efficacy	no	Allele C is not associated with response to fluticasone propionate and salmeterol in people with Asthma as compared to allele G.							
1444694895	rs1799983	epirubicin,fluorouracil,oxaliplatin	Efficacy	not stated	Allele G is not associated with response to epirubicin, fluorouracil and oxaliplatin in people with Neoplasm Metastasis and Stomach Neoplasms.	G	T	> 0.05	OR			
1447676829	rs12979860	boceprevir,peginterferon alfa-2a,peginterferon alfa-2b,ribavirin,telaprevir	Efficacy	yes	Genotype CC is associated with increased response to boceprevir, peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C as compared to genotypes CT + TT.			= 0.015	OR			
1444842369	rs3025039	bevacizumab,capecitabine,fluorouracil,irinotecan,leucovorin,oxaliplatin	Efficacy	yes	Genotype TT is associated with decreased response to bevacizumab, capecitabine, fluorouracil, irinotecan, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes CC + CT.			= 0.02	OR	0.71	0.53	0.96
1451116267	rs7580634	anakinra,canakinumab	Efficacy	no	Allele G is not associated with response to anakinra or canakinumab in children with Arthritis, Juvenile Rheumatoid as compared to allele T.			= 0.57				
1451116267	rs7580634	anakinra,canakinumab	Efficacy	no	Allele G is not associated with response to anakinra or canakinumab in children with Arthritis, Juvenile Rheumatoid as compared to allele T.			= 0.78				
1451116260	rs55709272	anakinra,canakinumab	Efficacy	no	Allele T is not associated with response to anakinra or canakinumab in children with Arthritis, Juvenile Rheumatoid as compared to allele C.			= 0.74				
1451116260	rs55709272	anakinra,canakinumab	Efficacy	no	Allele T is not associated with response to anakinra or canakinumab in children with Arthritis, Juvenile Rheumatoid as compared to allele C.			= 0.86				
1447676797	rs11313667	atenolol,hydrochlorothiazide,metoprolol	Efficacy	yes	Allele del is associated with increased response to atenolol, hydrochlorothiazide or metoprolol in people with Hypertension as compared to allele C.	del		= 7.2E-8	OR			
827814015	rs1045642	cyclosporine,tacrolimus	Dosage,Metabolism/PK	no	Allele A is not associated with clearance of cyclosporine or tacrolimus in people with Kidney Transplantation as compared to allele G.	A			Unknown			
827814015	rs1045642	cyclosporine,tacrolimus	Dosage,Metabolism/PK	no	Allele A is not associated with clearance of cyclosporine or tacrolimus in people with Kidney Transplantation as compared to allele G.	A			Unknown			
1447676810	rs1367094	atenolol,metoprolol	Efficacy	yes	Allele T is associated with increased response to atenolol or metoprolol in people with Hypertension as compared to allele C.	T		= 1.55E-07	OR			
1444842390	rs699947	bevacizumab,capecitabine,fluorouracil,irinotecan,leucovorin,oxaliplatin	Efficacy	yes	Genotype CC is associated with increased response to bevacizumab, capecitabine, fluorouracil, irinotecan, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotype AC.			= 0.05	OR	1.4	1.0	1.197
1451116220	rs62158854	anakinra,canakinumab	Efficacy	no	Allele T is not associated with response to anakinra or canakinumab in children with Arthritis, Juvenile Rheumatoid as compared to allele G.			= 0.65				
1451116220	rs62158854	anakinra,canakinumab	Efficacy	no	Allele T is not associated with response to anakinra or canakinumab in children with Arthritis, Juvenile Rheumatoid as compared to allele G.			= 0.84				
827814005	rs2032582	cyclosporine,tacrolimus	Dosage,Metabolism/PK	no	Genotype AT is not associated with clearance of cyclosporine or tacrolimus in people with Kidney Transplantation as compared to allele C.	C			Unknown			
827814005	rs2032582	cyclosporine,tacrolimus	Dosage,Metabolism/PK	no	Genotype AT is not associated with clearance of cyclosporine or tacrolimus in people with Kidney Transplantation as compared to allele C.	C			Unknown			
827814000	rs1128503	cyclosporine,tacrolimus	Dosage,Metabolism/PK	no	Allele A is not associated with clearance of cyclosporine or tacrolimus in people with Kidney Transplantation as compared to allele G.	A			Unknown			
827814000	rs1128503	cyclosporine,tacrolimus	Dosage,Metabolism/PK	no	Allele A is not associated with clearance of cyclosporine or tacrolimus in people with Kidney Transplantation as compared to allele G.	A			Unknown			
1444842405	rs833061	bevacizumab,capecitabine,fluorouracil,irinotecan,leucovorin,oxaliplatin	Efficacy	no	Allele C is not associated with response to bevacizumab, capecitabine, fluorouracil, irinotecan, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to allele T.			= 0.26	OR	0.81	0.56	1.17
1444694834	rs662	epirubicin,fluorouracil,oxaliplatin	Efficacy	yes	Genotype CC is associated with increased response to epirubicin, fluorouracil and oxaliplatin in people with Neoplasm Metastasis and Stomach Neoplasms as compared to genotypes CT + TT.	C	T	= 0.029	HR	1.95	1.07	3.54
1444694834	rs662	epirubicin,fluorouracil,oxaliplatin	Efficacy	yes	Genotype CC is associated with increased response to epirubicin, fluorouracil and oxaliplatin in people with Neoplasm Metastasis and Stomach Neoplasms as compared to genotypes CT + TT.	C	T	= 0.056	OR			
1447676770	rs8099917	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin,simeprevir	Efficacy	yes	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or simeprevir in people with Hepatitis C as compared to genotypes GG + GT.			= 0.004	OR	4.106		
1448266589	rs2734440	adalimumab,certolizumab pegol,etanercept,glucocorticoids,infliximab,methotrexate	Efficacy	no	Genotype TT is not associated with response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.	T		= 0.017	OR			
981754640	rs948854	antidepressants,benzodiazepine derivatives,mirtazapine,Selective serotonin reuptake inhibitors	Efficacy	yes	Allele C is associated with decreased response to antidepressants, benzodiazepine derivatives, mirtazapine or Selective serotonin reuptake inhibitors in women Depressive Disorder, Major as compared to allele T.			< 0.05	Unknown			
1447676752	rs201279313	atenolol,hydrochlorothiazide,metoprolol	Efficacy	yes	Genotype TTA/del is associated with increased response to atenolol, hydrochlorothiazide or metoprolol in people with Hypertension as compared to genotype TTA/TTA.	del		= 1.10E-07	OR			
1444694848	rs10517	epirubicin,fluorouracil,oxaliplatin	Efficacy	not stated	Allele G is not associated with response to epirubicin, fluorouracil and oxaliplatin in people with Neoplasm Metastasis and Stomach Neoplasms.	A	G	> 0.05	OR			
1447676759	rs12979860	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in children with Hepatitis C, Chronic as compared to genotypes CT + TT.			= 0.028	OR			
1448266578	rs2734414	adalimumab,certolizumab pegol,etanercept,glucocorticoids,infliximab,methotrexate	Efficacy	no	Genotype TT is not associated with response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AA + AT.	A		= 0.017	OR			
1448266567	rs7301582	adalimumab,certolizumab pegol,etanercept,glucocorticoids,infliximab,methotrexate	Efficacy	yes	Genotype CC is associated with decreased response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CT + TT.	C		= 0.035	OR	3.58		
1451116274	rs4251961	anakinra,canakinumab	Efficacy	no	Allele T is not associated with response to anakinra or canakinumab in children with Arthritis, Juvenile Rheumatoid as compared to allele C.			= 0.56				
1451116274	rs4251961	anakinra,canakinumab	Efficacy	no	Allele T is not associated with response to anakinra or canakinumab in children with Arthritis, Juvenile Rheumatoid as compared to allele C.			= 0.76				
1444694872	rs854560	epirubicin,fluorouracil,oxaliplatin	Efficacy	not stated	Allele A is not associated with response to epirubicin, fluorouracil and oxaliplatin in people with Neoplasm Metastasis and Stomach Neoplasms.	A	T	> 0.05	OR			
1448266553	rs2302489	adalimumab,certolizumab pegol,etanercept,glucocorticoids,infliximab,methotrexate	Efficacy	yes	Genotype TT is associated with decreased response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AA + AT.	A		= 0.017	OR	0.3	0.08	0.88
1444694886	rs2266637	epirubicin,fluorouracil,oxaliplatin	Efficacy	not stated	Allele C is not associated with response to epirubicin, fluorouracil and oxaliplatin in people with Neoplasm Metastasis and Stomach Neoplasms.	C	T	> 0.05	OR			
1447676729	rs1045642	agomelatine,Melatonin receptor agonists,Selective serotonin reuptake inhibitors,venlafaxine	Efficacy	yes	Genotype GG is associated with increased response to agomelatine, Melatonin receptor agonists, Selective serotonin reuptake inhibitors or venlafaxine in people with Depressive Disorder as compared to genotypes AA + AG.	A		= 0.0142	OR			
982033246	rs4961	atenolol,verapamil	Efficacy	no	Genotype GG is not associated with increased response to atenolol or verapamil in people with Hypertension as compared to genotypes GT + TT.	T			Unknown			
1449576280	rs261316	atenolol,hydrochlorothiazide	Efficacy	yes	Allele T is associated with decreased response to atenolol and hydrochlorothiazide in people with Hypertension as compared to allele C.	T		= 8.69E-08	OR	2.16	1.63	2.86
1449576280	rs261316	atenolol,hydrochlorothiazide	Efficacy	yes	Allele T is associated with decreased response to atenolol and hydrochlorothiazide in people with Hypertension as compared to allele C.	T		= 8.64E-06	OR	2.56	1.69	3.88
1449576280	rs261316	atenolol,hydrochlorothiazide	Efficacy	yes	Allele T is associated with decreased response to atenolol and hydrochlorothiazide in people with Hypertension as compared to allele C.	T		= 0.001	OR	1.86	1.35	2.57
1449576291	rs35123024	atenolol,hydrochlorothiazide	Efficacy	not stated	Allele C is associated with decreased response to atenolol and hydrochlorothiazide in people with Hypertension as compared to allele T.	C		= 3.46E-06	OR	3.71	2.13	6.45
1449576291	rs35123024	atenolol,hydrochlorothiazide	Efficacy	not stated	Allele C is associated with decreased response to atenolol and hydrochlorothiazide in people with Hypertension as compared to allele T.	T		= 3.77E-06	OR	2.56	1.72	3.82
1449576291	rs35123024	atenolol,hydrochlorothiazide	Efficacy	not stated	Allele C is associated with decreased response to atenolol and hydrochlorothiazide in people with Hypertension as compared to allele T.	C		= 0.033	OR	1.72	1.06	2.79
1450821537	rs11280056	folic acid,hydroxychloroquine,methotrexate,sulfasalazine	Efficacy	no	Allele del is associated with increased response to folic acid, hydroxychloroquine, methotrexate and sulfasalazine in people with Arthritis, Rheumatoid as compared to allele TTAAAGTTA.	del	del	= 0.1				
1184085972	rs747199	gemcitabine,paclitaxel	Efficacy	no	Allele G is associated with decreased response to gemcitabine and paclitaxel in women Breast Neoplasms as compared to allele C.	C	G	> 0.05	HR	3.391	1.13	10.19
1184085969	rs7867504	gemcitabine,paclitaxel	Efficacy	no	Genotypes CC + CT is not associated with increased response to gemcitabine and paclitaxel in women Breast Neoplasms as compared to genotype TT.	C	T	> 0.05	HR	2.6	1.1	6.3
1450821649	rs11280056	capecitabine,fluorouracil	Efficacy	no	Allele TTAAAGTTA is not associated with response to capecitabine or fluorouracil in people with Rectal Neoplasms as compared to allele del.							
1450821655	rs11280056	bevacizumab,capecitabine,cisplatin,docetaxel,epirubicin,oxaliplatin,trastuzumab	Efficacy	no	Genotypes TTAAAGTTA/del + del/del are not associated with response to bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotype del/del.			> 0.05				
1447676504	rs763780	adalimumab,etanercept,infliximab	Efficacy	no	Genotype CT is not associated with response to adalimumab, etanercept or infliximab in people with as compared to genotype TT.	C		= 0.390	OR			
1447676504	rs763780	adalimumab,etanercept,infliximab	Efficacy	no	Genotype CT is not associated with response to adalimumab, etanercept or infliximab in people with as compared to genotype TT.	C		= 0.690	OR			
1450821634	rs11280056	fluorouracil,leucovorin,oxaliplatin	Efficacy	no	Allele del is not associated with response to fluorouracil, leucovorin and oxaliplatin in people with Esophageal Neoplasms and Stomach Neoplasms.							
981476423	rs3892097	amitriptyline,clomipramine,doxepin,imipramine,maprotiline,nortriptyline,opipramol	Dosage,Efficacy	yes	Genotype TT is associated with decreased dose of amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or opipramol in people with Depression as compared to genotype CC.	T		= 0.03	Unknown			
1447987701	rs1415744	chlorpromazine,clozapine,haloperidol,olanzapine,quetiapine,risperidone,trifluoperazine	Efficacy	yes	Allele C is associated with increased response to chlorpromazine, clozapine, haloperidol, olanzapine, quetiapine, risperidone or trifluoperazine in people with Schizophrenia as compared to allele T.	C		= 0.02	OR			
827698925	rs3918242	Antihypertensives,hydralazine,Methyldopa,nifedipine	Efficacy	yes	Genotype CT is associated with decreased response to Antihypertensives, hydralazine, Methyldopa or nifedipine in people with Gestational hypertension as compared to genotype CC.			= 0.049	OR	2.81	1.0	8.1
1184086177	rs2032582	gemcitabine,paclitaxel	Efficacy,Toxicity	no	Allele A is not associated with response to gemcitabine and paclitaxel as compared to allele T.	A	T	> 0.05	OR			
1184086250	rs763780	gemcitabine,paclitaxel	Efficacy,Toxicity	no	Allele T is not associated with response to gemcitabine and paclitaxel in women with Breast Neoplasms as compared to allele C.	T	C	> 0.05	OR			
1184086238	rs11141915	gemcitabine,paclitaxel	Efficacy,Toxicity	no	Allele A is not associated with response to gemcitabine and paclitaxel in women with Breast Neoplasms as compared to allele C.	A	C	> 0.05	OR			
1184086242	rs12648166	gemcitabine,paclitaxel	Efficacy,Toxicity	no	Allele A is not associated with response to gemcitabine and paclitaxel in women with Breast Neoplasms as compared to allele G.	A	G	> 0.05	OR			
1184086228	rs28371759	gemcitabine,paclitaxel	Efficacy,Toxicity	no	Allele A is not associated with response to gemcitabine and paclitaxel in women with Breast Neoplasms as compared to allele G.	A	G	> 0.05	OR			
1184086220	rs1056836	gemcitabine,paclitaxel	Efficacy,Toxicity	no	Allele C is not associated with response to gemcitabine and paclitaxel in women with Breast Neoplasms as compared to allele G.	C	G	> 0.05	OR			
1184086224	rs4492666	gemcitabine,paclitaxel	Efficacy,Toxicity	no	Allele A is not associated with response to gemcitabine and paclitaxel in women with Breast Neoplasms as compared to allele C.	A	C	> 0.05	OR			
1184086212	rs818194	gemcitabine,paclitaxel	Efficacy,Toxicity	no	Allele A is not associated with response to gemcitabine and paclitaxel in women with Breast Neoplasms as compared to allele T.	A	T	> 0.05	OR			
1184086216	rs11211524	gemcitabine,paclitaxel	Efficacy,Toxicity	no	Allele A is not associated with response to gemcitabine and paclitaxel in women with Breast Neoplasms as compared to allele C.	A	C	> 0.05	OR			
1184086196	rs1048977	gemcitabine,paclitaxel	Efficacy,Toxicity	no	Allele C is not associated with response to gemcitabine and paclitaxel in women with Breast Neoplasms as compared to allele T.	C	T	> 0.05	OR			
1184086203	rs2072671	gemcitabine,paclitaxel	Efficacy,Toxicity	no	Allele A is not associated with response to gemcitabine and paclitaxel in women with Breast Neoplasms as compared to allele C.	A	C	> 0.05	OR			
1184086188	rs1128503	gemcitabine,paclitaxel	Efficacy,Toxicity	no	Allele A is not associated with response to gemcitabine and paclitaxel in women with Breast Neoplasms as compared to allele G.	A	G	> 0.05	OR			
1184086271	rs760370	gemcitabine,paclitaxel	Efficacy	yes	Allele A is associated with decreased response to gemcitabine and paclitaxel in women Breast Neoplasms as compared to allele G.	A	G	> 0.05	HR	3.391	1.13	10.19
1449576742	rs4244285	cyclophosphamide,doxorubicin	Efficacy	yes	Genotypes AA + AG are associated with decreased response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotype GG.			< 0.001	OR	3.21	1.757	5.928
1184086254	rs12046844	gemcitabine,paclitaxel	Efficacy,Toxicity	no	Allele A is not associated with response to gemcitabine and paclitaxel in women with Breast Neoplasms as compared to allele G.	A	G	> 0.05	OR			
1184999830	rs2298771	carbamazepine,oxcarbazepine	Efficacy	no	Genotype CC is not associated with resistance to carbamazepine or oxcarbazepine in people with Epilepsy as compared to genotype TT.	C	C	= 0.253	OR	4.18	0.36	48.74
1448532221	CYP2C19 normal metabolizer genotype	amoxicillin,clarithromycin,esomeprazole	Efficacy	yes	CYP2C19 normal metabolizer genotype is associated with decreased response to amoxicillin, clarithromycin and esomeprazole in people with Gastritis as compared to CYP2C19 poor metabolizer and intermediate metabolizer genotypes.			= 0.048	OR			
1184999851	rs2304016	carbamazepine,oxcarbazepine	Efficacy	no	Genotype GG is not associated with resistance to carbamazepine or oxcarbazepine in people with Epilepsy as compared to genotype AA.	A	A	= 0.714	OR	1.44	0.2	10.16
1184999842	rs17183814	carbamazepine,oxcarbazepine	Efficacy	no	Genotype AA is not associated with resistance to carbamazepine or oxcarbazepine in people with Epilepsy as compared to genotype GG.	A	A	= 0.139	OR	0.28	0.05	1.51
1184999741	rs2273697	carbamazepine,oxcarbazepine	Efficacy	no	Genotype AG is associated with resistance to carbamazepine or oxcarbazepine in people with Epilepsy as compared to genotype GG.	A	A	= 0.036	OR	1.99	1.05	3.77
827814765	rs1799853	acenocoumarol,warfarin	Dosage	not stated	Allele T is not associated with decreased dose of acenocoumarol or warfarin as compared to allele C.				Unknown			
981417489	rs3087243	adalimumab,etanercept,infliximab,Tumor necrosis factor alpha (TNF-alpha) inhibitors	Efficacy	no	Allele A is not associated with response to adalimumab, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.				Unknown			
981417494	rs7574865	adalimumab,etanercept,infliximab,Tumor necrosis factor alpha (TNF-alpha) inhibitors	Efficacy	no	Allele T is not associated with response to adalimumab, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.				Unknown			
1184999857	rs3740066	carbamazepine,oxcarbazepine	Efficacy	no	Genotype TT is not associated with resistance to carbamazepine or oxcarbazepine in people with Epilepsy as compared to genotype CC.	T	T	= 0.819	OR	1.19	0.27	5.2
981417506	rs13031237	adalimumab,etanercept,infliximab,Tumor necrosis factor alpha (TNF-alpha) inhibitors	Efficacy	no	Allele T is not associated with response to adalimumab, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.				Unknown			
981417500	rs3761847	adalimumab,etanercept,infliximab,Tumor necrosis factor alpha (TNF-alpha) inhibitors	Efficacy	no	Allele A is not associated with response to adalimumab, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.				Unknown			
1447680083	rs758723	olanzapine,quetiapine,risperidone	Efficacy	no	Allele A is not associated with response to olanzapine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	A		= 0.40	OR			
1447680089	rs10848635	olanzapine,quetiapine,risperidone	Efficacy	no	Allele A is not associated with response to olanzapine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	A		= 0.32	OR			
981417467	rs10919563	adalimumab,etanercept,infliximab,Tumor necrosis factor alpha (TNF-alpha) inhibitors	Efficacy	no	Allele A is not associated with response to adalimumab, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.				Unknown			
981417474	rs2812378	adalimumab,etanercept,infliximab,Tumor necrosis factor alpha (TNF-alpha) inhibitors	Efficacy	no	Allele A is not associated with response to adalimumab, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.			= 0.143	Unknown			
981417474	rs2812378	adalimumab,etanercept,infliximab,Tumor necrosis factor alpha (TNF-alpha) inhibitors	Efficacy	no	Allele A is not associated with response to adalimumab, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.				Unknown			
981417482	rs4810485	adalimumab,etanercept,infliximab,Tumor necrosis factor alpha (TNF-alpha) inhibitors	Efficacy	no	Allele T is not associated with response to adalimumab, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.				Unknown			
981417478	rs11586238	adalimumab,etanercept,infliximab,Tumor necrosis factor alpha (TNF-alpha) inhibitors	Efficacy	no	Allele C is not associated with response to adalimumab, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.				Unknown			
981417561	rs548234	adalimumab,etanercept,infliximab,Tumor necrosis factor alpha (TNF-alpha) inhibitors	Efficacy	no	Allele C is not associated with response to adalimumab, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele T.				Unknown			
981417569	rs6822844	adalimumab,etanercept,infliximab,Tumor necrosis factor alpha (TNF-alpha) inhibitors	Efficacy	no	Allele G is not associated with response to adalimumab, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele T.				Unknown			
1184754301	rs25487	cisplatin,radiotherapy	Efficacy	yes	Genotype TT is associated with decreased response to cisplatin and radiotherapy in people with Nasopharyngeal Neoplasms and Tobacco Use Disorder as compared to genotypes CC + CT.	T	C	= 0.034	HR	2.833	1.08	7.429
1184754301	rs25487	cisplatin,radiotherapy	Efficacy	yes	Genotype TT is associated with decreased response to cisplatin and radiotherapy in people with Nasopharyngeal Neoplasms and Tobacco Use Disorder as compared to genotypes CC + CT.	T	C	= 0.047	HR	2.019	1.01	4.036
1184754301	rs25487	cisplatin,radiotherapy	Efficacy	yes	Genotype TT is associated with decreased response to cisplatin and radiotherapy in people with Nasopharyngeal Neoplasms and Tobacco Use Disorder as compared to genotypes CC + CT.	T	C	= 0.065	OR			
981417578	rs6920220	adalimumab,etanercept,infliximab,Tumor necrosis factor alpha (TNF-alpha) inhibitors	Efficacy	no	Allele A is not associated with response to adalimumab, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.				Unknown			
981417573	rs3218253	adalimumab,etanercept,infliximab,Tumor necrosis factor alpha (TNF-alpha) inhibitors	Efficacy	no	Allele A is not associated with response to adalimumab, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.				Unknown			
981417521	rs2476601	adalimumab,etanercept,infliximab,Tumor necrosis factor alpha (TNF-alpha) inhibitors	Efficacy	no	Allele A is not associated with response to adalimumab, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.				Unknown			
981417516	rs4750316	adalimumab,etanercept,infliximab,Tumor necrosis factor alpha (TNF-alpha) inhibitors	Efficacy	no	Allele C is not associated with response to adalimumab, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.				Unknown			
981417547	rs394581	adalimumab,etanercept,infliximab,Tumor necrosis factor alpha (TNF-alpha) inhibitors	Efficacy	no	Allele C is not associated with response to adalimumab, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele T.				Unknown			
1447679991	rs2283271	olanzapine,quetiapine,risperidone	Efficacy	no	Allele A is not associated with response to olanzapine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	A		= 0.07	OR			
981417541	rs2104286	adalimumab,etanercept,infliximab,Tumor necrosis factor alpha (TNF-alpha) inhibitors	Efficacy	no	Allele C is not associated with response to adalimumab, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele T.				Unknown			
981417582	rs1980422	adalimumab,etanercept,infliximab,Tumor necrosis factor alpha (TNF-alpha) inhibitors	Efficacy	no	Allele C is not associated with response to adalimumab, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele T.			= 0.1	Unknown			
981417582	rs1980422	adalimumab,etanercept,infliximab,Tumor necrosis factor alpha (TNF-alpha) inhibitors	Efficacy	no	Allele C is not associated with response to adalimumab, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele T.				Unknown			
827815008	rs6265	paroxetine,sertraline	Efficacy	no	Allele T is not associated with response to paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele C.				Unknown			
1183689490	rs28401781	citalopram,fluoxetine,paroxetine,sertraline	Efficacy	no	Allele T is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele C.			= 0.267	OR	0.145	0.0193	1.09
1449155387	rs1143623	Tumor necrosis factor alpha (TNF-alpha) inhibitors,ustekinumab	Efficacy	yes	Genotypes CG + GG is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors or ustekinumab in people with Psoriasis as compared to genotype CC.	G		= 0.0041	OR	0.35	0.17	0.71
1449155387	rs1143623	Tumor necrosis factor alpha (TNF-alpha) inhibitors,ustekinumab	Efficacy	yes	Genotypes CG + GG is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors or ustekinumab in people with Psoriasis as compared to genotype CC.	G		= 0.0049	OR	0.25	0.09	0.66
1183689554	rs3747802	citalopram,fluoxetine,paroxetine,sertraline	Efficacy	no	Allele A is not associated with response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele G.			= 0.542	OR	0.641	0.215	1.91
1183689550	rs6946119	citalopram,fluoxetine,paroxetine,sertraline	Efficacy	no	Allele T is not associated with response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele C.			= 0.501	OR	0.765	0.384	1.53
1449155401	rs1143627	Tumor necrosis factor alpha (TNF-alpha) inhibitors,ustekinumab	Efficacy	yes	Genotypes AG + GG is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors or ustekinumab in people with Psoriasis as compared to genotype AA.	G		= 0.0016	OR	0.28	0.13	0.62
1449155401	rs1143627	Tumor necrosis factor alpha (TNF-alpha) inhibitors,ustekinumab	Efficacy	yes	Genotypes AG + GG is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors or ustekinumab in people with Psoriasis as compared to genotype AA.	G		= 0.011	OR	0.25	0.09	0.73
1183689563	rs182694	citalopram,fluoxetine,paroxetine,sertraline	Efficacy	no	Allele A is not associated with response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele G.			= 0.642	OR	1.1	0.741	1.63
1183689538	rs1109867	citalopram,fluoxetine,paroxetine,sertraline	Efficacy	no	Allele T is not associated with response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele G.			= 0.384	OR	0.699	0.396	1.23
1183689534	rs1109866	citalopram,fluoxetine,paroxetine,sertraline	Efficacy	no	Allele T is not associated with response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele C.			= 0.386	OR	0.714	0.404	1.26
1183689546	rs3755047	citalopram,fluoxetine,paroxetine,sertraline	Efficacy	no	Allele A is not associated with response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele G.			= 0.267	OR	0.574	0.283	1.16
1183689542	rs3731885	citalopram,fluoxetine,paroxetine,sertraline	Efficacy	no	Allele A is not associated with response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele G.			= 0.345	OR	0.571	0.282	1.16
1183689529	rs4148739	citalopram,fluoxetine,paroxetine,sertraline	Efficacy	no	Allele C is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele T.			= 0.162	OR	6.55	0.871	49.3
1450810253	rs12979860	peginterferon alfa-2a,peginterferon alfa-2b	Efficacy	yes	Allele C is associated with increased response to peginterferon alfa-2a or peginterferon alfa-2b in people with Hepatitis B, Chronic as compared to allele T.			= 0.000	OR	2.35	1.61	3.42
1450810272	rs8099917	peginterferon alfa-2a,peginterferon alfa-2b	Efficacy	yes	Allele T is associated with increased response to peginterferon alfa-2a or peginterferon alfa-2b in people with Hepatitis B, Chronic as compared to allele G.			= 0.005	OR	1.88	1.21	2.9
1449155493	rs6661932	adalimumab,infliximab	Efficacy	yes	Genotypes CT + TT is associated with decreased response to adalimumab or infliximab in people with Psoriasis as compared to genotype CC.			= 0.041	OR	13.08	1.11	154.37
1449155502	rs2546890	adalimumab,infliximab	Efficacy	yes	Genotypes AA + AG is associated with increased response to adalimumab or infliximab in people with Psoriasis as compared to genotype GG.			= 0.044	OR	0.12	0.01	0.95
1449155510	rs2145623	adalimumab,infliximab	Efficacy	yes	Genotypes CC + CG is associated with decreased response to adalimumab or infliximab in people with Psoriasis as compared to genotype GG.			= 0.037	OR	6.64	1.13	39.23
1449155520	rs9304742	adalimumab,infliximab	Efficacy	yes	Genotypes CC + CT is associated with increased response to adalimumab or infliximab in people with Psoriasis as compared to genotype TT.			= 0.008	OR	0.01	0.0	0.3
1449155529	rs645544	adalimumab,infliximab	Efficacy	yes	Genotype GG is associated with decreased response to adalimumab or infliximab in people with Psoriasis as compared to genotypes AA + AG.			= 0.036	OR	73.54	1.33	4075.18
1449155535	rs1061624	adalimumab,infliximab	Efficacy	yes	Genotypes AG + GG is associated with decreased response to adalimumab or infliximab in people with Psoriasis as compared to genotype AA.			= 0.025	OR	0.32	0.12	0.86
981483535	rs12979860	peginterferon alfa-2a,ribavirin	Efficacy	yes	Genotype CC is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.			= 0.04	Unknown			
981483541	rs8099917	peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	G		= 0.02	Unknown			
981483523	rs12979860	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	no	Genotypes CT + TT are associated with decreased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype CC.	T			OR	0.17	0.065	0.442
981483529	rs8099917	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	G		< 0.024	Unknown			
1447679482	rs723672	olanzapine,quetiapine,risperidone	Efficacy	no	Allele C is not associated with response to olanzapine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	C		= 0.16	OR			
1448926344	rs2298881	fluorouracil,Platinum compounds,radiotherapy	Efficacy	yes	Allele A is associated with increased response to fluorouracil, Platinum compounds or radiotherapy in people with Stomach Neoplasms as compared to allele C.			= 0.03	HR	0.82	0.62	0.98
1448926344	rs2298881	fluorouracil,Platinum compounds,radiotherapy	Efficacy	yes	Allele A is associated with increased response to fluorouracil, Platinum compounds or radiotherapy in people with Stomach Neoplasms as compared to allele C.			> 0.05	OR			
1448926357	rs10040363	fluorouracil,Platinum compounds,radiotherapy	Efficacy	yes	Allele G is associated with decreased response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele A.			= 0.01	OR			
1448926357	rs10040363	fluorouracil,Platinum compounds,radiotherapy	Efficacy	yes	Allele G is associated with decreased response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele A.			= 0.02	HR	1.26	1.03	1.54
1448926366	rs2075685	fluorouracil,Platinum compounds,radiotherapy	Efficacy	yes	Allele T is associated with decreased response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele G.			= 0.01	HR	1.3	1.06	1.59
1448926366	rs2075685	fluorouracil,Platinum compounds,radiotherapy	Efficacy	yes	Allele T is associated with decreased response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele G.			= 0.01	OR			
1448926403	rs2228001	fluorouracil,Platinum compounds,radiotherapy	Efficacy	no	Allele G is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele T.			> 0.05	OR			
1448926417	rs1870134	fluorouracil,Platinum compounds,radiotherapy	Efficacy	no	Allele C is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele G.			> 0.05	OR			
1448926423	rs13181	fluorouracil,Platinum compounds,radiotherapy	Efficacy	no	Allele G is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele T.			> 0.05	OR			
1448926429	rs238406	fluorouracil,Platinum compounds,radiotherapy	Efficacy	no	Allele T is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele G.			> 0.05	OR			
1448926435	rs1052555	fluorouracil,Platinum compounds,radiotherapy	Efficacy	no	Allele A is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele G.			> 0.05	OR			
1448926448	rs3810366	fluorouracil,Platinum compounds,radiotherapy	Efficacy	no	Allele G is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele C.			> 0.05	OR			
1448926454	rs50872	fluorouracil,Platinum compounds,radiotherapy	Efficacy	no	Allele A is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele G.			> 0.05	OR			
1448926460	rs3212986	fluorouracil,Platinum compounds,radiotherapy	Efficacy	no	Allele A is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele C.			> 0.05	OR			
1448926466	rs11615	fluorouracil,Platinum compounds,radiotherapy	Efficacy	no	Allele A is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele G.			> 0.05	OR			
1447679317	rs6942609	donepezil,galantamine,rivastigmine	Efficacy	no	Allele A is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele G.	A	A	= 1	OR			
1448926477	rs2276464	fluorouracil,Platinum compounds,radiotherapy	Efficacy	no	Allele C is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele G.			> 0.05	OR			
1448926488	rs2276466	fluorouracil,Platinum compounds,radiotherapy	Efficacy	no	Allele G is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele C.			> 0.05	OR			
1448926501	rs6498486	fluorouracil,Platinum compounds,radiotherapy	Efficacy	no	Allele C is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele A.			> 0.05	OR			
1448926507	rs1047768	fluorouracil,Platinum compounds,radiotherapy	Efficacy	no	Allele C is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele T.			> 0.05	OR			
1447679260	rs7094421	donepezil,galantamine,rivastigmine	Efficacy	no	Allele A is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele G.	A	A	= 1	OR			
1448926513	rs17655	fluorouracil,Platinum compounds,radiotherapy	Efficacy	no	Allele C is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele G.			> 0.05	OR			
1448926524	rs751402	fluorouracil,Platinum compounds,radiotherapy	Efficacy	no	Allele A is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele G.			> 0.05	OR			
1448926535	rs2094258	fluorouracil,Platinum compounds,radiotherapy	Efficacy	no	Allele T is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele C.			> 0.05	OR			
1448926546	rs2296147	fluorouracil,Platinum compounds,radiotherapy	Efficacy	no	Allele C is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele T.			> 0.05	OR			
769166457	rs45445694	capecitabine,raltitrexed	Efficacy	yes	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 is associated with decreased response to capecitabine and raltitrexed in people with Colorectal Neoplasms as compared to genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2.			< 0.01	Unknown			
1448926557	rs873601	fluorouracil,Platinum compounds,radiotherapy	Efficacy	no	Allele A is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele G.			> 0.05	OR			
1447679217	rs11101193	donepezil,galantamine,rivastigmine	Efficacy	no	Allele G is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele T.	G	G	= 1	OR			
1448926577	rs174538	fluorouracil,Platinum compounds,radiotherapy	Efficacy	no	Allele A is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele G.			> 0.05	OR			
1184165275	rs3804454	bevacizumab,ranibizumab	Efficacy	no	Allele G is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to allele T.	G	G	> 0.99	OR	1.75	0.37	8.22
1448926588	rs4462560	fluorouracil,Platinum compounds,radiotherapy	Efficacy	no	Allele G is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele C.			> 0.05	OR			
1184165271	rs323719	bevacizumab,ranibizumab	Efficacy	no	Allele A is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to allele G.	A	A	> 0.99	OR	0.55	0.1	2.88
1448926597	rs7402844	fluorouracil,Platinum compounds,radiotherapy	Efficacy	no	Allele C is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele G.			> 0.05	OR			
1184165267	rs12712973	bevacizumab,ranibizumab	Efficacy	no	Allele A is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to allele C.	A	A	> 0.99	OR	0.008	0.15	2.41
1448613071	rs2687116	carbamazepine,lamotrigine,phenytoin,primidone,valproic acid	Efficacy	yes	Allele C is associated with increased response to carbamazepine, lamotrigine, phenytoin, primidone or valproic acid in children with Epilepsy as compared to allele A.	A	A		OR			
1184165262	rs11580141	bevacizumab,ranibizumab	Efficacy	no	Allele A is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to allele G.	G	G	> 0.99	OR	1.74	0.42	7.18
1449155973	rs2072661	bupropion,nicotine,varenicline	Efficacy	no	Allele A is not associated with response to bupropion, nicotine and varenicline in people with Tobacco Use Disorder as compared to allele G.	A		= 0.59	OR	0.9	0.61	1.3
1184165258	rs12877323	bevacizumab,ranibizumab	Efficacy	no	Allele G is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to allele T.	G	G	> 0.99	OR	2.33	0.28	19.33
1448613065	rs2740574	carbamazepine,lamotrigine,phenytoin,primidone,valproic acid	Efficacy	yes	Allele C is associated with increased response to carbamazepine, lamotrigine, phenytoin, primidone or valproic acid in children with Epilepsy as compared to allele T.	C	C		OR			
1448926610	rs1052133	fluorouracil,Platinum compounds,radiotherapy	Efficacy	no	Allele G is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele C.			> 0.05	OR			
1184165254	rs6726454	bevacizumab,ranibizumab	Efficacy	no	Allele G is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to allele A.	G	G	> 0.99	OR	1.8	0.43	7.55
1448613059	rs3892097	carbamazepine,lamotrigine,phenytoin,primidone,valproic acid	Efficacy	yes	Allele C is associated with increased response to carbamazepine, lamotrigine, phenytoin, primidone or valproic acid in children with Epilepsy as compared to allele T.	C	C		OR			
1184165250	rs9679290	bevacizumab,ranibizumab	Efficacy	no	Allele C is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to allele G.	C	C	= 0.84	OR	1.87	0.45	7.77
1448926619	rs293795	fluorouracil,Platinum compounds,radiotherapy	Efficacy	no	Allele G is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele A.			> 0.05	OR			
1449155990	rs503464	bupropion,nicotine,varenicline	Efficacy	yes	Allele A is associated with increased response to bupropion, nicotine and varenicline in people with Tobacco Use Disorder as compared to allele T.	A		= 0.02	OR	0.59	0.38	0.92
1448613053	rs9332120	carbamazepine,lamotrigine,phenytoin,primidone,valproic acid	Efficacy	yes	Allele C is associated with increased response to carbamazepine, lamotrigine, phenytoin, primidone or valproic acid in children with Epilepsy as compared to allele T.	C	C		OR			
1449156003	rs55781567	bupropion,nicotine,varenicline	Efficacy	no	Allele G is not associated with response to bupropion, nicotine and varenicline in people with Tobacco Use Disorder as compared to allele C.	G		= 0.98	OR	1.0	0.73	1.5
1184165242	rs10490924	bevacizumab,ranibizumab	Efficacy	no	Allele T is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to allele G.	T	T	= 0.055	OR	1.53	0.99	2.36
1448613046	rs1065852	carbamazepine,lamotrigine,phenytoin,primidone,valproic acid	Efficacy	yes	Allele A is associated with increased response to carbamazepine, lamotrigine, phenytoin, primidone or valproic acid in children with Epilepsy as compared to allele G.	A	A		OR			
769166388	rs1801133	fluorouracil,leucovorin,oxaliplatin	Efficacy	yes	Allele A is associated with increased response to fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to allele G.			= 0.042	Unknown			
1184165232	rs1061170	bevacizumab,ranibizumab	Efficacy	no	Allele T is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to allele C.	T	T	> 0.99	OR	1.02	0.67	1.56
1448926630	rs1863332	fluorouracil,Platinum compounds,radiotherapy	Efficacy	no	Allele G is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele T.			> 0.05	OR			
769166385	rs1801131	fluorouracil,leucovorin,oxaliplatin	Efficacy	yes	Allele G is associated with increased response to fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to allele T.			= 0.004	Unknown			
1449156009	rs16969968	bupropion,nicotine,varenicline	Efficacy	no	Allele A is not associated with response to bupropion, nicotine and varenicline in people with Tobacco Use Disorder as compared to allele G.	A		= 0.75	OR	1.1	0.76	1.5
1446909124	rs61764370	cetuximab,panitumumab	Efficacy	no	Genotypes AC + CC is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotype AA.			= 0.79	OR	1.18	0.34	4.71
1448926639	rs863221	fluorouracil,Platinum compounds,radiotherapy	Efficacy	no	Allele G is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele T.			> 0.05	OR			
1449156016	rs2236196	bupropion,nicotine,varenicline	Efficacy	no	Allele G is not associated with response to bupropion, nicotine and varenicline in people with Tobacco Use Disorder as compared to allele A.	G		= 0.094	OR	0.75	0.54	1.1
1448926649	rs26279	fluorouracil,Platinum compounds,radiotherapy	Efficacy	no	Allele G is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele A.			> 0.05	OR			
1448926660	rs1346044	fluorouracil,Platinum compounds,radiotherapy	Efficacy	no	Allele C is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele T.			> 0.05	OR			
1448926669	rs2725335	fluorouracil,Platinum compounds,radiotherapy	Efficacy	no	Allele A is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele G.			> 0.05	OR			
1448926678	rs1801320	fluorouracil,Platinum compounds,radiotherapy	Efficacy	no	Allele C is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele G.			> 0.05	OR			
1448926689	rs7180135	fluorouracil,Platinum compounds,radiotherapy	Efficacy	no	Allele G is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele A.			> 0.05	OR			
1445205151	rs11322783	peginterferon alfa-2a,ribavirin	Efficacy	yes	Genotypes G/TT + TT/TT are associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotype GG.			= 0.02	OR	4.86		
1445205151	rs11322783	peginterferon alfa-2a,ribavirin	Efficacy	yes	Genotypes G/TT + TT/TT are associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotype GG.			= 0.03	OR	1.87		
1448926698	rs1478486	fluorouracil,Platinum compounds,radiotherapy	Efficacy	no	Allele A is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele G.			> 0.05	OR			
769248374	rs12980275	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Allele A is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to allele G.	G		= 0.0	OR	20.3	9.3	76.5
769248378	rs8099917	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Allele T is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to allele G.	G		= 0.0	OR	30.0	11.2	80.5
1447679007	rs4838392	donepezil,galantamine,rivastigmine	Efficacy	no	Allele G is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele A.	A	A	= 1	OR			
1447678987	rs3793790	donepezil,galantamine,rivastigmine	Efficacy	yes	Allele G is associated with increased response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele A.	A	A	= 0.03	OR			
1447678959	rs2177370	donepezil,galantamine,rivastigmine	Efficacy	yes	Allele A is associated with increased response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele G.	A	A	= 0.03	OR			
981482193	rs9471077	atorvastatin,pravastatin	Efficacy	yes	Genotypes AG + GG are associated with increased response to atorvastatin or pravastatin.			< 1.0E-4	HR	0.54	0.41	0.72
981482193	rs9471077	atorvastatin,pravastatin	Efficacy	yes	Genotypes AG + GG are associated with increased response to atorvastatin or pravastatin.			= 2.0E-4	HR	0.62	0.48	0.8
981482193	rs9471077	atorvastatin,pravastatin	Efficacy	yes	Genotypes AG + GG are associated with increased response to atorvastatin or pravastatin.			= 0.0026	HR	0.63	0.47	0.85
1447678879	rs9380142	capecitabine,fluorouracil	Efficacy	yes	Genotype GG is associated with decreased response to capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotypes AA + AG.	A	G	= 0.015	HR	2.46	1.19	5.05
1447678879	rs9380142	capecitabine,fluorouracil	Efficacy	yes	Genotype GG is associated with decreased response to capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotypes AA + AG.	A	G	= 0.022	HR	2.71	1.16	6.33
1184165568	rs7589621	bevacizumab,ranibizumab	Efficacy	no	Allele A is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to allele G.	A	A	> 0.99	OR	1.7	0.36	7.9
1184165564	rs323720	bevacizumab,ranibizumab	Efficacy	no	Allele C is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to allele T.	C	C	> 0.99	OR	0.57	0.11	2.91
1184165560	rs671976	bevacizumab,ranibizumab	Efficacy	no	Allele G is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to allele A.	G	G	> 0.99	OR	0.63	0.16	2.4
981482176	rs9462535	atorvastatin,pravastatin	Efficacy	yes	Genotypes AA + AC are associated with increased response to atorvastatin or pravastatin.			= 1.0E-4	HR	0.61	0.47	0.79
981482176	rs9462535	atorvastatin,pravastatin	Efficacy	yes	Genotypes AA + AC are associated with increased response to atorvastatin or pravastatin.			< 0.001	HR	0.51	0.39	0.68
981482176	rs9462535	atorvastatin,pravastatin	Efficacy	yes	Genotypes AA + AC are associated with increased response to atorvastatin or pravastatin.			= 0.0056	HR	0.66	0.5	0.89
981482185	rs9462535	atorvastatin,pravastatin	Efficacy	no	Genotype CC is not associated with increased response to atorvastatin or pravastatin.			= 0.5805	HR	0.9	0.63	1.29
981482185	rs9462535	atorvastatin,pravastatin	Efficacy	no	Genotype CC is not associated with increased response to atorvastatin or pravastatin.			= 0.7603	HR	0.95	0.7	1.3
981482185	rs9462535	atorvastatin,pravastatin	Efficacy	no	Genotype CC is not associated with increased response to atorvastatin or pravastatin.			= 0.8333	HR	0.98	0.71	1.52
1448530779	rs12980275	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	no	Genotype AA is not associated with response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AG + GG.			= 0.153	OR			
1448530773	rs8099917	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	no	Genotype TT is not associated with response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.			= 0.87	OR			
1448612688	rs3025039	lenalidomide,thalidomide	Efficacy	no	Allele C is not associated with decreased response to lenalidomide or thalidomide in people with Multiple Myeloma as compared to allele T.			= 0.022	OR			
1448530766	rs12979860	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	no	Genotype CC is not associated with response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.			= 0.111	OR			
1447678780	rs17179108	capecitabine,fluorouracil	Efficacy	yes	Genotype CT is associated with increased response to capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	C	T	= 0.045	HR	0.51	0.26	0.99
1447678780	rs17179108	capecitabine,fluorouracil	Efficacy	yes	Genotype CT is associated with increased response to capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	C	T	= 0.051	OR			
1448612673	rs308395	lenalidomide,thalidomide	Efficacy	yes	Genotypes CG + GG is associated with decreased response to lenalidomide or thalidomide in people with Multiple Myeloma as compared to genotype CC.			= 0.022	OR			
1447678770	rs371194629	capecitabine,fluorouracil	Efficacy	yes	Genotypes ATTTGTTCATGCCT/ATTTGTTCATGCCT + ATTTGTTCATGCCT/del is associated with increased response to capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype del/del.			= 0.010	OR			
1447678770	rs371194629	capecitabine,fluorouracil	Efficacy	yes	Genotypes ATTTGTTCATGCCT/ATTTGTTCATGCCT + ATTTGTTCATGCCT/del is associated with increased response to capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype del/del.			= 0.023	HR	0.6	0.38	0.93
1447678756	rs1063320	capecitabine,fluorouracil	Efficacy	no	Genotype CC is not associated with response to capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotypes CG + GG.	C	G	= 0.038	OR			
1447678756	rs1063320	capecitabine,fluorouracil	Efficacy	no	Genotype CC is not associated with response to capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotypes CG + GG.	C	G	= 0.078	HR	1.61	0.95	2.71
1447678763	rs1610696	capecitabine,fluorouracil	Efficacy	no	Genotypes CG + GG are not associated with response to capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	C	G	= 0.074	OR			
1447678763	rs1610696	capecitabine,fluorouracil	Efficacy	no	Genotypes CG + GG are not associated with response to capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	C	G	= 0.142	HR	0.72	0.46	1.12
1449140035	rs1128503	sirolimus,temsirolimus	Metabolism/PK	yes	Genotype GG is associated with decreased exposure to sirolimus and temsirolimus in people with Urinary Bladder Neoplasms as compared to genotypes AA + AG.	A	G	= 0.037	OR			
1449140035	rs1128503	sirolimus,temsirolimus	Metabolism/PK	yes	Genotype GG is associated with decreased exposure to sirolimus and temsirolimus in people with Urinary Bladder Neoplasms as compared to genotypes AA + AG.	A	G	= 0.049	OR			
1451106140	rs294610	atenolol,metoprolol	Efficacy	yes	Allele A is associated with increased response to atenolol or metoprolol in people with Hypertension as compared to allele C.			= 8.58E-7				
1451106140	rs294610	atenolol,metoprolol	Efficacy	yes	Allele A is associated with increased response to atenolol or metoprolol in people with Hypertension as compared to allele C.			= 3.41E-6				
1451106140	rs294610	atenolol,metoprolol	Efficacy	yes	Allele A is associated with increased response to atenolol or metoprolol in people with Hypertension as compared to allele C.			= 0.01				
1451106148	rs45545233	atenolol,metoprolol	Efficacy	yes	Genotypes CC + CT are associated with decreased response to atenolol or metoprolol in people with Hypertension as compared to genotype TT.			= 0.0013				
1451106148	rs45545233	atenolol,metoprolol	Efficacy	yes	Genotypes CC + CT are associated with decreased response to atenolol or metoprolol in people with Hypertension as compared to genotype TT.			= 0.007				
1449140049	rs776746	sirolimus,temsirolimus	Metabolism/PK	yes	Genotype CT is associated with decreased concentrations of sirolimus and temsirolimus in people with Urinary Bladder Neoplasms as compared to genotype CC.	C	T	= 0.020	OR			
1451155365	rs10929302	fluorouracil,irinotecan,oxaliplatin	Efficacy	no	Genotype AA is not associated with response to fluorouracil, irinotecan or oxaliplatin in people with Colorectal Neoplasms as compared to genotypes AG + GG.	A		> 0.01	OR			
1449271192	CYP2B6 poor metabolizer	buprenorphine,methadone	Efficacy	no	CYP2B6 poor metabolizer is not associated with response to buprenorphine or methadone in people with Opioid-Related Disorders as compared to CYP2B6 intermediate metabolizer and normal metabolizer.			= 0.727	OR			
1449271184	CYP1A2 ultrarapid metabolizer	buprenorphine,methadone	Efficacy	no	CYP1A2 ultrarapid metabolizer is not associated with response to buprenorphine or methadone in people with Opioid-Related Disorders as compared to CYP1A2 intermediate metabolizer and normal metabolizer.			= 0.498	OR			
827815352	rs8099917	peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.			< 1.0E-4	Unknown			
1449271209	CYP2C19 poor metabolizers and intermediate metabolizers	buprenorphine,methadone	Efficacy	no	CYP2C19 poor metabolizers and intermediate metabolizers is not associated with response to buprenorphine or methadone in people with Opioid-Related Disorders as compared to CYP2C19 normal metabolizer and ultra-metabolizer.			= 0.803	OR			
1447678642	rs17179101	capecitabine,fluorouracil	Efficacy	no	Genotype AC is not associated with response to capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	C	A	= 0.176	OR			
1447678642	rs17179101	capecitabine,fluorouracil	Efficacy	no	Genotype AC is not associated with response to capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	C	A	= 0.186	HR	0.54	0.22	1.35
1447678621	rs1707	capecitabine,fluorouracil	Efficacy	no	Genotype CC is not associated with response to capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotypes CT + TT.	C	T	= 0.600	OR			
1447678621	rs1707	capecitabine,fluorouracil	Efficacy	no	Genotype CC is not associated with response to capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotypes CT + TT.	C	T	= 0.709	HR	0.69	0.1	4.96
1449271224	CYP3A4 poor metabolizers and intermediate metabolizers	buprenorphine,methadone	Efficacy	no	CYP3A4 poor metabolizers and intermediate metabolizers is not associated with response to buprenorphine or methadone in people with Opioid-Related Disorders as compared to CYP3A4 normal metabolizers.			= 0.085	OR			
1449271217	CYP2D6 poor metabolizers and intermediate metabolizers	buprenorphine,methadone	Efficacy	no	CYP2D6 poor metabolizers and intermediate metabolizers is not associated with response to buprenorphine or methadone in people with Opioid-Related Disorders as compared to CYP2D6 normal metabolizer and ultra-metabolizer.			= 0.383	OR			
1447678633	rs1710	capecitabine,fluorouracil	Efficacy	no	Genotype GG is not associated with response to capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotypes CC + CG.	C	G	= 0.063	OR			
1447678633	rs1710	capecitabine,fluorouracil	Efficacy	no	Genotype GG is not associated with response to capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotypes CC + CG.	C	G	= 0.117	HR	1.54	0.9	2.63
1449271238	rs1800544	buprenorphine,methadone	Efficacy	no	Genotype GG is not associated with response to buprenorphine or methadone in people with Opioid-Related Disorders as compared to genotypes CC + CG.	G		= 0.802	OR			
1449713604	rs1136201	carboplatin,docetaxel,trastuzumab	Efficacy	yes	Allele G is associated with decreased response to carboplatin, docetaxel and trastuzumab in women with Breast Neoplasms.	G		= 0.05	HR	2.67	1.05	6.78
1449713624	rs2284922	carboplatin,docetaxel,trastuzumab	Efficacy	yes	Allele A is associated with increased response to carboplatin, docetaxel and trastuzumab in women with Breast Neoplasms.	G		= 0.05	HR	12.42	2.0	77.19
827815301	rs11572103	amodiaquine,artesunate	Efficacy,Metabolism/PK	no	Genotype AA is not associated with metabolism of amodiaquine and artesunate in children with Malaria as compared to genotypes AT + TT.	A		= 0.58	Unknown			
1449271245	rs1799971	buprenorphine,methadone	Efficacy	no	Genotypes AA + AG is not associated with response to buprenorphine or methadone in people with Opioid-Related Disorders as compared to genotype AA.	G		= 0.601	OR			
1449713641	rs2229571	carboplatin,docetaxel,trastuzumab	Efficacy	no	Allele C is not associated with decreased response to carboplatin, docetaxel and trastuzumab in women with Breast Neoplasms.	C		= 0.25	HR	2.02	0.66	6.13
1449271273	rs6311	buprenorphine,methadone	Efficacy	no	Genotype TT is not associated with response to buprenorphine or methadone in people with Opioid-Related Disorders as compared to genotypes CC + CT.	T		= 0.079	OR			
1449713634	rs2070096	carboplatin,docetaxel,trastuzumab	Efficacy	yes	Allele A is associated with decreased response to carboplatin, docetaxel and trastuzumab in women with Breast Neoplasms.	A		= 0.05	HR	3.27	1.16	9.17
1449271267	rs4680	buprenorphine,methadone	Efficacy	no	Genotype AA is not associated with response to buprenorphine or methadone in people with Opioid-Related Disorders as compared to genotypes AG + GG.	A		= 0.091	OR			
1449156631	rs199670311	fentanyl,remifentanil	Efficacy	yes	Allele T is associated with increased dose of fentanyl or remifentanil in people with Pain as compared to allele C.			= 0.04	OR			
1449156631	rs199670311	fentanyl,remifentanil	Efficacy	yes	Allele T is associated with increased dose of fentanyl or remifentanil in people with Pain as compared to allele C.			< 0.05	OR			
1446908428	rs61764370	capecitabine,cetuximab,oxaliplatin	Efficacy	yes	Genotype AC is associated with increased response to capecitabine, cetuximab and oxaliplatin in people with Rectal Neoplasms as compared to genotype AA.	C		= 0.044	OR			
981793872	rs3025000	bevacizumab,ranibizumab	Efficacy	yes	Genotypes CT + TT are associated with increased response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotype CC.	C		< 1.0E-4	Unknown			
981793872	rs3025000	bevacizumab,ranibizumab	Efficacy	yes	Genotypes CT + TT are associated with increased response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotype CC.	C		= 0.01	Unknown			
981793872	rs3025000	bevacizumab,ranibizumab	Efficacy	yes	Genotypes CT + TT are associated with increased response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotype CC.	C		= 0.01	Unknown			
1184886901	rs1695	fluorouracil,leucovorin,oxaliplatin	Efficacy	no	Allele G is not associated with response to fluorouracil, leucovorin and oxaliplatin in people with Esophageal Neoplasms and Stomach Neoplasms as compared to allele A.				OR			
1184886917	rs13181	fluorouracil,leucovorin,oxaliplatin	Efficacy	no	Allele T is not associated with response to fluorouracil, leucovorin and oxaliplatin in people with Esophageal Neoplasms and Stomach Neoplasms as compared to allele G.				OR			
827832031	rs1364043	fluvoxamine,milnacipran,paroxetine	Efficacy	yes	Genotype TT is associated with increased response to fluvoxamine, milnacipran and paroxetine in people with Depressive Disorder, Major as compared to genotypes GG + GT.			= 0.018	Unknown			
1184886844	rs45445694	fluorouracil,leucovorin,oxaliplatin	Efficacy	yes	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is associated with increased response to fluorouracil, leucovorin and oxaliplatin in people with Esophageal Neoplasms and Stomach Neoplasms as compared to genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.			= 0.02	OR			
1184886873	rs25487	fluorouracil,leucovorin,oxaliplatin	Efficacy	no	Allele T is not associated with response to fluorouracil, leucovorin and oxaliplatin in people with Esophageal Neoplasms and Stomach Neoplasms as compared to allele C.				OR			
981793920	rs3025000	bevacizumab,ranibizumab	Efficacy	yes	Genotypes CT + TT are associated with increased response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotype CC.	C		= 1.0E-4	OR	3.49	1.82	6.71
981793920	rs3025000	bevacizumab,ranibizumab	Efficacy	yes	Genotypes CT + TT are associated with increased response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotype CC.	C		< 0.001	OR	2.72	1.46	5.07
981793920	rs3025000	bevacizumab,ranibizumab	Efficacy	yes	Genotypes CT + TT are associated with increased response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotype CC.	C		= 0.006	OR	2.38	1.27	4.57
1451155689	CYP2D6 poor metabolizer phenotype	amitriptyline,tramadol	Dosage	no	CYP2D6 poor metabolizer phenotype is not associated with dose of amitriptyline or tramadol in people with Phantom limb syndrome as compared to CYP2D6 normal metabolizer phenotype.							
1448268147	rs7270101	azathioprine,mercaptopurine	Toxicity,Metabolism/PK	yes	Genotypes AC + CC is associated with increased metabolism of azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.			= 0.008	OR			
1448268147	rs7270101	azathioprine,mercaptopurine	Toxicity,Metabolism/PK	yes	Genotypes AC + CC is associated with increased metabolism of azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.			= 0.047	OR			
827815502	rs1979277	bevacizumab,fluorouracil,irinotecan,leucovorin	Efficacy	yes	Allele A is associated with increased response to bevacizumab, fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to allele G.			= 0.025	Unknown			
1446908230	rs121434568	erlotinib,gefitinib	Efficacy	yes	Allele G is associated with decreased response to erlotinib or gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.			< 0.001	HR	0.69	0.57	0.82
1446908230	rs121434568	erlotinib,gefitinib	Efficacy	yes	Allele G is associated with decreased response to erlotinib or gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.			= 0.005	HR	0.61	0.43	0.86
1451250000	rs1799752	enalapril,lisinopril	Efficacy	yes	Genotype del/del is associated with increased clinical benefit to enalapril or lisinopril in men with Hypertension as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.			= 0.0001				
1447682270	rs8099917	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Allele T is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in children with Hepatitis C as compared to allele G.			= 0.021	OR			
1183703414	rs1800629	adalimumab,etanercept,infliximab	Efficacy	yes	Genotypes AG + GG is associated with increased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to genotype AA.			= 0.002	OR	8.48	2.16	33.23
1447944264	rs183205964	capecitabine,fluorouracil,tegafur	Toxicity	yes	Allele C is associated with increased discontinuation of capecitabine, fluorouracil or tegafur in people with Neoplasms as compared to allele G.	C		= 0.015	OR	3.7	1.29	10.8
1448124443	rs56038477	capecitabine,fluorouracil	Dosage	yes	Genotype CT is associated with dose of capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	T		= 0.026	OR	3.96	1.17	13.33
1446895539	rs4939827	fluorouracil,irinotecan,oxaliplatin	Efficacy	no	Allele C is not associated with response to fluorouracil, irinotecan and oxaliplatin in people with Colorectal Neoplasms and Neoplasm Metastasis as compared to allele T.	C	T	= 0.30	OR			
1446895539	rs4939827	fluorouracil,irinotecan,oxaliplatin	Efficacy	no	Allele C is not associated with response to fluorouracil, irinotecan and oxaliplatin in people with Colorectal Neoplasms and Neoplasm Metastasis as compared to allele T.	C	T	= 0.36	OR			
1446895539	rs4939827	fluorouracil,irinotecan,oxaliplatin	Efficacy	no	Allele C is not associated with response to fluorouracil, irinotecan and oxaliplatin in people with Colorectal Neoplasms and Neoplasm Metastasis as compared to allele T.	C	T	= 0.48	OR			
1446895503	rs7013278	fluorouracil,irinotecan,oxaliplatin	Efficacy	no	Allele T is not associated with response to fluorouracil, irinotecan and oxaliplatin in people with Colorectal Neoplasms and Neoplasm Metastasis as compared to allele C.	C	T	= 0.20	OR			
1446895503	rs7013278	fluorouracil,irinotecan,oxaliplatin	Efficacy	no	Allele T is not associated with response to fluorouracil, irinotecan and oxaliplatin in people with Colorectal Neoplasms and Neoplasm Metastasis as compared to allele C.	C	T	= 0.29	OR			
1446895503	rs7013278	fluorouracil,irinotecan,oxaliplatin	Efficacy	no	Allele T is not associated with response to fluorouracil, irinotecan and oxaliplatin in people with Colorectal Neoplasms and Neoplasm Metastasis as compared to allele C.	C	T	= 0.50	OR			
1446895512	rs7014346	fluorouracil,irinotecan,oxaliplatin	Efficacy	no	Allele A is not associated with response to fluorouracil, irinotecan and oxaliplatin in people with Colorectal Neoplasms and Neoplasm Metastasis as compared to allele G.	G	A	= 0.21	OR			
1446895512	rs7014346	fluorouracil,irinotecan,oxaliplatin	Efficacy	no	Allele A is not associated with response to fluorouracil, irinotecan and oxaliplatin in people with Colorectal Neoplasms and Neoplasm Metastasis as compared to allele G.	G	A	= 0.40	OR			
1446895512	rs7014346	fluorouracil,irinotecan,oxaliplatin	Efficacy	no	Allele A is not associated with response to fluorouracil, irinotecan and oxaliplatin in people with Colorectal Neoplasms and Neoplasm Metastasis as compared to allele G.	G	A	= 0.68	OR			
1451135700	rs16969968	3-hydroxycotinine,cotinine,nicotine	Metabolism/PK	no	Allele A is not associated with concentrations of 3-hydroxycotinine, cotinine or nicotine in people with Tobacco Use Disorder as compared to allele G.	A		= 0.32				
1451135700	rs16969968	3-hydroxycotinine,cotinine,nicotine	Metabolism/PK	no	Allele A is not associated with concentrations of 3-hydroxycotinine, cotinine or nicotine in people with Tobacco Use Disorder as compared to allele G.	A		= 0.44				
1451135700	rs16969968	3-hydroxycotinine,cotinine,nicotine	Metabolism/PK	no	Allele A is not associated with concentrations of 3-hydroxycotinine, cotinine or nicotine in people with Tobacco Use Disorder as compared to allele G.	A		= 0.74				
1446895521	rs10795668	fluorouracil,irinotecan,oxaliplatin	Efficacy	no	Allele A is not associated with response to fluorouracil, irinotecan and oxaliplatin in people with Colorectal Neoplasms and Neoplasm Metastasis as compared to allele G.	G	A	= 0.02	OR			
1446895521	rs10795668	fluorouracil,irinotecan,oxaliplatin	Efficacy	no	Allele A is not associated with response to fluorouracil, irinotecan and oxaliplatin in people with Colorectal Neoplasms and Neoplasm Metastasis as compared to allele G.	G	A	= 0.10	OR			
1446895521	rs10795668	fluorouracil,irinotecan,oxaliplatin	Efficacy	no	Allele A is not associated with response to fluorouracil, irinotecan and oxaliplatin in people with Colorectal Neoplasms and Neoplasm Metastasis as compared to allele G.	G	A	= 0.32	OR			
1446895530	rs4779584	fluorouracil,irinotecan,oxaliplatin	Efficacy	no	Allele T is not associated with response to fluorouracil, irinotecan and oxaliplatin in people with Colorectal Neoplasms and Neoplasm Metastasis as compared to allele C.	C	T	= 0.66	OR			
1446895530	rs4779584	fluorouracil,irinotecan,oxaliplatin	Efficacy	no	Allele T is not associated with response to fluorouracil, irinotecan and oxaliplatin in people with Colorectal Neoplasms and Neoplasm Metastasis as compared to allele C.	C	T	= 0.87	OR			
1446895530	rs4779584	fluorouracil,irinotecan,oxaliplatin	Efficacy	no	Allele T is not associated with response to fluorouracil, irinotecan and oxaliplatin in people with Colorectal Neoplasms and Neoplasm Metastasis as compared to allele C.	C	T	= 0.91	OR			
1446895473	rs6983267	fluorouracil,irinotecan,oxaliplatin	Efficacy	no	Allele T is not associated with response to fluorouracil, irinotecan and oxaliplatin in people with Colorectal Neoplasms and Neoplasm Metastasis as compared to allele G.	G	T	= 0.45	OR			
1446895473	rs6983267	fluorouracil,irinotecan,oxaliplatin	Efficacy	no	Allele T is not associated with response to fluorouracil, irinotecan and oxaliplatin in people with Colorectal Neoplasms and Neoplasm Metastasis as compared to allele G.	G	T	= 0.51	OR			
1446895473	rs6983267	fluorouracil,irinotecan,oxaliplatin	Efficacy	no	Allele T is not associated with response to fluorouracil, irinotecan and oxaliplatin in people with Colorectal Neoplasms and Neoplasm Metastasis as compared to allele G.	G	T	= 0.90	OR			
1451135662	rs3733829	cotinine,nicotine	Metabolism/PK	no	Allele G is not associated with concentrations of cotinine or nicotine in people with Tobacco Use Disorder as compared to allele A.	G		= 0.47				
1451135662	rs3733829	cotinine,nicotine	Metabolism/PK	no	Allele G is not associated with concentrations of cotinine or nicotine in people with Tobacco Use Disorder as compared to allele A.	G		= 0.96				
1451135668	rs4105144	cotinine,nicotine	Metabolism/PK	no	Allele T is not associated with concentrations of cotinine or nicotine in people with Tobacco Use Disorder as compared to allele C.	T		= 0.75				
1451135668	rs4105144	cotinine,nicotine	Metabolism/PK	no	Allele T is not associated with concentrations of cotinine or nicotine in people with Tobacco Use Disorder as compared to allele C.	T		= 0.91				
1451135674	rs578776	3-hydroxycotinine,cotinine,nicotine	Metabolism/PK	no	Allele A is not associated with concentrations of 3-hydroxycotinine, cotinine or nicotine in people with Tobacco Use Disorder as compared to allele G.	A		= 0.82				
1451135674	rs578776	3-hydroxycotinine,cotinine,nicotine	Metabolism/PK	no	Allele A is not associated with concentrations of 3-hydroxycotinine, cotinine or nicotine in people with Tobacco Use Disorder as compared to allele G.	A		= 0.96				
1451135674	rs578776	3-hydroxycotinine,cotinine,nicotine	Metabolism/PK	no	Allele A is not associated with concentrations of 3-hydroxycotinine, cotinine or nicotine in people with Tobacco Use Disorder as compared to allele G.	A		= 1.00				
1451135683	rs6474412	3-hydroxycotinine,cotinine,nicotine	Metabolism/PK	no	Allele C is not associated with concentrations of 3-hydroxycotinine, cotinine or nicotine in people with Tobacco Use Disorder as compared to allele T.	C		= 0.21				
1451135683	rs6474412	3-hydroxycotinine,cotinine,nicotine	Metabolism/PK	no	Allele C is not associated with concentrations of 3-hydroxycotinine, cotinine or nicotine in people with Tobacco Use Disorder as compared to allele T.	C		= 0.36				
1451135683	rs6474412	3-hydroxycotinine,cotinine,nicotine	Metabolism/PK	no	Allele C is not associated with concentrations of 3-hydroxycotinine, cotinine or nicotine in people with Tobacco Use Disorder as compared to allele T.	C		= 0.98				
769164968	rs9597	cisplatin,irinotecan	Efficacy	yes	Genotype CG is associated with increased response to cisplatin and irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.			= 0.003	OR	8.5	2.1	34.6
1444699877	rs3836790	levodopa,methylphenidate	Efficacy	yes	Genotype ACATACACACTCAGACACACATACCATGCA/ACATACACACTCAGACACACATACCATGCA is associated with increased response to levodopa and methylphenidate in people with Parkinson Disease as compared to genotypes ACATACACACTCAGACACACATACCATGCA/del + del/del.			< 0.05	OR			
827816346	rs1801252	atenolol,carvedilol,diltiazem,metoprolol,verapamil	Efficacy	no	Genotypes AG + GG are not associated with increased response to atenolol, carvedilol, diltiazem, metoprolol or verapamil in people with Atrial Fibrillation as compared to genotype AA.	G	G	= 0.45	OR	0.86	0.58	1.27
981481458	rs760370	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype GG is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AA + AG.	G		= 0.035	Unknown			
827816261	rs1801253	atenolol,carvedilol,diltiazem,metoprolol,verapamil	Efficacy	yes	Genotypes CG + GG are associated with increased response to atenolol, carvedilol, diltiazem, metoprolol or verapamil in people with Atrial Fibrillation as compared to genotype CC.	G	G	= 0.04	OR	1.44	1.01	2.04
827816261	rs1801253	atenolol,carvedilol,diltiazem,metoprolol,verapamil	Efficacy	yes	Genotypes CG + GG are associated with increased response to atenolol, carvedilol, diltiazem, metoprolol or verapamil in people with Atrial Fibrillation as compared to genotype CC.	G	G	= 0.05	OR	1.42	1.0	2.03
981481472	rs12979860	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	T		< 0.001	OR	5.05	2.04	12.5
981481478	rs179008	interferon alfa-2a, recombinant	Efficacy	no	Allele A is not associated with response to interferon alfa-2a, recombinant in people with Hepatitis C, Chronic as compared to allele T.			= 0.069	Unknown			
981481554	rs8099917	peginterferon alfa-2a,ribavirin	Efficacy	yes	Genotype TT is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotype GT.	G		= 0.0037	Unknown			
981481560	rs8099917	peginterferon alfa-2a,ribavirin	Efficacy	yes	Genotype TT is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotype GT.	G		= 0.0028	Unknown			
981481567	rs8099917	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.			= 0.017	Unknown			
981481534	rs12979860	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	C		= 0.0054	Unknown			
981481540	rs8099917	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in Hepatitis C, Chronic as compared to genotypes GG + GT.			= 0.021	OR	5.83	1.26	26.92
769164773	rs7438284	lorazepam,valproic acid	Efficacy	yes	Allele A is associated with increased response to lorazepam and valproic acid in healthy individuals as compared to allele T.			< 0.05	Unknown			
1449170208	rs11615	granisetron,palonosetron	Efficacy	no	Allele A is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to allele G.			= 0.535	OR			
1449170208	rs11615	granisetron,palonosetron	Efficacy	no	Allele A is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to allele G.			= 1.00	OR			
1449170220	rs1128503	granisetron,palonosetron	Efficacy	no	Genotype AA is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotypes AG + GG.			= 0.251	OR			
1449170220	rs1128503	granisetron,palonosetron	Efficacy	no	Genotype AA is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotypes AG + GG.			= 0.888	OR			
1449170228	rs2032582	granisetron,palonosetron	Efficacy	no	Genotype TT is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotypes CT + TT.			= 0.230	OR			
1449170228	rs2032582	granisetron,palonosetron	Efficacy	no	Genotype TT is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotypes CT + TT.			= 0.601	OR			
1449170236	rs1045642	granisetron,palonosetron	Efficacy	no	Genotype AA is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotypes AG + GG.			= 0.158	OR			
1449170236	rs1045642	granisetron,palonosetron	Efficacy	no	Genotype AA is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotypes AG + GG.			= 0.496	OR			
1449170244	rs2231137	granisetron,palonosetron	Efficacy	no	Genotype TT is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotypes CC + CT.			= 0.051	OR			
1449170244	rs2231137	granisetron,palonosetron	Efficacy	no	Genotype TT is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotypes CC + CT.			= 0.342	OR			
1449170252	rs2231142	granisetron,palonosetron	Efficacy	no	Genotype TT is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotypes GG + GT.			= 0.110	OR			
1449170252	rs2231142	granisetron,palonosetron	Efficacy	no	Genotype TT is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotypes GG + GT.			= 0.231	OR			
1449170266	rs45460698	granisetron,palonosetron	Efficacy	no	Genotype del/del is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotypes AAG/AAG + AAG/del.			= 0.318	OR			
1449170266	rs45460698	granisetron,palonosetron	Efficacy	no	Genotype del/del is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotypes AAG/AAG + AAG/del.			= 1.00	OR			
1449170281	rs6766410	granisetron,palonosetron	Efficacy	no	Genotype CC is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotypes AA + AC.			= 0.309	OR			
1449170281	rs6766410	granisetron,palonosetron	Efficacy	no	Genotype CC is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotypes AA + AC.			= 0.599	OR			
1449170293	rs6807362	granisetron,palonosetron	Efficacy	no	Genotype GG is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotypes CC + CG.			= 0.293	OR			
1449170293	rs6807362	granisetron,palonosetron	Efficacy	no	Genotype GG is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotypes CC + CG.			= 1.00	OR			
769164370	rs10975641	citalopram,escitalopram	Efficacy	yes	Allele G is associated with increased response to citalopram and escitalopram in people with Depressive Disorder, Major as compared to allele C.			= 0.016	OR	0.11	0.013	0.949
769164370	rs10975641	citalopram,escitalopram	Efficacy	yes	Allele G is associated with increased response to citalopram and escitalopram in people with Depressive Disorder, Major as compared to allele C.			= 0.023	OR	0.179	0.035	0.907
769164370	rs10975641	citalopram,escitalopram	Efficacy	yes	Allele G is associated with increased response to citalopram and escitalopram in people with Depressive Disorder, Major as compared to allele C.				OR	0.68	0.51	0.91
1449170308	rs6443930	granisetron,palonosetron	Efficacy	no	Genotype GG is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotypes CC + CG.			= 0.056	OR			
1449170308	rs6443930	granisetron,palonosetron	Efficacy	no	Genotype GG is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotypes CC + CG.			= 0.290	OR			
1449170319	rs2111375	granisetron,palonosetron	Efficacy	no	Genotype AA is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotypes AG + GG.			= 0.670	OR			
1449170319	rs2111375	granisetron,palonosetron	Efficacy	no	Genotype AA is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotypes AG + GG.			= 1.00	OR			
1449170332	rs6715729	granisetron,palonosetron	Efficacy	no	Genotype GG is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotypes AA + AG.			= 0.563	OR			
1449170332	rs6715729	granisetron,palonosetron	Efficacy	no	Genotype GG is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotypes AA + AG.			= 1.00	OR			
1449170340	rs3212986	granisetron,palonosetron	Efficacy	yes	Genotypes AC + CC are associated with increased response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotype AA.			= 0.011	OR	11.251	1.741	72.712
1449170340	rs3212986	granisetron,palonosetron	Efficacy	yes	Genotypes AC + CC are associated with increased response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotype AA.			= 0.036	OR			
1449170340	rs3212986	granisetron,palonosetron	Efficacy	yes	Genotypes AC + CC are associated with increased response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotype AA.			= 0.729	OR			
1183491546	rs1061170	bevacizumab,ranibizumab	Efficacy	no	Genotype CC is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotypes CT + TT.	C		= 0.03	Unknown			
1183491546	rs1061170	bevacizumab,ranibizumab	Efficacy	no	Genotype CC is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotypes CT + TT.	C		= 0.18	Unknown			
1183491546	rs1061170	bevacizumab,ranibizumab	Efficacy	no	Genotype CC is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotypes CT + TT.	C		= 0.22	Unknown			
1183491546	rs1061170	bevacizumab,ranibizumab	Efficacy	no	Genotype CC is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotypes CT + TT.	C		= 0.30	Unknown			
1183491546	rs1061170	bevacizumab,ranibizumab	Efficacy	no	Genotype CC is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotypes CT + TT.	C		= 0.48	Unknown			
1183491546	rs1061170	bevacizumab,ranibizumab	Efficacy	no	Genotype CC is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotypes CT + TT.	C		= 0.61	Unknown			
1183491546	rs1061170	bevacizumab,ranibizumab	Efficacy	no	Genotype CC is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotypes CT + TT.	C		= 0.62	Unknown			
1183491546	rs1061170	bevacizumab,ranibizumab	Efficacy	no	Genotype CC is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotypes CT + TT.	C		= 0.71	Unknown			
1183491546	rs1061170	bevacizumab,ranibizumab	Efficacy	no	Genotype CC is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotypes CT + TT.	C		= 0.72	Unknown			
1447959676	rs2291858	interferon beta-1a,interferon beta-1b	Efficacy	yes	Allele G is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele A.			= 1.67E-4	OR			
1447959676	rs2291858	interferon beta-1a,interferon beta-1b	Efficacy	yes	Allele G is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele A.			= 5.53E-4	OR	10.64	2.38	47.47
1447959676	rs2291858	interferon beta-1a,interferon beta-1b	Efficacy	yes	Allele G is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele A.			= 2.48E-2	OR	1.71	1.1	2.55
1447959676	rs2291858	interferon beta-1a,interferon beta-1b	Efficacy	yes	Allele G is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele A.			= 0.169	OR			
1447959685	rs4278350	interferon beta-1a,interferon beta-1b	Efficacy	yes	Allele T is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele C.			= 1.34E-3	OR			
1447959685	rs4278350	interferon beta-1a,interferon beta-1b	Efficacy	yes	Allele T is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele C.			= 3.37E-3	OR	3.43	1.58	7.43
1447959685	rs4278350	interferon beta-1a,interferon beta-1b	Efficacy	yes	Allele T is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele C.			= 4.02E-2	OR	1.5	1.08	2.08
1447959685	rs4278350	interferon beta-1a,interferon beta-1b	Efficacy	yes	Allele T is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele C.			= 0.34	OR			
1447959667	rs1448673	interferon beta-1a,interferon beta-1b	Efficacy	yes	Allele G is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele A.			= 1.66E-4	OR			
1447959667	rs1448673	interferon beta-1a,interferon beta-1b	Efficacy	yes	Allele G is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele A.			= 9.21E-4	OR	2.98	1.6	5.56
1447959667	rs1448673	interferon beta-1a,interferon beta-1b	Efficacy	yes	Allele G is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele A.			= 1.48E-2	OR	2.4	1.28	4.58
1447959667	rs1448673	interferon beta-1a,interferon beta-1b	Efficacy	yes	Allele G is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele A.			= 0.826	OR			
1447959649	rs10494227	interferon beta-1a,interferon beta-1b	Efficacy	yes	Allele A is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele G.			= 8.15E-5	OR			
1447959649	rs10494227	interferon beta-1a,interferon beta-1b	Efficacy	yes	Allele A is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele G.			= 1.96E-4	OR	4.82	1.98	11.7
1447959649	rs10494227	interferon beta-1a,interferon beta-1b	Efficacy	yes	Allele A is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele G.			= 3.2E-2	OR	1.65	1.1	2.46
1447959649	rs10494227	interferon beta-1a,interferon beta-1b	Efficacy	yes	Allele A is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele G.			= 0.08	OR			
1447959658	rs3133084	interferon beta-1a,interferon beta-1b	Efficacy	yes	Allele A is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele G.			= 1.37E-4	OR			
1447959658	rs3133084	interferon beta-1a,interferon beta-1b	Efficacy	yes	Allele A is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele G.			= 7.15E-4	OR	4.02	1.85	8.74
1447959658	rs3133084	interferon beta-1a,interferon beta-1b	Efficacy	yes	Allele A is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele G.			= 1.55E-2	OR	1.51	1.12	2.02
1447959658	rs3133084	interferon beta-1a,interferon beta-1b	Efficacy	yes	Allele A is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele G.			= 0.654	OR			
1447959640	rs10760397	interferon beta-1a,interferon beta-1b	Efficacy	yes	Allele C is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele T.			= 6.51E-5	OR			
1447959640	rs10760397	interferon beta-1a,interferon beta-1b	Efficacy	yes	Allele C is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele T.			= 5.08E-4	OR	11.31	2.54	50.39
1447959640	rs10760397	interferon beta-1a,interferon beta-1b	Efficacy	yes	Allele C is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele T.			= 9.7E-3	OR	1.49	1.14	1.95
1447959640	rs10760397	interferon beta-1a,interferon beta-1b	Efficacy	yes	Allele C is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele T.			= 0.39	OR			
1183491593	rs11200638	bevacizumab,ranibizumab	Efficacy	no	Genotype AA is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotypes AG + GG.	A		= 0.10	Unknown			
1183491593	rs11200638	bevacizumab,ranibizumab	Efficacy	no	Genotype AA is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotypes AG + GG.	A		= 0.23	Unknown			
1183491593	rs11200638	bevacizumab,ranibizumab	Efficacy	no	Genotype AA is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotypes AG + GG.	A		= 0.25	Unknown			
1183491593	rs11200638	bevacizumab,ranibizumab	Efficacy	no	Genotype AA is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotypes AG + GG.	A		= 0.42	Unknown			
1183491593	rs11200638	bevacizumab,ranibizumab	Efficacy	no	Genotype AA is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotypes AG + GG.	A		= 0.64	Unknown			
1183491593	rs11200638	bevacizumab,ranibizumab	Efficacy	no	Genotype AA is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotypes AG + GG.	A		= 0.68	Unknown			
1183491593	rs11200638	bevacizumab,ranibizumab	Efficacy	no	Genotype AA is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotypes AG + GG.	A		= 0.69	Unknown			
1183491593	rs11200638	bevacizumab,ranibizumab	Efficacy	no	Genotype AA is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotypes AG + GG.	A		= 0.84	Unknown			
1183491593	rs11200638	bevacizumab,ranibizumab	Efficacy	no	Genotype AA is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotypes AG + GG.	A		= 0.99	Unknown			
1447959603	rs760316	interferon beta-1a,interferon beta-1b	Efficacy	yes	Allele C is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele T.			= 6.74E-6	OR			
1447959603	rs760316	interferon beta-1a,interferon beta-1b	Efficacy	yes	Allele C is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele T.			= 3.49E-4	OR	4.08	1.92	8.67
1447959603	rs760316	interferon beta-1a,interferon beta-1b	Efficacy	yes	Allele C is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele T.			= 1.23E-3	OR	1.94	1.33	2.8
1447959603	rs760316	interferon beta-1a,interferon beta-1b	Efficacy	yes	Allele C is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele T.			= 0.319	OR			
1183491577	rs10490924	bevacizumab,ranibizumab	Efficacy	no	Genotype TT is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotypes GG + GT.	G		= 0.06	Unknown			
1183491577	rs10490924	bevacizumab,ranibizumab	Efficacy	no	Genotype TT is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotypes GG + GT.	G		= 0.30	Unknown			
1183491577	rs10490924	bevacizumab,ranibizumab	Efficacy	no	Genotype TT is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotypes GG + GT.	G		= 0.33	Unknown			
1183491577	rs10490924	bevacizumab,ranibizumab	Efficacy	no	Genotype TT is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotypes GG + GT.	G		= 0.35	Unknown			
1183491577	rs10490924	bevacizumab,ranibizumab	Efficacy	no	Genotype TT is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotypes GG + GT.	G		= 0.51	Unknown			
1183491577	rs10490924	bevacizumab,ranibizumab	Efficacy	no	Genotype TT is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotypes GG + GT.	G		= 0.77	Unknown			
1183491577	rs10490924	bevacizumab,ranibizumab	Efficacy	no	Genotype TT is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotypes GG + GT.	G		= 0.80	Unknown			
1183491577	rs10490924	bevacizumab,ranibizumab	Efficacy	no	Genotype TT is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotypes GG + GT.	G		= 0.89	Unknown			
1183491577	rs10490924	bevacizumab,ranibizumab	Efficacy	no	Genotype TT is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotypes GG + GT.	G		= 0.97	Unknown			
1448107049	rs12979860	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.			< 0.01	OR			
1448107024	rs12979860	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.			= 0.007	OR	6.06	1.65	22.22
981479989	rs11716445	pravastatin,simvastatin	Efficacy	yes	Allele A is associated with decreased response to pravastatin or simvastatin in people with Hypercholesterolemia as compared to allele G.			= 0.01	Unknown			
1450415747	rs776746	atazanavir / ritonavir	Metabolism/PK	yes	Genotype CC is associated with increased concentrations of atazanavir / ritonavir in people with HIV Infections as compared to genotypes CT + TT.	C		< 0.001	OR			
1450415747	rs776746	atazanavir / ritonavir	Metabolism/PK	yes	Genotype CC is associated with increased concentrations of atazanavir / ritonavir in people with HIV Infections as compared to genotypes CT + TT.	C		= 0.007	OR			
1450415756	rs4149056	atazanavir / ritonavir	Metabolism/PK	yes	Genotypes CC + CT is associated with increased concentrations of atazanavir / ritonavir in people with HIV Infections as compared to genotype TT.	T		= 0.013	OR			
1450415756	rs4149056	atazanavir / ritonavir	Metabolism/PK	yes	Genotypes CC + CT is associated with increased concentrations of atazanavir / ritonavir in people with HIV Infections as compared to genotype TT.	T		= 0.036	OR			
1450186421	rs2108622	acenocoumarol,warfarin	Dosage	yes	Genotypes CT + TT are associated with increased dose of acenocoumarol or warfarin as compared to genotype CC.			= 0.002	OR			
1450186421	rs2108622	acenocoumarol,warfarin	Dosage	yes	Genotypes CT + TT are associated with increased dose of acenocoumarol or warfarin as compared to genotype CC.			= 0.02	OR			
1450186421	rs2108622	acenocoumarol,warfarin	Dosage	yes	Genotypes CT + TT are associated with increased dose of acenocoumarol or warfarin as compared to genotype CC.			= 0.36	OR			
1183491842	rs1799752	angiotensin II,losartan	Efficacy	no	Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is not associated with increased response to angiotensin II and losartan in healthy individuals as compared to genotype del/del.				Unknown			
1451120506	rs28404156	Beta blocking agents, selective	Efficacy	yes	Allele A is associated with increased response to Beta blocking agents, selective in people with Hypertension as compared to allele G.			= 2.18E-7				
1451120506	rs28404156	Beta blocking agents, selective	Efficacy	yes	Allele A is associated with increased response to Beta blocking agents, selective in people with Hypertension as compared to allele G.	A		= 9.33E-5				
1451120506	rs28404156	Beta blocking agents, selective	Efficacy	yes	Allele A is associated with increased response to Beta blocking agents, selective in people with Hypertension as compared to allele G.	A		= 1.8E-4				
1447680639	rs1042713	corticosteroids,Leukotriene receptor antagonists,selective beta-2-adrenoreceptor agonists	Efficacy	no	Allele A is not associated with response to corticosteroids, Leukotriene receptor antagonists and selective beta-2-adrenoreceptor agonists in children with Asthma as compared to genotype GG.			= 0.65	OR	0.94	0.73	1.22
1447680645	rs1042713	corticosteroids,Leukotriene receptor antagonists	Efficacy	no	Allele A is not associated with response to corticosteroids and Leukotriene receptor antagonists in children with Asthma as compared to genotype GG.			= 0.52	OR	1.11	0.8	1.55
1445206674	rs4803217	peginterferon alfa-2a,ribavirin	Efficacy	yes	Genotypes AC + CC are associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotype AA.			= 0.03	OR	3.21		
1445206674	rs4803217	peginterferon alfa-2a,ribavirin	Efficacy	yes	Genotypes AC + CC are associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotype AA.			= 0.20	OR	1.44		
1447680618	rs1042713	corticosteroids,selective beta-2-adrenoreceptor agonists	Efficacy	yes	Allele A is associated with decreased response to corticosteroids and selective beta-2-adrenoreceptor agonists in children with Asthma as compared to genotype GG.			= 0.0021	OR	1.52	1.17	1.99
1447959074	rs1061622	adalimumab,etanercept,infliximab,ustekinumab	Efficacy	yes	Genotypes GG + GT are associated with decreased response to adalimumab, etanercept, infliximab or ustekinumab in people with Psoriasis as compared to genotype TT.	G		= 0.04	OR	2.01	1.0	4.02
1183606890	rs3812718	carbamazepine,valproic acid	Efficacy	no	Allele T is not associated with response to carbamazepine or valproic acid in people with Epilepsy as compared to allele C.			= 0.39	OR	0.94	0.85	1.05
1444665876	rs8099917	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin,telaprevir	Efficacy	yes	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to genotypes GG + GT.			< 0.01	OR			
1444665876	rs8099917	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin,telaprevir	Efficacy	yes	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to genotypes GG + GT.			= 0.0318	OR	1.99	1.062	3.76
1449154644	rs113993960	ivacaftor,tezacaftor	Efficacy	yes	Genotype del/del is associated with increased response to ivacaftor and tezacaftor in people with Cystic Fibrosis.			< 0.001	OR			
1449154644	rs113993960	ivacaftor,tezacaftor	Efficacy	yes	Genotype del/del is associated with increased response to ivacaftor and tezacaftor in people with Cystic Fibrosis.			< 0.001	OR			
1449154644	rs113993960	ivacaftor,tezacaftor	Efficacy	yes	Genotype del/del is associated with increased response to ivacaftor and tezacaftor in people with Cystic Fibrosis.				OR			
1449154644	rs113993960	ivacaftor,tezacaftor	Efficacy	yes	Genotype del/del is associated with increased response to ivacaftor and tezacaftor in people with Cystic Fibrosis.				OR			
1444665886	rs11322783	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin,telaprevir	Efficacy	yes	Genotype TT/TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.			< 0.01	OR			
1444665886	rs11322783	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin,telaprevir	Efficacy	yes	Genotype TT/TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.			> 0.05	OR			
1449154699	rs113993960	ivacaftor,tezacaftor	Efficacy	yes	Genotype CTT/del is associated with increased response to ivacaftor and tezacaftor in people with Cystic Fibrosis.			< 0.001	OR			
1449154699	rs113993960	ivacaftor,tezacaftor	Efficacy	yes	Genotype CTT/del is associated with increased response to ivacaftor and tezacaftor in people with Cystic Fibrosis.			< 0.001	OR			
1449154699	rs113993960	ivacaftor,tezacaftor	Efficacy	yes	Genotype CTT/del is associated with increased response to ivacaftor and tezacaftor in people with Cystic Fibrosis.				OR			
1449154699	rs113993960	ivacaftor,tezacaftor	Efficacy	yes	Genotype CTT/del is associated with increased response to ivacaftor and tezacaftor in people with Cystic Fibrosis.				OR			
1448532419	rs1049174	peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype GG is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CC + CG.			= 0.005	OR	6.0	1.71	21.08
1184999713	rs2273697	carbamazepine,oxcarbazepine	Efficacy	yes	Genotype AG is associated with resistance to carbamazepine or oxcarbazepine in people with Epilepsy as compared to genotype GG.	A	A	= 0.007	OR	2.14	1.23	3.71
1184999606	rs3812718	carbamazepine,oxcarbazepine	Efficacy	yes	Genotype TT is associated with resistance to carbamazepine or oxcarbazepine in people with Epilepsy as compared to genotype CC.	T	T	< 0.001	OR	3.41	1.73	6.7
1451153660	CYP2D6 poor metabolizer phenotype	noroxycodone,oxycodone	Metabolism/PK	not stated	CYP2D6 poor metabolizer phenotype is associated with increased concentrations of noroxycodone and oxycodone in women with Neoplasms and Pain as compared to CYP2D6 normal metabolizer phenotype.							
1184999651	rs3812718	carbamazepine,oxcarbazepine	Efficacy	yes	Genotype TT is associated with resistance to carbamazepine or oxcarbazepine in people with Epilepsy as compared to genotype CC.	T	T	= 0.002	OR	3.55	1.62	7.78
699642174	rs1487278	mirtazapine,venlafaxine	Efficacy	yes	Allele C is associated with increased response to mirtazapine and venlafaxine in people with Depression as compared to genotype TT.			= 0.007	Unknown			
1444705817	rs8099917	peginterferon alfa-2a,ribavirin	Efficacy	yes	Genotype TT is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GT + TT.			< 0.0001	OR			
1444843741	rs8099917	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.			= 0.004	OR	2.8	1.4	5.6
981501267	rs12979860	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Dosage,Efficacy	yes	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b or ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	C		= 9.0E-6	OR	5.79	2.67	12.57
827704840	rs1695	cyclophosphamide,epirubicin	Efficacy	yes	Genotypes AA + AG are associated with increased response to cyclophosphamide and epirubicin in women with Breast Neoplasms as compared to genotype GG.	A	A	= 0.024	Unknown			
981482129	rs20455	atorvastatin,pravastatin	Efficacy	yes	Genotypes AG + GG are associated with increased response to atorvastatin or pravastatin as compared to genotype AA.			= 1.0E-4	HR	0.6	0.46	0.78
981482129	rs20455	atorvastatin,pravastatin	Efficacy	yes	Genotypes AG + GG are associated with increased response to atorvastatin or pravastatin as compared to genotype AA.			< 1.0E-4	HR	0.5	0.37	0.67
981482129	rs20455	atorvastatin,pravastatin	Efficacy	yes	Genotypes AG + GG are associated with increased response to atorvastatin or pravastatin as compared to genotype AA.			= 0.0045	HR	0.65	0.49	0.88
982047048	rs1800471	adalimumab,etanercept,infliximab	Efficacy	no	Genotype CG is not associated with response to adalimumab, etanercept and infliximab in people with Arthritis, Rheumatoid as compared to genotype GG.			= 1.0	Unknown			
1451133740	rs6313	morphine,nortriptyline	Efficacy	no	Allele A is not associated with response to morphine and nortriptyline in people with Pain as compared to allele G.	A		= 0.981				
981482201	rs9471077	atorvastatin,pravastatin	Efficacy	no	Genotype AA is not associated with increased response to atorvastatin or pravastatin.			= 0.6309	HR	1.1	0.74	1.64
981482201	rs9471077	atorvastatin,pravastatin	Efficacy	no	Genotype AA is not associated with increased response to atorvastatin or pravastatin.			= 0.7914	HR	0.95	0.67	1.36
981482201	rs9471077	atorvastatin,pravastatin	Efficacy	no	Genotype AA is not associated with increased response to atorvastatin or pravastatin.			= 0.7984	HR	0.96	0.7	1.31
1183634353	rs1374385	citalopram,fluoxetine,paroxetine	Efficacy	no	Allele C is not associated with response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to allele G.			> 0.05	OR			
655386848	rs1799889	citalopram,fluoxetine	Efficacy	yes	Allele G is associated with decreased response to citalopram and fluoxetine in people with Depressive Disorder, Major as compared to allele A.			= 0.014	Unknown			
1444705593	rs8099917	peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype GG is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT.			= 9.25E-9	OR	2.39	1.16	4.94
1449576782	rs2032582	cyclophosphamide,doxorubicin	Efficacy	no	Allele C is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele T.				OR			
769171479	rs57098334	fluoxetine,paroxetine	Efficacy	yes	Genotype (CCCACCCGA)12/(CCCACCCGA)12 is associated with increased response to fluoxetine and paroxetine in people with Depression.			< 1.0E-4	Unknown			
769180270	rs8187725	catecholamines,metformin	Other,Metabolism/PK	yes	Allele T is associated with decreased metabolism of catecholamines and metformin as compared to allele C.			< 0.001	Unknown			
1449156661	rs4839603	fentanyl,remifentanil	Efficacy	yes	Genotype GG is associated with decreased dose of fentanyl or remifentanil in people with Pain as compared to genotypes AA + AG.			< 0.05	OR			
1449156661	rs4839603	fentanyl,remifentanil	Efficacy	yes	Genotype GG is associated with decreased dose of fentanyl or remifentanil in people with Pain as compared to genotypes AA + AG.			< 0.05	OR			
981481546	rs12979860	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	T		= 0.0024	OR	8.983	2.173	37.145
981481546	rs12979860	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	T		= 0.0083	OR	24.98	2.27	259.9
769245465	rs4244285	aspirin,clopidogrel	Efficacy	yes	Allele A is associated with decreased response to aspirin and clopidogrel in people with Coronary Artery Disease as compared to allele G.			= 0.015	Unknown			
1183633740	rs2432742	diuretics,hydrochlorothiazide,Thiazides, plain	Efficacy	no	Allele A is not associated with response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele G.	A		= 7.03E-06	Unknown			
1183633740	rs2432742	diuretics,hydrochlorothiazide,Thiazides, plain	Efficacy	no	Allele A is not associated with response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele G.	A		= 6.16E-01	OR			
1444698141	rs12979860	peginterferon alfa-2b,ribavirin	Efficacy	not stated	Genotype CC is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C and HIV Infections as compared to genotype TT.				OR			
1184469067	rs7912580	olanzapine,quetiapine,risperidone,ziprasidone	Efficacy	no	Genotype AG is associated with increased response to olanzapine, quetiapine, risperidone or ziprasidone in people with Schizophrenia as compared to genotype GG.			> 0.05	OR			
1448267268	TPMT poor metabolizer	thioguanosine diphosphate,thioguanosine monophosphate,thioguanosine triphosphate	Metabolism/PK	yes	TPMT poor metabolizer is associated with increased concentrations of thioguanosine diphosphate, thioguanosine monophosphate and thioguanosine triphosphate in people with Inflammatory Bowel Diseases as compared to genotype *1/*1.			= 0.001	OR			
827704813	rs1695	cyclophosphamide,epirubicin,fluorouracil	Efficacy	yes	Allele A is associated with increased response to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele G.			= 0.0209	Unknown			
827704813	rs1695	cyclophosphamide,epirubicin,fluorouracil	Efficacy	yes	Allele A is associated with increased response to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele G.	A	A	= 0.143526	Unknown			
827699118	rs45445694	carboplatin,pemetrexed	Efficacy	no	Allele (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 is not associated with response to carboplatin and pemetrexed in people with Mesothelioma as compared to genotype (CCGCGCCACTTCGCCTGCCTCCGTCCCG)3.				Unknown			
827812172	rs5009910	cisplatin,fluorouracil,mitoxantrone	Efficacy	yes	Allele C is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele T.	C		= 2.4E-5	Unknown			
1449002496	rs4735715	anastrozole,exemestane	Efficacy	no	Allele A is not associated with increased response to anastrozole and exemestane in women with Breast Neoplasms as compared to allele G.	G	A	= 4.476E-7	OR	0.59	0.48	0.73
827813338	rs717620	atorvastatin,simvastatin	Efficacy	yes	Allele T is associated with decreased dose of atorvastatin and simvastatin.			= 0.023	HR	1.29	1.04	1.61
827813338	rs717620	atorvastatin,simvastatin	Efficacy	yes	Allele T is associated with decreased dose of atorvastatin and simvastatin.	C		= 0.023	HR	1.32	1.04	1.69
827813338	rs717620	atorvastatin,simvastatin	Efficacy	yes	Allele T is associated with decreased dose of atorvastatin and simvastatin.	C		= 0.65	Unknown			
981417557	rs10499194	adalimumab,etanercept,infliximab,Tumor necrosis factor alpha (TNF-alpha) inhibitors	Efficacy	no	Allele C is not associated with response to adalimumab, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to genotype G.				Unknown			
981417565	rs2736340	adalimumab,etanercept,infliximab,Tumor necrosis factor alpha (TNF-alpha) inhibitors	Efficacy	no	Allele C is not associated with response to adalimumab, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele T.				Unknown			
981750822	rs1386494	citalopram,fluoxetine,paroxetine	Efficacy	no	Allele C is not associated with response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to allele T.				Unknown			
981750795	rs6311	citalopram,fluoxetine,paroxetine	Efficacy	no	Allele C is not associated with response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to allele T.				Unknown			
981479632	rs8099917	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.			= 0.016	OR	61.5	2.2	1735.8
981500957	rs25531	antipsychotics,haloperidol,olanzapine,risperidone	Efficacy	no	Allele C is not associated with response to antipsychotics, haloperidol, olanzapine or risperidone in people with Schizophrenia as compared to allele T.				Unknown			
981500798	rs3800373	citalopram,fluoxetine,mirtazapine,paroxetine,Selective serotonin reuptake inhibitors,venlafaxine	Efficacy	no	Allele C is not associated with increased response to citalopram, fluoxetine, mirtazapine, paroxetine, Selective serotonin reuptake inhibitors or venlafaxine in people with Mood Disorders as compared to allele A.			= 0.09	OR	1.27	0.96	1.69
981500798	rs3800373	citalopram,fluoxetine,mirtazapine,paroxetine,Selective serotonin reuptake inhibitors,venlafaxine	Efficacy	no	Allele C is not associated with increased response to citalopram, fluoxetine, mirtazapine, paroxetine, Selective serotonin reuptake inhibitors or venlafaxine in people with Mood Disorders as compared to allele A.			= 0.25	OR	1.17	0.9	1.53
769164776	rs7439366	lorazepam,valproic acid	Efficacy	yes	Allele T is associated with increased response to lorazepam and valproic acid in healthy individuals as compared to allele C.			< 0.05	Unknown			
981475614	rs1048943	capecitabine,docetaxel	Efficacy	yes	Genotypes AG + GG are associated with increased response to capecitabine and docetaxel in women with Breast Neoplasms as compared to genotype AA.			= 3.0E-4	Unknown			
981483885	rs12979860	peginterferon alfa-2b,ribavirin,telaprevir	Efficacy	yes	Genotype CC is associated with increased response to peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C, Chronic as compared to genotypes CT + TT.			< 0.001	Unknown			
981865171	rs1946518	interferon alfa-2a, recombinant,interferon alfa-2b, recombinant,interferons,peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Allele T is associated with increased response to interferon alfa-2a, recombinant, interferon alfa-2b, recombinant, interferons, peginterferon alfa-2a, peginterferon alfa-2b or ribavirin in people with Hepatitis C, Chronic as compared to allele G.	T	T	= 0.019	OR	1.537	1.072	2.205
1451124591	rs6025211	cisplatin,fluorouracil,mitoxantrone	Efficacy	yes	Genotypes CC + TT are associated with increased response to cisplatin, fluorouracil and mitoxantrone in people with Liver Neoplasms as compared to genotype CT.	T		= 0.047				
982031571	rs12979860	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	C		< 1.0E-4	Unknown			
982030363	rs3761555	Selective serotonin reuptake inhibitors,venlafaxine	Efficacy	yes	Genotype TT is associated with decreased response to Selective serotonin reuptake inhibitors or venlafaxine in people with Depressive Disorder, Major as compared to genotypes CC + CT.			= 0.017	OR	0.162	0.037	0.718
982046831	rs3740556	carboplatin,cisplatin	Efficacy	no	Genotypes AA + AG are not associated with response to carboplatin and cisplatin in people with Carcinoma, Small Cell as compared to genotype GG.			= 0.16	HR	1.56	0.84	2.86
982030340	rs1992647	Selective serotonin reuptake inhibitors,venlafaxine	Efficacy	no	Genotype AA is associated with decreased response to Selective serotonin reuptake inhibitors or venlafaxine in people with Depressive Disorder, Major as compared to genotype GG.			= 0.003208	OR	0.388	0.176	0.856
982046870	rs20575	adalimumab,etanercept,infliximab	Efficacy	yes	Genotype CC is associated with increased response to adalimumab, etanercept and infliximab in people with Arthritis, Rheumatoid as compared to genotypes CG + GG.	C		= 0.019	Unknown			
982046870	rs20575	adalimumab,etanercept,infliximab	Efficacy	yes	Genotype CC is associated with increased response to adalimumab, etanercept and infliximab in people with Arthritis, Rheumatoid as compared to genotypes CG + GG.	C		= 0.019	Unknown			
1043737589	rs9934438	acenocoumarol,phenprocoumon	Dosage,Toxicity	yes	Genotype GG is associated with increased dose of acenocoumarol or phenprocoumon as compared to genotypes AA + AG.	A			OR	1.7	1.1	2.5
1183701031	rs307805	cisplatin,fluorouracil,oxaliplatin	Efficacy	no	Genotypes CC + CT are not associated with response to cisplatin, fluorouracil and oxaliplatin in people with Stomach Neoplasms as compared to genotype TT.			> 0.05	Unknown			
1444705070	rs11881222	peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype AA is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C and HIV Infections as compared to genotypes AG + GG.			= 0.00003	OR	3.5	1.9	6.3
1444705133	rs8099917	interferon alfa-n1,peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype TT is associated with increased response to interferon alfa-n1, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	T		= 0.017	OR			
1444705262	rs8099917	peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotypes GG + GT is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C.			= 1.48E-17	OR	15.79	8.37	29.76
1451133560	rs1045642	morphine,nortriptyline	Efficacy	yes	Genotype GG is associated with increased response to morphine and nortriptyline in people with Pain as compared to genotypes AA + AG.	G		= 4.89E-5				
1451133560	rs1045642	morphine,nortriptyline	Efficacy	yes	Genotype GG is associated with increased response to morphine and nortriptyline in people with Pain as compared to genotypes AA + AG.			= 0.022				
982043089	rs5370	atenolol,irbesartan	Efficacy	yes	Genotype GT is associated with increased response to atenolol and irbesartan in men with Essential hypertension as compared to genotype GG.	G		= 0.007	Unknown			
1451134687	rs1799971	oxycodone,sufentanil	Dosage	no	Genotypes AG + GG are not associated with dose of oxycodone or sufentanil in people with Pain, Postoperative as compared to genotype AA.	G		> 0.05				
1183629536	CYP2D6*4	debrisoquine,dextromethorphan	Metabolism/PK	not stated	CYP2D6 *4/*4 is associated with decreased metabolism of debrisoquine or dextromethorphan.				Unknown			
1183699179	rs74090038	carboplatin,cisplatin	Efficacy	no	Genotype CC is not associated with response to carboplatin or cisplatin in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CT + TT.	T		= 0.218	OR	1.59	0.76	3.32
1447520644	rs5443	hydralazine / isosorbide dinitrate	Efficacy	yes	Genotype TT is associated with increased response to hydralazine / isosorbide dinitrate in people with Heart Failure as compared to genotypes CC + CT.	T		= 0.02	OR			
1183679601	CYP2C19*1	omeprazole,rabeprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to omeprazole or rabeprazole in people with Helicobacter Infections.	*1		= 0.402	OR	1.5	0.58	3.85
1183681894	CYP2D6*4	hydromorphone,ketorolac,morphine,opioids,oxycodone	Efficacy	not stated	CYP2D6 *4/*4 is associated with decreased response to hydromorphone, ketorolac, morphine, opioids or oxycodone in women.				OR			
1183699139	rs2494752	carboplatin,cisplatin	Efficacy	yes	Genotype AG is associated with decreased response to carboplatin or cisplatin in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + GG.	G		= 0.05	OR	2.18	1.0	4.77
1183679975	CYP2C19*1	famotidine,lansoprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to famotidine and lansoprazole in men with Helicobacter Infections.	*1		> 0.05	OR			
1183680817	rs3842	lamivudine,lopinavir,ritonavir,zidovudine	Efficacy	no	Allele C is not associated with increased resistance to lamivudine, lopinavir, ritonavir and zidovudine in people with HIV Infections as compared to allele T.	T		= 1.00	OR	1.62	0.48	4.79
1184165246	rs10898563	bevacizumab,ranibizumab	Efficacy	no	Allele G is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to allele A.	G	G	> 0.99	OR	1.06	0.69	1.64
1184086246	rs4694362	gemcitabine,paclitaxel	Efficacy,Toxicity	no	Allele T is not associated with response to gemcitabine and paclitaxel in women with Breast Neoplasms as compared to allele C.	C	T	> 0.05	OR			
1184086183	rs1045642	gemcitabine,paclitaxel	Efficacy,Toxicity	no	Allele T is not associated with response to gemcitabine and paclitaxel in women Breast Neoplasms.	G	T	> 0.05	OR			
1183960616	rs720106	cisplatin,gemcitabine	Efficacy	yes	Genotype TT is associated with decreased response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CC + CT.			= 0.007	HR	3.006	1.81	4.98
1184086234	rs776746	gemcitabine,paclitaxel	Efficacy,Toxicity	no	Allele C is not associated with response to gemcitabine and paclitaxel in women with Breast Neoplasms as compared to allele T.	C	T	> 0.05	OR			
1447959629	rs10819043	interferon beta-1a,interferon beta-1b	Efficacy	yes	Allele T is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele C.			= 5.83E-5	OR			
1447959629	rs10819043	interferon beta-1a,interferon beta-1b	Efficacy	yes	Allele T is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele C.			= 2.54E-4	OR			
1447959629	rs10819043	interferon beta-1a,interferon beta-1b	Efficacy	yes	Allele T is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele C.			= 1.72E-2	OR	1.44	1.1	1.88
1447959629	rs10819043	interferon beta-1a,interferon beta-1b	Efficacy	yes	Allele T is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele C.			= 0.367	OR			
1183960004	rs6311	fluvoxamine,paroxetine	Efficacy	no	Allele C is not associated with response to fluvoxamine or paroxetine in people with Depressive Disorder, Major as compared to allele T.			> 0.05	OR			
1183944237	SLC6A4 HTTLPR short form (S allele)	fluoxetine,paroxetine	Efficacy	yes	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased response to fluoxetine or paroxetine in people with Depressive Disorder, Major.			= 0.0150	OR			
1448099041	rs10423928	sitagliptin,vildagliptin	Efficacy	no	Allele A is not associated with response to sitagliptin or vildagliptin in people with Diabetes Mellitus, Type 2 as compared to allele T.			= 0.47	OR			
1184510745	rs11568993	cetuximab,panitumumab	Efficacy	no	Genotype CC is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotype CT.			= 0.954	OR	1.05	0.2	6.74
1184349374	rs776746	efavirenz,nevirapine	Metabolism/PK	no	Genotype TT is not associated with metabolism of efavirenz or nevirapine in people with HIV Infections as compared to genotype CC.			= 0.06	OR			
1184349374	rs776746	efavirenz,nevirapine	Metabolism/PK	no	Genotype TT is not associated with metabolism of efavirenz or nevirapine in people with HIV Infections as compared to genotype CC.			= 0.58	OR			
1184468139	HLA-A*01:01:01:01	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	HLA-A *01:01:01:01 is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C.			= 0.02	OR	0.5	0.28	0.89
1451147584	rs41303343	ambrisentan,aripiprazole,atorvastatin,donepezil,olanzapine	Metabolism/PK	no	Allele A is not associated with metabolism of ambrisentan, aripiprazole, atorvastatin, donepezil or olanzapine in healthy individuals as compared to allele del.							
1184747531	rs1045642	atazanavir,ritonavir	Toxicity	no	Genotypes AA + AG is not associated with increased discontinuation of atazanavir and ritonavir in people with HIV Infections as compared to genotype GG.			> 0.05	OR			
1447813829	rs1629140	anthracyclines and related substances,bevacizumab,cyclophosphamide,docetaxel,epirubicin,taxanes	Efficacy	no	Allele A is not associated with response to anthracyclines and related substances, bevacizumab, cyclophosphamide, docetaxel, epirubicin and taxanes in women with Breast Neoplasms as compared to allele G.	A	G	= 0.103	OR	1.84	1.16	2.93
1449576772	rs74743371	cyclophosphamide,doxorubicin	Efficacy	no	Allele G is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele T.				OR			
1446899495	rs11623866	carboplatin,lonafarnib,paclitaxel	Efficacy	yes	Genotype GG is associated with response to carboplatin, lonafarnib and paclitaxel in women with Ovarian Neoplasms.			= 0.002	HR	6.42	2.01	19.41
1446899495	rs11623866	carboplatin,lonafarnib,paclitaxel	Efficacy	yes	Genotype GG is associated with response to carboplatin, lonafarnib and paclitaxel in women with Ovarian Neoplasms.			= 0.006	HR	9.589	1.89	48.54
981954829	rs1045642	carbamazepine,phenobarbital,phenytoin,valproic acid	Efficacy	no	Allele G is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy as compared to allele A.				Unknown			
1184886879	rs1045642	fluorouracil,leucovorin,oxaliplatin	Efficacy	no	Allele T is not associated with response to fluorouracil, leucovorin and oxaliplatin in people with Esophageal Neoplasms and Stomach Neoplasms as compared to allele A.				OR			
1449566942	rs12138564	bevacizumab,ranibizumab	Efficacy	no	Allele T is associated with increased response to bevacizumab and ranibizumab in people with Macular Degeneration as compared to allele G.			= 5.74E-7	OR			
1449566942	rs12138564	bevacizumab,ranibizumab	Efficacy	no	Allele T is associated with increased response to bevacizumab and ranibizumab in people with Macular Degeneration as compared to allele G.			= 1.38E-5	OR			
1449566942	rs12138564	bevacizumab,ranibizumab	Efficacy	no	Allele T is associated with increased response to bevacizumab and ranibizumab in people with Macular Degeneration as compared to allele G.			= 0.029	OR			
1445297339	rs1045642	atazanavir,bilirubin	Metabolism/PK	no	Genotype GG is not associated with concentrations of atazanavir or bilirubin in people with HIV Infections as compared to genotypes AA + AG.			> 0.05	OR			
1444705702	rs7512595	peginterferon alfa-2b,ribavirin	Efficacy	yes	Allele A is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele G.			= 5.34E-4	OR	1.81	1.29	2.55
1444705641	rs6806020	peginterferon alfa-2b,ribavirin	Efficacy	yes	Allele C is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele T.			= 3.98E-5	OR	1.54	1.25	1.9
1444705790	rs12979860	peginterferon alfa-2b,ribavirin	Efficacy	no	Genotypes CC + CT is not associated with response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype TT.		C	= 0.3478	OR			
1444694858	rs4880	epirubicin,fluorouracil,oxaliplatin	Efficacy	not stated	Allele G is not associated with response to epirubicin, fluorouracil and oxaliplatin in people with Neoplasm Metastasis and Stomach Neoplasms.	A	G	> 0.05	OR			
1444665914	rs12979860	interferon alfa-2b, recombinant	Efficacy	no	Genotype CC is not associated with response to interferon alfa-2b, recombinant in people with Melanoma as compared to genotypes CT + TT.	C	T	= 0.176	OR			
1444665914	rs12979860	interferon alfa-2b, recombinant	Efficacy	no	Genotype CC is not associated with response to interferon alfa-2b, recombinant in people with Melanoma as compared to genotypes CT + TT.	C	T	= 0.600	HR	0.282	0.308	1.409
1444665914	rs12979860	interferon alfa-2b, recombinant	Efficacy	no	Genotype CC is not associated with response to interferon alfa-2b, recombinant in people with Melanoma as compared to genotypes CT + TT.	C	T	= 0.600	HR	1.587	0.282	8.92
1444665914	rs12979860	interferon alfa-2b, recombinant	Efficacy	no	Genotype CC is not associated with response to interferon alfa-2b, recombinant in people with Melanoma as compared to genotypes CT + TT.	C	T	= 0.727	OR			
1444843603	rs12980275	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype AA is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AG + GG.				OR	3.118	2.146	4.529
1444706383	rs12980275	peginterferon alfa-2b,ribavirin	Efficacy	no	Genotype AA is not associated with response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AG + GG.			= 0.12	OR			
1444694879	rs1695	epirubicin,fluorouracil,oxaliplatin	Efficacy	not stated	Allele G is not associated with response to epirubicin, fluorouracil and oxaliplatin in people with Neoplasm Metastasis and Stomach Neoplasms.	A	G	> 0.05	OR			
1444694818	rs1800566	epirubicin,fluorouracil,oxaliplatin	Efficacy	yes	Genotypes AA + AG are associated with decreased response to epirubicin, fluorouracil and oxaliplatin in people with Neoplasm Metastasis and Stomach Neoplasms as compared to genotype GG.	A	G	= 0.005	HR			
1444694818	rs1800566	epirubicin,fluorouracil,oxaliplatin	Efficacy	yes	Genotypes AA + AG are associated with decreased response to epirubicin, fluorouracil and oxaliplatin in people with Neoplasm Metastasis and Stomach Neoplasms as compared to genotype GG.	A	G	= 0.017	HR	1.97	1.23	3.16
1444668556	rs8099917	interferon alfa-2a, recombinant,interferon alfa-2b, recombinant,ribavirin	Efficacy	yes	Genotype TT is associated with increased response to interferon alfa-2a, recombinant, interferon alfa-2b, recombinant and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.			= 0.0001	OR	2.39	1.19	3.81
1444706170	rs12979860	peginterferon alfa-2a,ribavirin	Efficacy	yes	Genotype CC is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C and HIV Infections as compared to genotypes CT + TT.			= 0.006	OR			
1444706170	rs12979860	peginterferon alfa-2a,ribavirin	Efficacy	yes	Genotype CC is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C and HIV Infections as compared to genotypes CT + TT.			= 0.01	OR	25.07	1.86	337.0
1444934680	rs11942466	capecitabine,radiotherapy	Efficacy	yes	Genotypes AA + AC is associated with decreased response to capecitabine and radiotherapy in people with Rectal Neoplasms as compared to genotype CC.	A		= 0.0149	OR	0.26	0.06	0.79
1185012177	HLA-B*40:01:01	lamivudine,nevirapine,stavudine	Efficacy	yes	HLA-B *40:01:01 is associated with response to lamivudine, nevirapine and stavudine in people with HIV.	*40:01:01		= 0.02	HR	0.29	0.1	0.82
981954797	rs1128503	carbamazepine,phenobarbital,phenytoin,valproic acid	Efficacy	no	Allele A is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy as compared to allele G.				Unknown			
1449310654	rs1799853	sulfonamides, urea derivatives	Efficacy	no	Allele T is not associated with response to sulfonamides, urea derivatives in people with Diabetes Mellitus as compared to allele C.	C	C	> 0.05	OR			
1444705811	rs12980275	peginterferon alfa-2a,ribavirin	Efficacy	yes	Genotype AA is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AG + GG.			< 0.0001	OR			
1444842399	rs2010963	bevacizumab,capecitabine,fluorouracil,irinotecan,leucovorin,oxaliplatin	Efficacy	no	Allele G is not associated with response to bevacizumab, capecitabine, fluorouracil, irinotecan, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to allele C.			= 0.81	OR	1.12	0.46	2.73
1444843589	rs8103142	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype CT.			= 0.009	OR			
1444843860	rs12979860	deleobuvir,faldaprevir	Efficacy	yes	Genotype CC is associated with increased response to deleobuvir and faldaprevir in people with Hepatitis C as compared to genotypes CT + TT.			= 0.02	OR			
1444843860	rs12979860	deleobuvir,faldaprevir	Efficacy	yes	Genotype CC is associated with increased response to deleobuvir and faldaprevir in people with Hepatitis C as compared to genotypes CT + TT.			= 0.05	OR			
1444705538	rs10853728	peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotype GG is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CC + CG.			= 0.0117	OR	0.291	0.111	0.759
982045444	rs2032582	lamivudine,nevirapine,zidovudine	Efficacy	not stated	Allele A is associated with response to lamivudine, nevirapine or zidovudine in people with HIV Infections as compared to allele C.	A			Unknown			
1448427752	rs2032582	granisetron,palonosetron	Efficacy	no	Genotype AA is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting.				OR			
1444707745	rs10877012	peginterferon alfa-2b,ribavirin	Efficacy	yes	Genotypes GT + TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype GG.	T	T	= 0.02	OR			
1447682460	rs11322783	boceprevir,peginterferon alfa-2a,peginterferon alfa-2b,ribavirin,telaprevir	Efficacy	yes	Allele TT is associated with increased response to boceprevir, peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to allele G.			= 4.7e-4	OR	2.35	1.46	3.79
1447520846	rs1045642	sirolimus,tacrolimus	Metabolism/PK	no	Allele A is not associated with metabolism of sirolimus or tacrolimus in people with Kidney Transplantation as compared to allele G.				OR			
1449713612	rs2229046	carboplatin,docetaxel,trastuzumab	Efficacy	yes	Allele C is associated with decreased response to carboplatin, docetaxel and trastuzumab in women with Breast Neoplasms.	C		= 1.51E-3	HR	4.95	1.91	2.79
1448431572	rs2231142	n-desethyl sunitinib,sunitinib	Toxicity,Metabolism/PK	no	Genotype TT is associated with increased concentrations of n-desethyl sunitinib and sunitinib in women with Carcinoma, Renal Cell.				OR			
1449002176	rs12248560	clopidogrel,clopidogrel thiol metabolite H4	Metabolism/PK	no	Allele T is not associated with exposure to clopidogrel or clopidogrel thiol metabolite H4 as compared to allele C.	T	C	> 0.05	OR			
1448428843	rs34650714	allopurinol,febuxostat	Dosage	yes	Allele T is associated with decreased dose of allopurinol or febuxostat in people with Gout as compared to allele C.	T		= 0.007	OR			
1448926568	rs4246215	fluorouracil,Platinum compounds,radiotherapy	Efficacy	no	Allele T is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele G.			> 0.05	OR			
1449002468	rs13260300	anastrozole,exemestane	Efficacy	no	Allele T is not associated with increased response to anastrozole and exemestane in women with Breast Neoplasms as compared to allele C.	T	C	= 2.15E-7	OR	0.61	0.51	0.74
1448634657	rs2305948	carfilzomib,dexamethasone,lenalidomide	Efficacy	yes	Genotypes CT + TT is associated with increased response to carfilzomib, dexamethasone and lenalidomide in people with Multiple Myeloma as compared to genotype CC.	T		= 0.007	OR	0.05	0.01	0.47
1448530796	rs8109886	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	no	Genotype CC is not associated with response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AA + AC.			= 0.987	OR			
1448530787	rs7248668	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	no	Genotype AA is not associated with response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AG + GG.			= 0.429	OR			
1449140022	rs6785049	sirolimus,temsirolimus	Metabolism/PK	yes	Genotype GG is associated with increased exposure to sirolimus and temsirolimus in people with Urinary Bladder Neoplasms as compared to genotypes AA + AG.	A	G	= 0.049	OR			
1449713618	rs773123	carboplatin,docetaxel,trastuzumab	Efficacy	yes	Allele A is associated with decreased response to carboplatin, docetaxel and trastuzumab in women with Breast Neoplasms.	A		= 0.05	HR	2.67	1.02	7.03
1449310630	rs757110	sulfonamides, urea derivatives	Efficacy	yes	Genotypes AA + CC is associated with increased response to sulfonamides, urea derivatives in people with Diabetes Mellitus as compared to genotype AC.	A	C	= 0.04	OR	1.33		
1449271199	CYP2C9 poor metabolizer	buprenorphine,methadone	Efficacy	no	CYP2C9 poor metabolizer is not associated with response to buprenorphine or methadone in people with Opioid-Related Disorders as compared to CYP2C9 intermediate metabolizer and normal metabolizer.			= 0.496	OR			
1449576749	rs6151031	cyclophosphamide,doxorubicin	Efficacy	yes	Genotype CTGGTGAGGAGAGAACC/del is associated with decreased response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotype CTGGTGAGGAGAGAACC/CTGGTGAGGAGAGAACC.			< 0.001	OR	5.088	2.284	11.71
1449162960	rs7439366	morphine,morphine-3-glucuronide	Dosage	no	Allele T is associated with increased concentrations of morphine or morphine-3-glucuronide in women with Pain, Postoperative as compared to allele C.	C			OR			
1444843660	rs11322783	peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	no	Genotype TT/TT is not associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes G/TT + GG.			= 0.078	OR			
1449192335	rs121909011	ivacaftor / lumacaftor	Efficacy	not stated	Allele T is associated with response to ivacaftor / lumacaftor.				OR			
1449160237	rs36029	3,4-methylenedioxymethamphetamine	Other	yes	Genotype AA is associated with increased response to 3,4-methylenedioxymethamphetamine as compared to genotypes AG + GG.	A	G	= 0.049	OR			
1449160237	rs36029	3,4-methylenedioxymethamphetamine	Other	yes	Genotype AA is associated with increased response to 3,4-methylenedioxymethamphetamine as compared to genotypes AG + GG.	A	G	> 0.05	OR			
1449160237	rs36029	3,4-methylenedioxymethamphetamine	Other	yes	Genotype AA is associated with increased response to 3,4-methylenedioxymethamphetamine as compared to genotypes AG + GG.	A	A	> 0.05	OR			
1449155997	rs55853698	bupropion,nicotine,varenicline	Efficacy	no	Allele G is not associated with response to bupropion, nicotine and varenicline in people with Tobacco Use Disorder as compared to allele T.	G		= 0.94	OR	1.0	0.73	1.4
1446904186	rs56061981	peginterferon alfa-2a,peginterferon alfa-2b	Efficacy	yes	Genotypes CT + TT are associated with increased response to peginterferon alfa-2a or peginterferon alfa-2b in people with Hepatitis C, Chronic as compared to genotype CC.	C	T	= 0.045	OR	4.0	1.03	15.53
1446904186	rs56061981	peginterferon alfa-2a,peginterferon alfa-2b	Efficacy	yes	Genotypes CT + TT are associated with increased response to peginterferon alfa-2a or peginterferon alfa-2b in people with Hepatitis C, Chronic as compared to genotype CC.	C	T	> 0.05	OR			
1184175118	rs80143932	cytarabine,idarubicin	Efficacy	yes	Allele G is associated with increased response to cytarabine and idarubicin in people with Leukemia, Myeloid, Acute as compared to allele C.	C	G	= 0.025	OR			
1184175118	rs80143932	cytarabine,idarubicin	Efficacy	yes	Allele G is associated with increased response to cytarabine and idarubicin in people with Leukemia, Myeloid, Acute as compared to allele C.	C	G	= 0.0423	OR			
1450928579	rs2768759	aspirin,prasugrel	Efficacy	yes	Genotypes AC + CC are associated with decreased response to aspirin or prasugrel as compared to genotype AA.			< 0.00001				
1450928579	rs2768759	aspirin,prasugrel	Efficacy	yes	Genotypes AC + CC are associated with decreased response to aspirin or prasugrel as compared to genotype AA.			< 0.0001				
1450928579	rs2768759	aspirin,prasugrel	Efficacy	yes	Genotypes AC + CC are associated with decreased response to aspirin or prasugrel as compared to genotype AA.			= 0.0002				
1450821075	rs1126742	amiloride,spironolactone	Efficacy	yes	Genotype GG is associated with decreased response to amiloride or spironolactone in people with Hypertension as compared to genotypes AA + AG.	G		= 0.008				
1450823635	rs2514218	aripiprazole,risperidone	Efficacy	yes	Genotype CC is associated with increased response to aripiprazole or risperidone in people with Psychotic Disorders, schizoaffective disorder or Schizophrenia as compared to genotypes CT + TT.			= 0.044				
1448263056	rs1042713	ephedrine,phenylephrine	Metabolism/PK	no	Genotype AA is associated with decreased dose of ephedrine or phenylephrine in people with Hypotension as compared to genotype GG.	A		= 0.01	Unknown	24.0	0.0	42.0
1450935937	rs1800888	fluticasone propionate,salmeterol	Efficacy	no	Allele C is not associated with response to fluticasone propionate and salmeterol in people with Asthma as compared to allele T.							
1184565781	rs55948420	mephenytoin,omeprazole	Metabolism/PK	no	Allele A is not associated with metabolism of mephenytoin and omeprazole as compared to allele G.			> 0.05	OR			
1184565781	rs55948420	mephenytoin,omeprazole	Metabolism/PK	no	Allele A is not associated with metabolism of mephenytoin and omeprazole as compared to allele G.			> 0.05	OR			
1451107100	rs1042713	atenolol,metoprolol	Efficacy	yes	Genotype AA is associated with increased response to atenolol or metoprolol in people with Tachycardia as compared to genotypes AG + GG.			= 0.002				
1451107100	rs1042713	atenolol,metoprolol	Efficacy	yes	Genotype AA is associated with increased response to atenolol or metoprolol in people with Tachycardia as compared to genotypes AG + GG.	A		= 0.03				
1451107100	rs1042713	atenolol,metoprolol	Efficacy	yes	Genotype AA is associated with increased response to atenolol or metoprolol in people with Tachycardia as compared to genotypes AG + GG.	A		= 0.04				
1451107100	rs1042713	atenolol,metoprolol	Efficacy	yes	Genotype AA is associated with increased response to atenolol or metoprolol in people with Tachycardia as compared to genotypes AG + GG.	A		= 0.19				
1451107134	rs1042714	atenolol,metoprolol	Efficacy	no	Allele G is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele C.			= 0.39				
1451107134	rs1042714	atenolol,metoprolol	Efficacy	no	Allele G is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele C.			= 0.47				
1451107134	rs1042714	atenolol,metoprolol	Efficacy	no	Allele G is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele C.			= 0.54				
1451107134	rs1042714	atenolol,metoprolol	Efficacy	no	Allele G is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele C.			= 0.63				
1451107134	rs1042714	atenolol,metoprolol	Efficacy	no	Allele G is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele C.			= 0.83				
981478948	rs3812718	carbamazepine,oxcarbazepine	Dosage,Efficacy	no	Allele C is not associated with response to carbamazepine or oxcarbazepine in people with Epilepsy as compared to allele T.	C	C	= 0.686	OR	1.0		
827812184	rs7608731	cisplatin,fluorouracil,mitoxantrone	Efficacy	yes	Allele C is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele T.	C		= 2.4E-5	Unknown			
1448266865	rs1042522	capecitabine,paclitaxel	Efficacy	yes	Genotype GG is associated with decreased response to capecitabine and paclitaxel in people with Stomach Neoplasms as compared to genotype CC.	G		< 0.001	RR	3.89	1.915	7.903
1448266865	rs1042522	capecitabine,paclitaxel	Efficacy	yes	Genotype GG is associated with decreased response to capecitabine and paclitaxel in people with Stomach Neoplasms as compared to genotype CC.	G		< 0.001	OR			
1448266865	rs1042522	capecitabine,paclitaxel	Efficacy	yes	Genotype GG is associated with decreased response to capecitabine and paclitaxel in people with Stomach Neoplasms as compared to genotype CC.	G		< 0.001	OR			
1449567013	rs242939	bevacizumab,ranibizumab	Efficacy	no	Allele C is not associated with response to bevacizumab and ranibizumab in people with as compared to allele T.			= 2.25E-6	OR			
1449567013	rs242939	bevacizumab,ranibizumab	Efficacy	no	Allele C is not associated with response to bevacizumab and ranibizumab in people with as compared to allele T.			= 0.162	OR			
1449567013	rs242939	bevacizumab,ranibizumab	Efficacy	no	Allele C is not associated with response to bevacizumab and ranibizumab in people with as compared to allele T.			= 0.214	OR			
1448107229	rs113993960	ivacaftor / lumacaftor	Efficacy	yes	Genotype del/del is associated with increased response to ivacaftor / lumacaftor in people with Cystic Fibrosis as compared to genotypes CTT/CTT + CTT/del.	del		< 0.001	OR	2.5	1.7	3.7
982034681	rs1799752	acetylcholine,nitroprusside	Efficacy	yes	Allele ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with increased response to acetylcholine or nitroprusside in healthy individuals as compared to allele del.	del		< 0.05	Unknown			
1449146811	rs2289669	tipiracil hydrochloride,trifluridine	Efficacy	no	Allele A is not associated with response to tipiracil hydrochloride and trifluridine in people with Colorectal Neoplasms as compared to allele G.	A	G	= 0.10	HR	0.53	0.25	1.13
1449146811	rs2289669	tipiracil hydrochloride,trifluridine	Efficacy	no	Allele A is not associated with response to tipiracil hydrochloride and trifluridine in people with Colorectal Neoplasms as compared to allele G.	A	G	= 0.15	HR	1.6	0.85	3.04
1449146811	rs2289669	tipiracil hydrochloride,trifluridine	Efficacy	no	Allele A is not associated with response to tipiracil hydrochloride and trifluridine in people with Colorectal Neoplasms as compared to allele G.	A	G	= 0.55	HR	1.14	0.74	1.75
1449146811	rs2289669	tipiracil hydrochloride,trifluridine	Efficacy	no	Allele A is not associated with response to tipiracil hydrochloride and trifluridine in people with Colorectal Neoplasms as compared to allele G.	A	G	= 0.88	HR	0.93	0.33	2.59
1183960659	rs3817657	cisplatin,gemcitabine	Efficacy	no	Genotype TT is not associated with response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CC + CT.			= 1	HR	0.819	0.55	1.2
655387194	rs61888800	antidepressants,desipramine,fluoxetine	Efficacy	not stated	Genotype GG is associated with increased response to antidepressants, desipramine and fluoxetine in people with Depressive Disorder, Major.			= 0.02	Unknown			
982046897	rs767455	adalimumab,etanercept,infliximab	Efficacy	yes	Genotype TT is associated with increased response to adalimumab, etanercept and infliximab in people with Arthritis, Psoriatic as compared to genotypes CC + CT.	C		= 0.042	Unknown			
1448568253	rs45445694	bevacizumab,capecitabine,cisplatin,docetaxel,epirubicin,oxaliplatin,trastuzumab	Efficacy	yes	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 is associated with decreased response to bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.			= 0.006	OR	0.4	0.2	0.7
827822867	rs4073	bevacizumab,cyclophosphamide	Efficacy	yes	Genotypes AA + AT are associated with decreased response to bevacizumab and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype TT.	A		= 0.006	Unknown			
1444694865	rs1799895	epirubicin,fluorouracil,oxaliplatin	Efficacy	not stated	Allele G is not associated with response to epirubicin, fluorouracil and oxaliplatin in people with Neoplasm Metastasis and Stomach Neoplasms.	C	G	> 0.05	OR			
1447813737	rs833058	anthracyclines and related substances,bevacizumab,cyclophosphamide,docetaxel,epirubicin,taxanes	Efficacy	no	Allele T is not associated with response to anthracyclines and related substances, bevacizumab, cyclophosphamide, docetaxel, epirubicin and taxanes in women with Breast Neoplasms as compared to allele C.	T	C	= 0.003	OR	2.36	1.49	3.75
827707457	rs1570360	bevacizumab,irinotecan	Efficacy	yes	Genotype GG is associated with decreased response to bevacizumab and irinotecan in people with Colorectal Neoplasms as compared to genotypes AA + AG.			= 0.032	Unknown			
1184175240	rs9937	carboplatin,gemcitabine	Efficacy	no	Genotype AA is not associated with response to carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	A	G	> 0.05	OR			
1183960654	rs183484	cisplatin,gemcitabine	Efficacy	no	Genotype CC is not associated with response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AC.			= 1	HR	0.952	0.64	1.4
981865177	rs187238	interferon alfa-2a, recombinant,interferon alfa-2b, recombinant,interferons,peginterferon alfa-2a,peginterferon alfa-2b,ribavirin	Efficacy	yes	Allele C is associated with decreased response to interferon alfa-2a, recombinant, interferon alfa-2b, recombinant, interferons, peginterferon alfa-2a, peginterferon alfa-2b or ribavirin in people with Hepatitis C, Chronic as compared to allele G.	G	G	= 0.0302	OR	1.524	1.04	2.233
1184086208	rs60369023	gemcitabine,paclitaxel	Efficacy,Toxicity	no	Allele G is not associated with response to gemcitabine and paclitaxel in women with Breast Neoplasms as compared to allele A.	A	G	> 0.05	OR			
1444706633	rs2228570	peginterferon alfa-2b,ribavirin	Efficacy	yes	Allele A is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele G.			= 0.021	OR	0.438	0.204	0.882
1444706633	rs2228570	peginterferon alfa-2b,ribavirin	Efficacy	yes	Allele A is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele G.			= 0.042	OR	0.469	0.223	0.99
982035781	rs2238032	lacidipine,nifedipine,nitrendipine	Efficacy	yes	Genotype TT is associated with increased response to lacidipine, nifedipine or nitrendipine in people with Hypertension as compared to genotypes GG + GT.			= 2.6E-4	Unknown			
982035861	rs2239050	lacidipine,nifedipine,nitrendipine	Efficacy	no	Genotype CC is not associated with response to lacidipine, nifedipine or nitrendipine in people with Hypertension as compared to genotype CG.				Unknown			
1183681930	rs4149056	atorvastatin,simvastatin	Efficacy	no	Genotype CC is not associated with increased response to atorvastatin or simvastatin in people with Hyperlipidemias as compared to genotypes CT + TT.	C		> 0.05	OR			
1446902880	rs4742610	trandolapril,verapamil	Efficacy	yes	Allele T is associated with resistance to trandolapril and verapamil in people with Hypertension as compared to allele C.			= 3.2e-5	OR	1.5	1.24	1.81
1446902880	rs4742610	trandolapril,verapamil	Efficacy	yes	Allele T is associated with resistance to trandolapril and verapamil in people with Hypertension as compared to allele C.			= 0.0011	OR	1.55	1.19	2.02
1446902880	rs4742610	trandolapril,verapamil	Efficacy	yes	Allele T is associated with resistance to trandolapril and verapamil in people with Hypertension as compared to allele C.			= 0.0066	OR	1.53	1.13	2.08
1446902880	rs4742610	trandolapril,verapamil	Efficacy	yes	Allele T is associated with resistance to trandolapril and verapamil in people with Hypertension as compared to allele C.			= 0.70	OR	1.13	0.61	2.07
1444934874	rs1056515	bevacizumab,fluorouracil,irinotecan,leucovorin	Efficacy	yes	Genotype TT is associated with increased response to bevacizumab, fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotypes GG + GT.	G		= 0.012	OR			
769173655	rs2372536	folic acid,methotrexate	Efficacy	yes	Genotype CC is associated with increased response to folic acid and methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CG + GG.			< 0.05	Unknown	2.5	1.3	4.7
1450814406	rs1801133	Vitamin B-complex, Incl. Combinations	Efficacy	yes	Allele A is associated with increased response to Vitamin B-complex, Incl. Combinations in people with Depressive Disorder, Major.			< 0.001				
1450973700	rs429358	donepezil,galantamine,rivastigmine	Efficacy	yes	Genotypes CC + CT is associated with decreased response to donepezil, galantamine and rivastigmine in people with Alzheimer Disease as compared to genotype TT.	E4		= 0.023	OR	0.454	0.23	0.896
1444936362	rs2108622	aspirin,clopidogrel	Efficacy	yes	Genotypes CC + CT is associated with decreased response to aspirin and clopidogrel in people with Acute coronary syndrome as compared to genotype TT.	T	T	= 0.029	OR	3.532	1.132	10.612
1183491605	rs2230199	bevacizumab,ranibizumab	Efficacy	no	Genotype GG is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotypes CC + CG.	C		= 0.03	Unknown			
1183491605	rs2230199	bevacizumab,ranibizumab	Efficacy	no	Genotype GG is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotypes CC + CG.	C		= 0.07	Unknown			
1183491605	rs2230199	bevacizumab,ranibizumab	Efficacy	no	Genotype GG is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotypes CC + CG.	C		= 0.28	Unknown			
1183491605	rs2230199	bevacizumab,ranibizumab	Efficacy	no	Genotype GG is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotypes CC + CG.	C		= 0.30	Unknown			
1183491605	rs2230199	bevacizumab,ranibizumab	Efficacy	no	Genotype GG is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotypes CC + CG.	C		= 0.34	Unknown			
1183491605	rs2230199	bevacizumab,ranibizumab	Efficacy	no	Genotype GG is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotypes CC + CG.	C		= 0.51	Unknown			
1183491605	rs2230199	bevacizumab,ranibizumab	Efficacy	no	Genotype GG is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotypes CC + CG.	C		= 0.67	Unknown			
1183491605	rs2230199	bevacizumab,ranibizumab	Efficacy	no	Genotype GG is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotypes CC + CG.	C		= 0.72	Unknown			
1183491605	rs2230199	bevacizumab,ranibizumab	Efficacy	no	Genotype GG is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotypes CC + CG.	C		= 0.85	Unknown			
